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A review of published clinical data shows that
there is a substantial increase in complete response rate,
from an average of 30% to 70%, when heat is added to
radiation. In the present study, the interaction of heat and
radiation has been investigated quantitatively in measurable
superficial human tumour metastases. Ninety-six nodules, in
10 patients, have provided evidence of enhancement of
radiation response by the addition of heat 3-4 hours after a
single dose of radiation.
Growth delay, tumour regression rate, maximum
volume reduction and time to maximum response have been
calculated from growth curves obtained from ultrasonic and
caliper tumour volume measurements. Thermal enhancement
ratios (TER) have been derived from growth delay
measurements. The greater effect of heat plus radiation,
compared with radiation alone, was reflected in thermal
enhancement ratio (TER) values ranging from > 1.6 - 4.2.
Nodules subjected to the combined treatment regressed more
rapidly than those receiving radiation alone with median
tumour volume halving times of 15.5 and 70 days respectively.
The total volume reduction was also greater in heated nodules
and the nadir values were observed later compared with
nodules receiving radiation alone.
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Xenon clearance and thermal wash-out techniques
were used to examine the effect of a standard hyperthermia
treatment (43°C minimum temperature for 60 minutes) on small,
superficial tumours. There was no evidence of vascular
destruction and in most instances tumour and normal tissue
behaved similarly with a transient increase in blood flow
immediately after heating.
With the radiofrequency system employed,
54% (30/56) of nodules were successfully heated to the
prescribed level (43°C for 30 or 60 minutes). The median
volume of successfully heated nodules was significantly
smaller than that of the failures (p = 0. 002). Temperature
distribution was homogeneous in 73% of nodules, but
non-uniform in 27%. The potential relevance of these
observations to the clinical situation is discussed.
The observations on tumour response are encouraging
and suggest that prospective clinical studies of sequential
radiation - heat therapy should be undertaken, although there
are no quantitative data of the type described in the present
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Interest in hyperthermia as an antitumour agent stems
from a clinical observation made in 1866 when a
histologically diagnosed sarcoma regressed following an
episode of erysipelas (Busch, 1866). Subsequently, 10 out of
23 patients with malignant tumours were reported to have a
complete tumour regression after intentional induction of
erysipelas (Coley, 1893) . The development of a bacterial
extract to stimulate fever in cancer patients however was
less successful, both in terms of efficacy and toxicity.
lATffiiWTfm
Despitee this, the possibility of utilising anti-cancer
properties of heat has been pursued for more than a century.
Activity has intensified over the past 25 years as the
biological potential of heat has been elucidated by the
application of radiobiological techniques, in vivo and
in vitro. However, concurrent technical advances in heat
delivery and thermometry have not been able to overcome the
anatomical and physiological constraints of tumour heating
and have severely limited clinical application.
The inadequacies of tumour heating, in terms of severity
and uniformity of temperature distribution, have directed
interest towards an adjuvant role for hyperthermia. Present
clinical exploitation of hyperthermia relies on its combined
application with radiotherapy or chemotherapeutic agents.
Although published clinical data is still insufficiently
precise to delineate the contribution of heat in this
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context, there is growing evidence to support the possibility
of a therapeutic gain.
1.2 The Biological Basis for Clinical Hyperthermia
1.2.i Hyperthermia as a Single Agent
Heat kills mammalian cells in a predictable, repeatable
manner that is both temperature and time-dependant (Henle &
Dethlefsen, 1980, Westra & Dewey, 1971). For this reason,
the concept of a "thermal dose" requires consideration of
both parameters. Of the several attempts to define thermal
dose, minutes equivalent at 43 °C is the most generally
accepted, referring exposures at different temperature levels
to a standard reference temperature (43°C) (Sapareto &
Dewy, 1984). In theory, such a system allows comparison
between heat applications, an important maneouvre in clinical
hyperthermia where delivery of a standard, reproducible heat
dose is impossible at present. Numerous in vitro and in vivo
animal experiments have demonstrated that with increasing
temperature, the time required to produce a given level of
cell kill is reduced and, at least for the approximate
temperature range 42-46°C, this can be expressed as a simple
relationship; for every degree centigrade rise in temperature
treatment time can be halved to produce the appropriate
iso-effect (Field & Morris, 1983). However, the validity of
this relationship has not been confirmed for the conditions
encountered in clinical hyperthermia.
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Keat damage can be quantified by clonagenic cell assay
and the resultant survival curves are remarkably similar to
those obtained following irradiation with an initial shoulder
followed by an exponential decrease in survival ( Fig. 1) .
Figure 1
Survival Curves Showing the Effect of Time and
Temperature on Response of Cells In Vitro
Survival curves showing the response of V79 cells to different temperatures. Time at
temperature is plotted against surviving fraction, x 37"C, □ - 4TC. #42°C, 043JC. A 44°C.
time at temperature shown (minutes)
Time at temperature is plotted against surviving
fraction
Although individual cell types vary widely in their
sensitivity to heat (Dewey et al, 1977), there is no
consistent difference in response between normal and
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malignant cells (Hahn, 1982). Despite this, a clinically-
useful tumour : normal tissue differential can be expected
because micro-environmental conditions and tumour kinetics
strongly influence the heat effect. Thus, cells' sensitivity
to heat is greatest in areas of nutritional deprivation and
low PH, conditions which arise more commonly within tumour
than in normal tissue probably as a result of the
aberrant, vulnerable tumour-neovasculature (Gerweck, 1977,
Overgaard & Bichel, 1977). Also, enhanced sensitivity of
S phase cells (Westra & Dewey, 1971) may allow selective
killing of faster cycling tumour cells, with the relative
protection of slowly proliferating normal cells responsible
for late tissue damage.
The possibility of selectively heating tumour, compared
with surrounding normal tissue, may also contribute to a
differential effect. In animal and clinical studies
intra-tumoral temperatures, higher by several degrees
compared with adjacent normal tissue, have been described
(Kim et al, 1982). Less efficient heat dissipation resulting
from poor tumour perfusion may be responsible (Jain et
al, 1979), but the limited published tumour blood flow data,
especially from clinical studies, do not allow the
generalisation that tumour perfusion is less than that in
normal tissue. More important may be the ability of normal
tissues to vasodilate in response to heat, with consequent
increased blood flow, whereas the tumour vasculature can be
16
considered to be in a state of maximum vasodilation, and
therefore unable to adapt to stimuli (Mattsson et al, 1980).
The precise mechanism of heat cell kill remains unknown.
Nevertheless, cell damage is often histologically evident
immediately after heating and is usually expressed within a
matter of hours (Overgaard & Overgaard, 1975, Hill &
Denekamp, 1982, Coss & Dewey, 1983). Diverse functional,
morphological and biochemical changes have been described in
cells following exposure to heat, but the biological basis
for cell death is poorly understood. For example, heat
interferes with membrane function (Kwock et al, 1978,
Yatvin, 1977), inhibits metabolism (Streffer, 1982) and
macromolecular synthesis (Henle & Deeper, 1979) and alters
cytoskeletal conformation (Lin et al, 1985), and the possible
implications of these lesions have been reviewed
(Leeper, 1984) .
Heat cytotoxicity may rely on more than one lethal
cellular mechanism. Cells heated in S-phase for example,
show marked thermal sensitivity which is not expressed until
after the subsequent mitosis, whereas cells mostly die
before mitosis (Coss & Dewey, 1983). The correlation of
chromosome aberrations with S-phase cell killing supports the
implication of a DNA-related mechanism, whereas this is
probably not applicable with cells (Dewey et al, 1980).
Wong & Dewey (1982) have described an increase in single
stranded regions of DNA as a result of heat induced
inhibition of replicon initiation and retardation of DNA
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chain elongation. This could permit exchange between DNA
molecules and produce chromosome aberrations (Warters &
Stone, 1983). The enzymes believed to be responsible for
these DNA abnormalities may be made relatively deficient by
the accumulation of non-histone protein on the nuclear
matrix/nuclear membrane. This accumulation seems to be a
constant dose related effect of heat (Roti Roti &
Winward, 1978, Warters & Roti Roti, 1982).
Cells exposed to heat develop a transient resistance to
further temperature elevation known as thermotolerance (for
review see Field & Anderson 1982) . This phenomenon is also
described in murine normal and tumour tissues (Law, 1981,
Neilson & Overgaard, 1982) , but it has not yet been
demonstrated in a clinical setting. However, the recent
demonstration of thermotolerance in human tumour cell lines
and xenografts indicates the likelihood that the process is
universal and must be considered in clinical application
(Rofstad et al, 1984, Rofstad & Brustad, 1984). At
temperatures below 43°C, thermotolerance develops during the
heating process, but at higher temperatures it tends to
appear shortly after completion of heating. In both cases,
decay of tolerance is slow, taking 17-14 days in most normal
tissues, but there is some evidence that it may occur more
rapidly in tumours, a property which could enhance tumour
sensitivity relative to normal tissues (for review see
Urano, 1986).
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1.2.ii Hyperthermia Combined with Irradiation
Heat and radiation are effective in combination because
of preferential toxicity on different cell populations.
Thus, those cells most resistant to radiation, such as
hypoxic, S-phase and low PH cells, are at least as sensitive,
if not more sensitive, to heat than the general cell
population (Westra & Dewey, 1971, Gerweck & Rottinger, 1976,
Hahn, 1974). Therefore, a potentially useful additive effect
can be achieved irrespective of the sequencing and scheduling
of the two modalities as no true interaction is involved.
Conversely, hyperthermia also has a radiosensitising
effect, as the result of a direct interaction between the two
modalities (for review see Dewey et al, 1977, Hahn, 1982).
Enhanced radiation damage is expressed by an increase in the
slope (Dq) , and decrease in extrapolation number (n) of the
radiation cell survival curve (Dewey et al, 1977). As with
direct heat toxicity, thermal radiosensitisation is most
marked in S-phase cells and consequently this radioresistant
population can be made more radiosensitive than cells.
After heating, loss of activity of the enzyme DNA polymerase
beta correlates well with radiosensitisation but it is not
clear whether the decreased activity is due to alteration of
chromatin structure, by for example non-histone proteins, or
to a direct effect on the enzyme (Jorritsma et al, 1984) .
Because thermal radiosensitisation involves a true
interactive process it is critically dependent on sequencing,
and on the time interval between the two modalities. Maximal
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sensitisation is achieved with simultaneous application and
any separation of the two components decreases the effect
until, with intervals of 3-4 hours, it is reduced virtually
to zero (Dewey et al, 1977, Denekamp et al, 1980,
Overgaard, 1980). Unfortunately, hyperthermic
radiosensitisation may occur similarly in normal tissue and
tumour which limits the usefulness of the interaction unless
selective tumour heating operates, or normal tissues can be
excluded from the heat application.
1.2.iii Hyperthermia Combined with Chemotherapy
Hyperthermia and cytotoxic chemotherapy can be applied
in combination to exploit different effects; heat
modification of the drug effect or drug modification of the
heat effect. In either case, the outcome, potentiation or
protection, is to some extent dictated by the sequencing of
the two modalities. Of these possible interactions,
hyperthermic chemopotentiation has been the most investigated
and as a result, several mechanisms of action for the process
have been described. These include increased free drug
level, increased cell uptake, induction of activation enzymes
and inhibition of repair (Dahl, 1986).
In clinical practice, whole body hyperthermia provides a
means of achieving chemo-potentiation in metastatic disease.
The combination of chemotherapy with local or regional
hyperthermia allows for possible therapeutic enhancement of
tumour effect, relative to normal tissues, thus promoting a
therapeutic gain.
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1.3 Heat Delivery in Clinical Practice
Intense technical activity has generated a versatile
range of heating techniques in an attempt to accommodate
diverse clinical situations. Obviously, selection of the most
appropriate method necessitates clinical assessment of the
required treatment volume and physical consideration of the
optimal means of heating the region. Each heat producing
modality has its own physical properties, and every tumour
possesses unique characteristics in terms of size, depth and
local anatomy so that individual methods may have specific
application or limitations in a given setting (Perez, 1983).
The clinical extent of heating is broadly divided into
systemic (whole body), regional or localised hyperthermia.
The methodological options and clinical application will be
considered for each below, and the results, in terms of
tumour and normal tissue effects, will be summarised in the
next section.
1.3.i Whole Body Hyperthermia (WBH)
Currently, there are three main approaches to systemic
heating:
(a) Direct skin contact
(b) Power deposition using externally applied
non-ionising radiations.
(c) Extra-corporeal perfusion
Regardless of technique, 42°C is considered the safe
upper limit of core temperature elevation and is usually
monitored by oesophageal, rectal and bladder thermometers.
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Above 42°C the incidence of toxicity increases sharply and,
depending on the method of heating, a number of side effects
may become evident. Whole body hyperthermia toxicity, along
with other aspects of the biology of systemic heating, has
recently been reviewed (Robins & Neville, 1984).
The narrow temperature range for therapeutic
effectiveness and safety, and the serious side effects
associated with overheating, make the ability to control heat
deposition a major consideration in selecting a technique for
whole body heating. At present, extra corporeal perfusion
seems to offer the greatest potential for rapid and accurate
temperature control (Parks, et al, 1979). In this system,
femoral arterial blood is exteriorised, pumped through a heat
exchanger and returned via the femoral vein. High flow
through-put and freedom from rate-limiting heat transfer
interfaces permit rapid control of temperature.
In contrast, externally applied power-absorption heating
methods employ non-ionising radiation to raise core
temperature. Microwave antennae (Pomp, 1978) and infra-red
lamps (Heckel, 1975) have been used successfully to achieve
systemic heating. Recently, a radiant heat device has been
described (Robins et al, 1985) which allows target
temperatures to be achieved within approximately 60 minutes,
and which avoids the need for general anaesthesia and
endotracheal intubation. Other authors, however, consider
general anaesthesia to be essential to the safety and
efficiency of whole body hyperthermia (Cronau et al, 1984).
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The simplest approach to whole body hyperthermia is
direct contact heating, in which the skin is encased in
heated fluid, such as water, melted wax or air, and
conductive and convective processes then permit heat transfer
into the body. The practical clinical alternatives are hot
wax baths as pioneered by Pettigrew et al (1974), heated
water blankets (Barlogie et al, 1979, Larkin et al, 1977)
and, as an extension of the latter, the space suit
(Bull et al, 1978).
Disseminated malignancies are generally refractory to
conventional therapy. The necessity for an effective
systemic treatment approach in this situation provides a
potential therapeutic role for whole body hyperthermia. With
a safe upper temperature limit of 42°C, this form of heating
is likely to prove more useful when combined with
chemotherapy and/or radiation than when used as a sole agent.
The potential of chemo-thermotherapy has been outlined in
Section 1.2.iii and clinical results will be reviewed in a
following Section (1.4.ii).
1.3.ii Localised and Regional Hyperthermia
Because localised and regional treatments employ the
same heating modalities they will be considered together. In
any case, in current clinical practice the distinction
between the two is rather arbitrary, with the term
"localised" and "regional" usually implying superficial and
deep heating respectively. Ideally, systems should be
sufficiently adaptable to achieve adequate heating throughout
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a treatment volume at any site, regardless of depth within
the body. At present the bulk of clinical information
concerns superficial tumours and reports of deep heating are
sparse.
Current clinical practice relies on two major modalities
for tissue heating; electromagnetic radiation
[radio-frequency (RF) and microwave (MW)] and
ultrasound (US).
(a) Electromagnetic Heating
Radio-frequency and microwave regions of the
electromagnetic spectrum cover frequencies between 300KHz and
300GHz but the clinically useful range is limited to 1MHz to
10GHz, corresponding to wave lengths in air of 1,000M to 1mm.
Electromagnetic energy in this frequency range can be
transmitted through, absorbed by and reflected within the
body tissues. Lower frequencies allow better tissue
penetration whereas higher frequencies facilitate focusing.
In general, the requirements for uniform heating of
deeper-seated tissues are best met by the lower RF frequency.
On the other hand, the enhanced focusing provided by higher
microwave frequency allows better differential heating of
tumour compared with normal tissue. Both radiofrequency and




The attraction of delivering heat interstitially lies in
the potential to improve 'uniformity', and to
selectively deliver high temperatures to tumour.
Radiofreguency and microwave have both been adapted to
provide safe and effective interstitial heating but the
details of application such as material for implantation
and thermometry, geometry and probe spacing differ.
Radiofrequency in the range 0.5 - 1MHz generates
resistive heating by electric currents driven between
pairs of electrodes (Cosset 1984, Cosset et al, 1984,
Emani et al, 1984a, Lilly et al, 1983, Manning et
al, 1982, Vora et al, 1982, Yabumoto & Suyama, 1984).
Acting as electrodes, conventional brachytherapy implant
needles can be made more comfortable for the patient by
incorporating a plastic terminal portion at either end.
Additionally, the "metallic-plastic" probes allow
heating to be confined within the metallic portion so
that, by selection of 'active' lengths, the surrounding
normal tissues can be spared (Cosset et al, 1984).
The alternative is to use radiative diathermy by means
of coaxial microwave antennae which can be inserted into
the plastic catheters commonly used for brachytherapy
implantation (Coughlin et al, 1984, Emami et al, 1984a,
Gidman, et al, 1984, Wong et al, 1984.
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Interstitial hyperthermia is no longer employed as a
sole agent and is mostly used in association with
brachytherapy; "interstitial thermo-radiotherapy".
However, the combination of interstitial heating with
external irradiation (Yabumoto & Suyama, 1984) or with
external and interstitial irradiation is being explored.
(ii) Deep Regional Heating
Interstitial techniques have proved effective for small
to moderate sized (50-250 mis), accessible volumes but
are highly invasive and unsuitable for multifractionated
courses or for treatment of inaccessible, large,
irregular tumours. Recently, the possibility of
overcoming some of the constraints of conventional
interstitial techniques has been proposed by magnetic
induction heating of implanted ferromagnetic seeds
(Lilly et al, 1985, Stauffer et al, 1984). Seeds are
surgically implanted within the treatment volume and
later heated by the magnetic fields created within a
concentric coil positioned around the patient. Once the
seeds are in position, heat can be delivered repeatedly.
Both constant power, and constant temperature seeds have
been evaluated in theoretical and animal studies with
the latter providing better temperature distributions
(Matloubieh et al, 1984).
Several non-invasive electromagnetic deep heating
systems are currently being evaluated, but in general
the long wavelengths, large applicator size and broad
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surface area coverage necessary for adequate penetration
result in unfocused regional heating (Oleson, 1982,
Turner, 1984, Song et al, 1986). Clinically, the
techniques have mainly been evaluated in thoracic,
abdominal and pelvic tumours with, as yet, no convincing
evidence of selective tumour heating (Storm et al, 1985,
Abe et al, 1986, Sapozink et al, 1986).
(iii) Intracavitary heating
Warm saline irrigation provides the simplest technique
for intracavitary heating and lends itself to
intravesical application (Hall et al, 1974). The
concurrent promotion of intravesical chemotherapy, and
the recognition of synergism between heat and radiation,
has made thermal chemotherapeutic intravesical
irrigation a logical union. Unfortunately, clinical
studies have not yet determined whether this is an
effective treatment (Kubota et al, 1984) .
Intracavitary applicators, generally designed to operate
at microwave frequencies, are available for hyperthermia
treatment of hollow viscera and, in the light of
radiotherapy experience, gynaecological malignancies are
an obvious area for their assessment. Consequently,
carcinoma of the uterine cervix supplies much of the
available data, which reports encouraging tumour
responses but proper evaluation of the technique must
follow (Tian et al, 1984, Kohno et al, 1984).
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Endoscopic introduction of radiofrequency and microwave
antennae is an alternative approach for attempted tumour
heating in accessible hollow viscera. The feasibility
of endotract heating has been assessed in a series of
oesophageal tumours and appears to have been well
tolerated (Sugimachi et al, 1984). However, as
intratumoural temperatures were not measured and as
radiation and chemotherapy were given simultaneously
with heat, the authors' conclusion that hyperthermia is
a highly effective treatment for oesophageal cancer is
not justified.
(b) Ultrasound Heating
The capacity of ultrasound to heat tissues is long
established, but its comparability with other heating methods
for the induction of hyperthermia in superficial animal and
human tumours was only demonstrated in the late 1970s
(Marmor & Hahn, 1978). At frequencies of 0.3-lOMHz the
mechanical friction set up by molecular vibrations in tissues
is transformed into heat. At frequencies useful from the
point of view of penetration into tissue, the corresponding
wave lengths permit beam focusing, with the result of greater
deposition of energy at tumour depth compared with overlying
and surrounding normal tissues. This feature endows
ultrasound with a potential advantage over other heating
modalities, but its clinical application is limited by high
absorption in bone, and by the acoustic mismatch at
gas/tissue interfaces (Lele, 1985). The advantages and
disadvantages are summarised in Table 1 and contrasted with
those of electro-magnetic heating.
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1.4 Clinical Achievement with Hyperthermia
As yet there is no conclusive evidence that hyperthermia
has any impact on cancer cure rates. However, this may not
so much reflect the effectiveness of hyperthermia as the
nature of the available clinical material, which in most
experience involves advanced tumours with a high likelihood
of systemic disease. Patient prognosis may also preclude
examination of local control rates and late normal tissue
effects, and necessitate the introduction of other end points
for evaluating hyperthermia. Some, such as symptom
palliation, have clinical use, but biological inferences
cannot be drawn from parameters such as response rate.
Although the advantage of adding hyperthermia to other
treatment modalities has not been established, the unique
properties of this agent warrant optimism. As heat is most
effectively delivered to poorly vascularised regions of
tumour, in which microenvironmental conditions favour
enhanced heat cytotoxicity, hyperthermia should provide a
means of delivering treatment to those areas of tumour which
may harbour radioresistant cells and have poor drug access.
Clinical benefits may result from applying hyperthermia as a
local treatment, systemic agent, or by combining the two
approaches. It is conceivable that tumours resistant to
conventional treatment, such as radiation, have a higher
likelihood of metastatic disease, so that attempts to improve
local control must be accompanied by intensified systemic
treatment for any worthwhile survival effect. However, at
certain sites, such as cervix, ovary, oropharynx and
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colorectum, it has been estimated that improved local
treatment is likely to be more effective than the
introduction of systemic treatment in terms of potential
increase in survival (Suit, 1982).
Survival aside, what has clinical effort established
regarding the optimal utilisation of hyperthermia and its
role in cancer management? Alone, hyperthermia produces
impressive tumour responses, but is an inadequate treatment
and is more likely to make a useful contribution to
management in combination with radiotherapy or chemotherapy
(Meyer, 1984). Further discussion is therefore confined to
hyperthermia in an adjuvant setting.
Phase I studies have established that therapeutically
useful temperatures can safely be achieved locally or
systemically, and in combination with drugs or radiation.
Local heating has mostly involved the external application of
heat to superficial lesions, and in this situation toxicity
has been defined and minimised. Attempts to improve heat
treatment in terms of temperature achieved and uniformity of
dose have also led to the development of interstitial
techniques and intracavitary devices.
1.4.i Results of Localised Hyperthermia Combined With
Radiation
Published results from centres using combined heat and
radiation are difficult to interpret collectively.
Heterogeneous groups of patients, often heavily pre-treated,
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tend to have been given combination treatment in a
non-standardised fashion. However, despite the suboptimal
clinical setting an impressive and consistent increase in
complete response rate, from an average of 30% after
radiation alone to an average of about 70% following combined
heat and radiation, has been demonstrated (Overgaard, 1982).
Although the reported increase in complete response rate is
encouraging, this end-point in itself does not provide
information about the severity of treatment, nor on the
possible advantages of heat and radiation in terms of
survival and local control.
Information on long term response in comparable lesions
after single or combined modality treatment is available in a
limited number of series, and provides an opportunity to
establish thermal enhancement ratios (TER). In experimental
animal tumours, values for TER are derived from ratios of
radiation response giving the same biological effect in the
absence or presence of heat (Robinson et al, 1974).
Construction of dose response curves from clinical data is
difficult, hence TER values have usually been derived from
comparison of tumour responses to the same dose of radiation
with or without tumour heating (Kim et al, 1982,
Archangeli et al, 1983 , Scott et al, 1982) . Patients with
multiple lesions provide an opportunity to assess a range of
radiation dosages in the same tumour, to obtain dose response
information, and calculate Thermal enhancement ratios along
conventional lines (Overgaard & Overgaard, 1984). A TER so
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derived may be considerably smaller than those deduced fro~
comparison of responses (Gillette, 1982).
Thermal enhancement of radiation response is, at worst ,
comparable with the enhancing effect of chemical hypoxic-cell
sensitisers and, at best, is considerably greater (Table 2).
This effect should be accentuated by defining optimum
schedules for combination treatment, in biologically suitable
tumours.
The influence of sequencing of the two modalities has
been demonstrated in animal tumours, where simultaneous
administration achieved a 67-75% cure rate compared with only
20% after sequential treatment (Emami et al, 1984b,
Mittal et al, 1984). The clinical relevance of the
biological rationale proposed in these studies is supported
by the observation of a greater TER in human tumours after
"simultaneous" rather than sequential treatment
(Overgaard & Overgaard. 1984). The pattern of enhancement
was similar in the surrounding skin with a TER of 1.4 after
simultaneous application whereas sequential treatment only
enhanced the tumour response. The study concluded that
although tumour effect was maximal with simultaneous
treatment no therapeutic gain was achieved, whereas the
lesser tumour effect with sequential treatment resulted in a
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sensitising effect of heat can therefore only be utili-
where the tumour is susceptible to selective heating. Any
interval between radiation and heat markedly reduces
hyperthermic radiosensitisation until, by 3-4 hours, true
interaction ceases and direct heat cytotoxicity is solely
responsible for the heat effect. The tumour
micro-environment provides optimal conditions for
hyperthermic cell kill, so that where normal tissue is
included in the heated volume sequential application ensures
a therapeutic gain.
Arcangeli (1983) has compared four different schedules
of combined radiation and hyperthermia, and, on the basis of
these results has emphasised the variation in thermal
enhancement, in tumour and skin, and the therapeutic gain
that can be obtained by modifying the therapeutic protocol.
Although the magnitude of enhancement varied, it was
consistently greater in tumour than normal tissue
irrespective of radiation fraction size or whether
hyperthermia immediately followed irradiation or was delayed
four hours. Comparative hyperthermia studies of this type
are difficult to execute but provide valuable indications of
the relative benefits of different treatment regimes.
However, the derived information does not necessarily
translate to other treatment settings because of the strong
dependence on the heating technique employed and lesion
characteristics. It is particularly dangerous to extrapolate
from results obtained in superficial lesions to the potential
benefit of deep tumour heating.
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Hyperthermic therapeutic advantage is hindered by
inadequate, non-homogenous tumour temperatures, compounded by
poor normal tissue sparing. Since the suggestion that
interstitial techniques might overcome these problems of heat
delivery and localisation, and provide an ideal vehicle for
combination with irradiation, several institutions have
developed and evaluated systems (Vora et al, 1982,
Cossett, 1984, Coughlin et al, 1983). The principles of the
technique are discussed in Section 1.3.
Until now, clinical assessment of interstitial
thermo-radiotherapy has largely been confined to patients
with superficial relapses in previously irradiated areas.
Despite this, the procedure appears to be well tolerated.
Rapid tumour necrosis is reported with the formation of open
wounds, but healing is usually complete (Emami et al, 1984a) .
Occasionally, however, extensive painful necrosis has
occurred (Cosset, 1984).
Evaluation of tumour response from pooled published data
is confined to examination of complete and partial response
rates and there are no studies comparing effect in comparable
lesions treated with brachytherapy alone. A complete
response rate of 65%, from a total response rate of 83%, may
now be a rather conservative estimate of effect since this
encompasses the entire interstitial experience and includes
early, less reliable prototypes (Cosset, 1984). The enormous
variation in radiation and thermal dose between, and within,
series has allowed limited investigation of dose response
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relationships, but supports the influence of both minim'"
tumour temperature and radiation dose on biological effect
(Aristizabel & Oleson, 1984).
At present, interstitial hyperthermia seems to offer
greater uniformity of heating in non-surface lesions than any
other available technique. In combination with interstitial
brachytherapy, which as sole or partial primary treatment
can achieve local control rates of 70-100%, it may be
possible to demonstrate a therapeutic advantage at least in
terms of long-term control rate.
Phase I trials have identified prognostic variable^
which should be incorporated into the design of
Phase II and III protocols (Oleson et al, 1984) . Comparison
of response by histology has not shown any consistent
correlation, although irradiation doses have probably been
chosen to compensate for histological radiosensitivity. The
influence of tumour volume on response to combined treatment,
is conflicting. There is, however, emerging evidence that,
although large volumes are more difficult to treat, they are
more likely to benefit from the addition of heat to radiation
(Kim et al, 1982, Dewhirst et al, 1984) . With external
heating systems, the depth of tumour below the skin surface
is an important variable which effects the ability to heat
tumours and can be translated into poorer response
Perez et al, 1984) . Minimum tumour temperature provides the
best correlation of temperature with response
(Oleson et al, 1984) and confirms earlier or similar
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observations in large animal spontaneous tumours
(Dewhirst et al, 1984).
1.4.ii Results of Whole Body Hyperthermia Combined with
Systemic Chemotherapy (Thermo chemotherapy - TCT)
Phase I and II studies combining WBH with systemic
chemotherapy agents have demonstrated the feasibility of this
approach. However, extracting information regarding tumour
response from these studies is hazardous, but has been
attempted by Engelhardt (Engelhardt et al, 1983,
Engelhardt, 1985) . Of 377 patients treated in 11 centres,
positive effects were described in 147. Little information
is available from the remainder as in many instances the
terms used to describe response were too imprecise for
collective assessment.
Initial studies indicate that whole body hyperthermia
may be particularly promising in tumours with a high growth
fraction such as small cell bronchogenic carcinoma and
high-grade non-Hodgkin's lymphoma. A pilot study in small
cell carcinoma has perpetuated the encouraging climate
(Engelhardt, 1983) and has initiated a randomised trial from
which results are awaited. Interim data suggests that the
addition of WBH has improved response rates and nearly
doubled the median duration of response.
The design of future randomised trials should be
improved by a better understanding of drug-temperature
interaction in individual tumour types. Present information
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on scheduling and the pharmaco-dynamic effects of heat are
inadequate for logical planning of further treatment.
1.4.iii Results of Regional Hyperthermic Chemotherapy
Perfusion
Regional isolated perfusion was introduced in 1957 and
modified in 1967 to incorporate heat (Creech et al, 1958,
Stehlin, 1969) . Its main clinical application has been in
limb perfusion for malignant melanoma and sarcoma, both as an
adjuvant treatment in high-risk patients and in patients with
overt disease. Although more than 3,500 patients have
undergone this procedure there are no controlled studies to
evaluate the technique and the clinical role remains to be
defined.
The contribution of heat to the effects seen with
thermochemotherapy has been indicated in two studies
comparing hyperthermic with normothermic perfusion (Martijn
et al, 1981, Cavaliere et al, 1982) . Both implied improved
results with hyperthermic treatment. No further statement
regarding hyperthermic limb perfusion should be made without
the benefit of randomised studies and fortunately these are
now under way.
1.5 Optimisation of Heat Delivery and Effect
After twenty years of clinical effort it is still no*-
clear what contribution, if any, hyperthermia can make to
cancer management. Continued allocation of resources and
intensification of effort require some degree of confidence
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in the likely advantages of combining heat with radiation or
chemotherapy, in terms of survival, local control and early
and late normal tissue damage. These issues can only be
satisfactorily addressed in Phase III studies.
Unfortunately, current technical limitations of thermometry
and heat delivery make the design and implementation of
stringent protocols unattainable, but the alternative of
imprecise, non-comparable treatments is unsatisfactory
However, while technical developments proceed, it seems valid
to assess what the best heating presently available can
achieve in the standardised clinical setting of a trial,
although it would be inappropriate to attempt to answer
biological questions with such a system. The European
Society for Hyperthermic Oncology (ESHO) is presently
attempting to set up Phase III studies in advanced carcinoma
of the breast, advanced neck nodes and malignant melanoma.
Radiation dose is a critical consideration in the design
of combined modality trials. Anticipating heat potentiation
of normal tissue effects, a reduction in conventional
radiation dose might be considered appropriate. However,
this assumes a uniform biological heat effect throughout the
treated volume, but this is unlikely in the face of
inhomogeneous clinical heating. For example, with most
localised heating devices, temperatures in adjacent normal
tissues, where micrometastases are likely to occur,
infrequently reach temperatures adequate for potentiation of
the radiation effect. Therefore, it is vital that the
inadequacy of the hyperthermic contribution to treatment of
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micrometastatic disease is taken into account when
determining the radiation schedule. In many Phase I trials
of combined hyperthermia and radiation, not only has the
radiation dose been sub-optimal, but, in addition,
unconventional radiation dose/fractionation schemes, with
unproven adjuvant efficacy, have been employed. Future
trials should be designed to combine hyperthermia with the
best conventional radiotherapy.
However it may be that, in combination with heat,
alternative radiation dose/fractionation schedules would be
more effective, at least in certain tumour types. Therefore,
concurrent with Phase III studies employing conventional
radiation practices, these possibilities should be explored
in carefully designed Phase II studies.
There are two major approaches to optimising the heat
effect; technical development and biological manipulation.
1.5.i Technical Developments
An ideal thermometry system would provide continuous
temperature measurement to the nearest 0.1°C, have spacial
resolution of < 1cm. and be well tolerated by patients. A
non-invasive system is the only means of encompassing these
criteria and a number of techniques are currently being
explored for their potential to provide images of thermal
distribution. There are two possible approaches to this;
the first involves the detection of thermal radiation images
from tissue, but is limited to superficial situations, and
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the second concerns the measurement of heat-sensitive tissue
properties. At present, the latter is the main focus of
investigation in deep tumour thermometry. Ultrasound
(Husson et al, 1982) , nuclear magnetic resonance
(Parker et al, 1983, Parker, 1984) and computerised
transaxial tomography (Fallone et al, 1982, Cetas, 1984) are
all interesting possibilities which require further
evaluation to ensure that they can provide the necessary
accuracy and spacial resolution and that they are compatible,
in terms of synchronous function, with the commonly used
heating methods. The practical problem of simultaneously
employing the bulky equipment required both for heat delivery
and temperature measurement can only really be overcome in
specially designed dual-function machinery.
The invasive nature of current thermometry systems
severely limits the number of measurement points available
during heat delivery. However, description of temperature
distribution throughout a region of interest has been
attempted by interpretation of information available from
implanted thermometry probes. Thus, thermal modelling relies
on applicator power deposition pattern and tissue
characteristics to infer an entire treatment volume
temperature based on measurement at only a few points.
Present models make many assumptions, and the availability of
an accurate technique for measuring tissue perfusion would
make a major contribution to improving the validity of these
analytical methods.
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The ability to measure tumour blood flow would offer
additional advantages. Firstly, it would allow the selection
of tumours according to their potential 'heatability', and
secondly it would provode a means of assessing the effect of
vasoactive drugs aimed at decreasing tumour blood flow in an
attempt to further facilitate selective tumour heating.
1.5.ii Biological Manipulation
The sequence of critical cellular events involved in
heat killing, heat radiosensitisation, heat chemopotentiation
and thermal tolerance need to be determined, and points of
reversibility and irreversibility defined. This would allow
identification of targets most likely to enhance the heat
effect in tumour or to diminish normal tissue response. The
possibility of selective modification of events within tumour
promises a potential therapeutic gain.
The strong influence of microenvironmental conditions
heat cell toxicity offers an opportunity for altering the
effectiveness of hyperthermia by manipulation of the
internal milieu. Accordingly, attemots to lower
intratumoural PH have been pursued by, for example, the
infusion of glucose (Jahde & Rajewsky, 1982a). The
relationship between serum glucose concentration and
intratumoural PH was carefully examined with the finding that
intratumoural PH could be reduced from about 6.9 to 6.2 by
maintaining the serum glucose concentration at 50 mM. More
intriguing was the finding of a reduced cell survival in
tumours heated to 42.2°C for one hour after attaining a serum
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glucose concentration of 50 mM (Jahde & Rajewsky, 1982b) .
The greatly enhanced thermotoxicity of some chemotherapeutic
agents, such as BCNU, in the presence of low PH further
supports the notion that efforts to reduce PH in human
tumours may be a worthwhile manoeuvre.
Selective reduction of tumour blood flow should provide
improved tumour heating and induce those micro-environmental
conditions most favourable to cytotoxicity. Experimental
work in animal tumours suggests that a significant fall in
tumour blood flow can be achieved by a number of
pharmacological manoeuvres, and this is discussed in
Chapter 2. As yet there is no clinical data supporting the
feasibility or usefulness of this approach.
The biological implications of thermotolerance in
clinical heating have not yet been determined. Although
thermotolerance in tumour cells may diminish the anticipated
cytotoxic effect of subsequent heat treatments, its
development in normal tissue may be protective and provide a
means of augmenting the therapeutic efficacy of localised
hyperthermia. So far it has not been possible to identify
exploitable differences in the process of thermotolerance in
tumour and normal tissue, and until the mechanism is better
understood it is probably best to avoid thermotolerance
altogether by allowing sufficient time between heat fractions
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2.1. Introduction - The Clinical Implication of Tumour Blood
Flow
Sustained growth of a solid tumour requires provision of
a tumour microcirculation. The necessity for this renders a
tumour potentially vulnerable and has raised the possibility
of targeting treatment towards the tumour neovasculature
(Denekamp, 1982). Alternatively, there are sound theoretical
reasons why tumour blood flow may be responsible for
decreased effectiveness of established treatments. For
example, with radiotherapy, chemotherapy and hyperthermia,
the disorganised aberrant tumour vasculature, with its
consequent metabolic heterogeneity, probably plays a central
role in determining treatment failure. Thus, hypoxic tumour
regions harbour cells which enjoy a degree of protection from
radiation injury (Thomlinson & Gray, 1955) and similarly,
nutritionally deprived cells exhibit resistance to cycle
specific chemotherapy agents (Twentyman, 1976, Valeriote &
van Putten, 1975) . The distribution of systemic agents
between tumour and normal tissue depends on the relative
vascular perfusions. Variable blood flow within a tumour
makes drug access unreliable in necrotic, poorly nourished,
areas (Goldacre & Sylven, 1962) . With hyperthermia the
inhomogeneity of tumour blood flow makes it difficult to
achieve uniform heating within a treatment volume
(Gullino et al, 1982).
It would therefore seem reasonable to suggest that
harnessing tumour blood flow might either increase the
efficacy of existing treatments or provide a novel means of
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destroying tumours. Thus, selective manipulation of tumour
blood flow should enable optimal conditions to be provided
for application of different treatment modalities.
Additionally, tumour:normal tissue differentials could be
exaggerated to exploit a therapeutic gain. Alternatively,
inhibiting angiogenesis or destroying existing tumour vessels
is an intriguing approach to tumour therapy.
2.2 Angiogenesis
The provision of optimal conditions for tumour cell
proliferation requires an intimate relationship between
individual tumour cells and their nutritive capillaries.
Correlation between tumour cell proliferation rate and
capillary proximity has been demonstrated using tritiated
thymidine to calculate a labelling index (Tannock, 1968). At
increasing distance from open capillaries, a decrease in the
labelling index of malignant cells was demonstrated.
Initiating and sustaining angiogenesis is therefore a
critical tumour process, but is not unique to malignant
tissue. Neovascularisation accompanies wound healing,
chronic inflammatory conditions (Fromer & Klintworth, 1975)
and certain immune reactions (Sidky & Auerbach, 1975).
Inflammatory cells, such as activated macrophages and
lymphocytes, have strong angiogenic activity and presumably
play a prominent role in these conditions. From study of
experimental systems, the difference between angiogenesis
induced by tumour and non-tumour tissues seems to be
quantitative rather than qualitative.
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Neoplastic cells acquire, or reveal, angiogenic activity-
early in the process of transformation from the normal cell
state, before the morphological stigmata of neoplasia become
evident (Gimbrone & Gullino, 1976a & b) . In mouse and rat
mammary gland, the frequency with which hyperplastic lesions
undergo neoplastic transformation can be predicted from their
angiogenic capacity (Maiorana & Gullino, 1978). Similarly,
hyperplastic lesions of human breast display angiogenic
activity before the onset of histological malignancy (Brem et
al, 1978; Chodak et al, 1980).
Humoral mediators of angiogenesis have long been
suspected (Ide et al, 1939) , but detection of soluble
angiogenic factors in animal and human tumour homogenates is
more recent (Folkman et al, 1971) . The active agent in these
crude angiogenic tumour extracts has been termed "tumour
angiogenesis factor" or TAF, although the precise structure
had not been identified. A chondrosarcoma-derived growth
factor which stimulates capillary endothelial cell migration
and proliferation has now been purified and its activity
in vivo confirmed (Shing et al, 1984 and 1985) .
The sequence of events involved in angiogenesis has been
reconstructed from light microscopic observations
(Clark & Clark, 1939; Warren & Shubik, 1966) and confirmed
by electron microscopic studies (Warren et al, 1972). The
literature is rich in detailed descriptions of the minutiae
of the process (Schor & Schor, 1983; Folkman 1974). Briefly,
new vessels arise from pre-existing, but altered, "host"
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vessels in which endothelial proliferation produces buds
which emerge as capillary sprouts. These generally advance
along the course of least resistance, although tumour type
has some influence on the architectural arrangement of the
new vascular network (Goodall et al, 1965; Hirano &
Zimmerman, 1972) . Anastomoses between adjacent capillary
sprouts create capillary loops.
Once neovascularisation has been established it must be
maintained and updated so that in fact the capillary network
is a dynamic system constantly undergoing remodelling,
retraction and degeneration. To achieve this, endothelial
turnover must be rapid and proliferation rates of 30-40 times
those seen in normal vessels have been described in
experimental tumours by Denekamp & Hobson (1982).
2.3 Morphology and Architecture of Tumour Neovasculature
A morphological classification of tumour vessel types is
given in Table 3. The capillary is of fundamental interest
being the nutritive structure which dictates the availability
and exchange of nutrients, metabolites and chemical
substances. Because of their rapid construction, tumour
vessels often represent immature vascular channels, devoid of
an external basement membrane and lined by a single layer of
epithelial cells. In parts, cords of tumour cells may
entirely constitute the vessel wall (Willis, 1960). Random
fusion between capillary sprouts produces a tortuous
capillary network conducive to sluggish blood flow which is
further impeded by dilatations and sacculations within the
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vessel walls. Episodes of complete stasis have been observed
in an experimental tumour system, making it likely that flow,
at least in some regions of tumour, is not only inefficient
but also intermittent (Reinhold, 1971, Suzuki et al, 1982).
TABLE 3
MORPHOLOGICAL CLASSIFICATION OF BLOOD
VESSELS FOUND WITHIN TUMOTJR
Arteries and arterioles
Capillaries with basement membrane
Capillary sprouts
Sinusoidal vessels - interrupted endothelial lining
Blood channels without endothelial lining
Giant capillaries
Capillaries with fenestrated endothelium
Venules and veins
Arterio - venous anastomoses
Expansion of the neovasculature occurs concurrently, but
not necessarily equally, with tumour growth so that the
delicate vessels become distorted, elongated and compressed
by rising extravascular pressure. If this process leads to
complete cessation of flow, necrosis follows in the area of
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supply. Simultaneous construction and obliteration of tumour
vessels enforces inhomogeneity of tumour blood flow.
Newly formed tumour vessels appear to be defective in
both adrenergic innervation and contractile smooth muscle
elements (Hafstrom et al, 1980; Mattsson et al, 1979).
Gullino and Grantham (1961a) demonstrated vascular reactivity
after intratumoural injection of adrenalin and suggested that
normal host vessels incorporated within the mass might be
responsible. Certainly, normal arteries and arterioles seem
to be highly resistant to neoplastic invasion and can be
traced through densely infiltrating tumour in which the
normal architecture has been completely destroyed
(Willis, 1973) . Some tumours, such as lymphoma, rely on
co-opting existing vessels to supply much of their
nutritional demands (Denekamp & Hobson, 1982). Persistence
of these vessels may provide some tumour vasomotor activity,
but this will be compromised by stretching and elongation of
the incorporated vessels as the tumour mass expands.
Vascular morphology varies between tumours of different
histology, the same histology and between different regions
of the same tumour. Progressive tumour size, or age, enhances
this diversity. In small tumours a haphazardly organised
fine capillary bed intermingles with unchanged incorporated
normal vessels with intact vessel innervation. Subsequent
tumour growth causes distortion and disruption, with
occlusion of fine wall capillaries and functional alteration
of the more robust normal vasculature. The inhomogeneity
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seen in the early stages of tumour formation becomes
exaggerated with tumour progression.
2.4 Functional Properties of Tumour Neovasculature
Vascular reactivity relies on two parameters; vessel
innervation and the presence of contractile elements, and
both are defective in tumour vessels. Pharmacoangiography,
using vasoconstrictive drugs to visualise tumour vessels
against a background of constricted normal vasculature,
proffers functional evidence of contractile inadequacy
(Ekelund, 1979). However, the inclusion of innervated normal
vessels may provide some vascular reactivity, and a number of
experimental animal studies suggest even an increased
sensitivity to vasoconstricting drugs in the vascular bed of
the tumour compared to normal tissue. The hypoxic tumour
environment could be responsible for this.
If incorporated normal vessels are the main contributors
to tumour reactivity, then the characteristics of the host
tissue vasculature should determine the qualitative and
quantitative response observed. However, this is probably
not a static contribution because of the effect of tumour
expansion on incorporated vessels (see 2.3). Consequently it
is impossible to predict the overall influence that this will
exert on tumour blood flow. These features may help to
explain some of the conflicting reports regarding the effect
of vasoactive, and other, stimuli on tumour blood flow
(see section 5).
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2.5 Measurement Of Tumour Blood Flow
2.5.i Concepts of Flow
Morphological assessment of tumour vascularity is a poor
reflection of functional blood flow. An extravagant
production of capillaries in the stroma of carcinomata,
resulting in an increased capillary density per unit volume
of tumour compared with normal tissue, does not necessarily
equate with a greater tumour blood flow. Functional, rather
than morphological, techniques are necessary to derive blood
flow measurement per unit volume of tissue, and such methods
have only become available relatively recently
(Gullino & Grantham, 1961b). There are now a number of
different approaches to tumour blood flow measurement in
animals but it is important to recognise that direct
comparison between techniques may be inappropriate. For
example, the precise aspect of flow being measured by a given
technique must be established. Venous outflow techniques
measure total volume blood flow, a term which describes total
blood throughput irrespective of the contribution of
different types of transmitting vessels. Concealed within
this parameter is capillary flow or perfusion, but the
technique cannot detect what proportion of total tumour flow
is available for this vital function. In addition, regional
inhomogeneity of flow within a tumour mass cannot be
appreciated by this 'blanket' approach. More relevant to
tumour biology and therapy is nutritional flow, or tissue
perfusion, which describes accessibility of capillary blood
and constituents to tumour cells. A number of techniques
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claim to measure this parameter but there are pitfalls which
must be recognised and will be outlined in the section below.
2.5.ii Flow Measurement Techniques
Tumour blood flow can now be measured in animals by a
variety of techniques (Table 4). The published data is
difficult to interpret collectively because direct comparison
requires a common absolute unit of blood flow, usually
mis./min./100g. of tissue, and results in the literature are
frequently expressed as ratios of tumour to normal tissue
flow or as fractional proportion of cardiac output per/gm. of
tissue. Technical, tumour and host variables further deter
unification and have prevented the emergence of recognised
patterns of tumour flow, or of predictable changes in flow
induced by chemical and physical agents.
Whether or not animal data makes a useful contribution
to our understanding of tumour blood flow in a clinical
setting is not clear. A tumour arising spontaneously, within
the appropriate normal tissue, is a different biological
system from that produced by the implantation of experimental
tumour into accessible normal tissue. Furthermore, the two
tumour systems have very different cellular kinetics with
animal tumours often doubling in volume over hours or days,
whereas for human tumours doubling over a period of months is
not uncommon. Expansion of the vascular component of a
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tumour must emulate parenchymal growth. The preponderance of
primitive vessels in experimental tumours is in keeping with
rapid vascularisation. A high endothelial labelling index in
the order of 30-40 times of that of normal endothelium, in
experimental animal tumours confirms the intense vascular
effort necessary to maintain tumour growth. Human tumour
vasculature often expresses features of maturation, but
endothelium labelling index is unknown with mention of only
one report in the literature (Denekamp & Hobson, 1982) .
Observations on the vasculature of human tumours xenografts
are not necessarily applicable to tumours in man as the
stroma is of host origin (Giovanella & Fogh, 1978).
Table 4 describes the most commonly used flow measuring
techniques with respect to method, parameter measured and
clinical application. The relative advantages and
disadvantages, are outlined below.
(a) Venous Outflow
Quantification of tumour circulation was engineered by
Gullino & Grantham using "tissue-isolated" tumours
(Gullino & Grantham, 1961b). Organs, such as ovary and
kidney which can be isolated with respect to blood
supply are implanted with tumour which, if growth is
successful, eventually replaces normal tissue providing
a completely encapsulated tumour preparation for
circulatory studies. By catheterisation of the exiting
vein, venous outflow can be recorded and total volume
blood flow measured. It is not possible from the
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derived value to discriminate between nutritional and
shunted blood.
(b) Tumour Uptake Techniques
The proportional distribution of cardiac output to
different tissues reflects local tissue blood flow.
This principle forms the basis of a variety of
techniques in which a tracer substance is introduced
into the systemic circulation and is distributed to
tumour and normal tissues. Detection of proportional
tracer uptake provides a measure of tumour blood flow.
Radioactive microspheres were first used to measure
tumour blood flow by Rudolph & Heymann (1967) and have
now been extensively applied to the problem. The method
involves injection of microspheres into the left
ventricle of the heart to ensure good mixing.
Peripheral trapping must be complete and irreversible
otherwise recirculation distorts distribution. In
normal capillaries 15 Mm microspheres are virtually 100%
trapped (Archie et al, 1973) and those that bypass the
microcirculation, by way of arteriovenous shunts, become
lodged in the primary capillary bed prohibiting
recirculation (Kaihara et al, 1968). Aberrant tumour
vessels with a greater variability of size are likely to
lead to errors unless a combination of different size
spheres is used. Another drawback to the method is that
in areas of low flow the number of microspheres trapped
may be too few for statistical significance (Buckberg et
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al, 1971). Further, the method requires sacrifice of
the animal, and excision of the tissues of interest,
making it unsuitable for human application. It has,
however, proved a useful technique in animal studies
allowing repeated measurement in the same tissue by
using microspheres labelled with different isotopes, and
providing an absolute value for flow provided the
cardiac output can be calculated (Peterson, 1979).
Adaptation of the technique for clinical tumour blood
flow measurement now seems a possibility as a technique
using bio-degradable human albumen microspheres, with
external quantification of activity, has recently been
devised for estimating the fractional distribution of
cardiac output to organs in non cancer patients.
Intravenously injected radioactive tracers such as
Rubidium 86, Carbon 14, Iodine 131-anti pyrene are
similarly allocated to tumour and normal tissues
according to the proportional distribution of cardiac
output (Sapirstein, 1948) . In this case the tracer
substances are effectively trapped by peripheral
cellular extraction, and following sacrifice of the
animal radioactivity can be measured in the appropriate
tissues. Similar in many ways to the microsphere
technique, it is simpler in practice because good mixing
of the tracer in the right and left ventricle after
intravenous injection eliminates the need for left
ventricular catheterisation. This makes it a suitable
technique for use in small animals such as the mouse.
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Although Rubidium and potassium do not cross the blood
brain barrier, Iodine 131-anti pyrene, being lipophilic,
does and can therefore be used to measure brain blood
flow.
(c) Tumour Clearance Techniques
An alternative approach is to deliver a chemical or
physical agent to tumour and use the rate of its
clearance as a measure of blood flow. A number of
85 133radioactive isotopes such as Kryton and Xenon ,
have been employed in this way (Kety, 1951) . For
133
example, Xenon is an extremely lipophilic gamma
emitting (0.081 MeV) radioactive gas, which readily
disperses throughout tissue compartments and passes
through the alveolar membrane of the lungs. Rapid
133
excretion of Xenon via the lungs results in
n-eg'ligible activity in the recirculating blood which is
redistributed according to cardiac output. Following
133
intra-tumoural injection, Xenon diffuses rapidly and
is considered to be in diffusion equilibrium with the
tissue and therefore with the blood passing through it.
The rate of clearance of the isotope will depend both on
the rate of blood flow, and on the partition coefficient
(Lambda) of the isotope between blood and tissue. As
the partition coefficient is influenced by the
proportional lipid content of the tissue, biopsy is
required for accurate measurement in any individual
tissue (Kallman et al, 1972). However, the
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impracticality of this in clinical studies usually
results in the use of a standard coefficient. The
133
technique is attractive because Xenon washouts from
the tumour can be monitored externally making this a
technique appropriate for clinical studies (Mantyla et
al, 1982, Olch et al, 1983a).
Measurement of blood flow by thermal clearance relies on
the principle that temperature decay after a transient
or prolonged thermal perturbation is a function of
convected heat transfer by blood flow within the tissue.
The technique was originally developed by Gibbs (1933)
and has been widely applied to physiological studies
(for review see Eberhart et al, 1980) . The technique
usually involves implantation of a probe with both
heating and thermometry functions, but a number of
variations have been described. For example,
Johnson (1976) applied external heat sinks and sources
to superficial tumours in order to document thermal flux
as a representation of blood flow change in underlying
tissue. Although flow changes were detected with this
method following 4 Gy irradiation, the sensitivity and
reproducibility of the technique was not described.
The physical parameters associated with localised
hyperthermia have also been considered to give an
estimate of perfusion in the heated tissue (Roemer et
al, 1985) . The interpretive difficulties inherent in
applying simple mathematical models, such as the
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"bio-heat" transfer equation (Eberhart et al, 1980), to
derive absolute flow values are encountered in either
approach. Heat-induced vasoactive changes are a further
problem with this technique and it is therefore
essential to minimise thermal perturbations. This
imposes exacting constraints on the temperature
resolution and stability of the thermometry and heating
systems.
Other Flow Measuring Techniques
In theory, both uptake and clearance techniques provide
a measure of tumour perfusion, but neither has adequate
resolution to examine events at the level of individual
capillaries. The heterogeneity of tumour vasculature
makes it important to have this information available
when investigating the distribution of drugs, oxygen and
heat in neoplastic tissues. In experimental animals,
transparent chambers allow direct, continuous
observations of individual tumour capillaries in vivo,
but tumour growth is restricted to a sheet-like,
2-dimensional, structure which imposes limitations on
the system when examining physiological responses
(Algire 1952, Clark, 1952). Nevertheless, the setup has
provided quantitative and qualitative information
regarding vascular development (Reinhold, 1979). Flow
calculation using this system involves measurement of
red cell velocity, by a dual slit photomatic technique,
and calculation of vessel diameter, using an image
shearing monitor. Serial measurement can be made over a
period of days and the effects of pharmacological agents
or heat monitored (Dudar & Jain, 1984).
Doppler ultrasound provides an alternative approach to
estimating flow in individual vessels. Provided the
vessel diameter is known, flow can be calculated from
the ultrasound measurement of red cell velocity
profiles. A criticism of any method incorporating
vessel diameter is that this is not a static parameter
and a single observation is not representative.
2.6 Intrinsic Factors Affecting Tumour Blood Flow
2.6.i Tumour Type
The variation in human tumour growth rate can broadly be
categorised according to histological type. For example,
Burkitt's lymphoma is a rapidly growing tumour which can
double in volume in less than 40 hours (Iversen et al, 1974),
whereas primary colo-rectal lesions are often slow growing
with doubling times in the order of 63 2d. In order to
sustain the energetic growth of Burkitt's lymphoma the tumour
vascular kinetics, morphology and architecture are likely to
differ from that seen in the slower growing tumour. It is,
therefore, not surprising that the measured blood flow from
different tumour types is correspondingly diverse. Raczka et
al, (1983) observed tumour growth and blood flow in two
experimental tumours, the Lewis lung carcinoma and the
JW sarcoma, over a two week period. Initially, the flow was
greater in the Lewis lung carcinoma than in the sarcoma, but
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by 11-14 days post transplantation the situation had
reversed, with the sarcoma flow unchanged, but that in the
carcinoma having decreased by 50%. Histological examination
of the tumours showed necrosis in the Lewis lung carcinoma
whereas none was observed in the sarcoma. Raczka inferred
that the tendency to develop necrosis may influence blood
flow.
Techniques such as Rubidium 86 and radio-labelled
microspheres, which can estimate blood flow in different
regions of tumour, allow for separate identification of flow
within central and peripheral areas. In most tumours
necrosis occur centrally whereas peripheral tissue is
composed of viable, proliferating cells. Using these
techniques, perfusion appears to be greater at the periphery,
compared with the centre (Young et al, 1979; Groothuis et
al, 1983). Techniques which sum these component areas give a
flow value which to some extent reflects the degree of
necrosis present. When comparison of vascular volume in
different tumours is confined to viable areas, there seems to
be remarkable consistency (Jirtle & Clifton, 1971). Despite
this report, Vaupel (1973) observed significant inhomogeneity
of blood flow when sampling at a number of peripheral sites
within the same tumour. This inconsistency may be a
reflection of the tumour type studied and of the technique
employed.
The degree of tumour differentiation, as judged
histologically, is an indicator of cell kinetics and has been
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used by Allen et al (1975) to look at blood flow in relation
to cellular activity. In this study ENU induced rat tumours,
of well differentiated and anaplastic histologies, were grown
to an equivalent size. Blood flow in the well-differentiated
tumours was greater than that in their anaplastic
counterparts. Mantyla (1979a) supports this finding in his
study of superficial human metastasis using Xenon 133 to
measure blood flow. Well differentiated tumours had higher
flow values compared with anaplastic carcinomas, although the
highest flows of all were seen in a group of lymphomas.
In summary, it seems most likely that tumour perfusion
is dependent on tumour type. The exact tumour
characteristics which dictate this spread of values have been
studied in animal tumours, and to a much more limited extent
in a clinical setting. The intimate relationship of tumour
features such as cell-proliferation rate, tumour doubling
time, cell loss and tumour necrosis makes it difficult to
implicate any one component, or to quantitate its influence.
The following sections (2.6.ii and 2.6.iii) emphasise the
interdependence of these gross tumour features.
2.6.ii Primary and Metastatic Tumour
In experimental and clinical studies metastases respond
better to chemotherapy than do the primary tumours from which
they are derived (Steel & Adams, 1975; Laster et al, 1969) .
Differential drug access may account for this disparity as
Houghton suggested by demonstrating a significantly greater
uptake of cyclophosphamide in pulmonary metastases compared
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with primary tumour (Houghton et al, 1976). A greater
proportion of necrotic tissue in large primaries could
account for this difference, but Donelli found a higher
concentration of adriamycin in metastatic tumours compared
with primary growths when only viable regions were compared
(Donelli et al, 1977). Possibly the microvasculature of
metastases is 'superior' to that of primary tumours, allowing
not only better drug delivery but also greater tumour cell
proliferation thus providing a favourable environment for
enhanced chemosensitivity (Hill & Stanley, 1975). These
studies only indirectly reflect blood flow, through
information on drug delivery and distribution. Direct
measurement however confirms higher blood flow values in
metastatic lesions compared with primary disease (Raczka et
al, 1983) .
2.6.iii Tumour Size
As tumours increase in size their relative vascular
volume and blood flow decreases (Gullino & Grantham, 1961a,
Vaupel, 1977). Necrosis has been implicated in this trend
because of its close correlation both with tumour size and
blood flow (Edlich et al, 1969, Cataland et al, 1962, Jirtle
et al, 1978) . Vascular surface area also decreases with
increasing tumour size, but this precedes the fall in
vascular volume and is in keeping with the observation that
it is the smallest vessels that are compromised first
(Yamaura & Sato, 1974). Increasing intratumoural pressure,
with increasing tumour mass, could be responsible for
compression of these thin walled fragile vessels.
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Additionally, endothelial cell proliferation may become
retarded as tumours enlarge (Tannock, 1970). The outcome is
the development of necrotic areas transected by vascular
spaces containing blood which does not exchange with general
circulation and is effectively stagnant (Tannock &
Steel, 1969). Alternatively, transmitting vessels may shunt
blood through tumour substance without allowing it to
contribute to tumour nutrition. Increased shunting may be a
feature of enlarging tumours; Weiss has estimated that at
least 40% of blood flow into rats tumours was delivered to
shunting vessels (Weiss et al, 1979).
2 . 6.iv Tumour Site
Alteration of tumour perfusion by manipulation of the
surrounding normal vasculature, suggests that the tissue in
which a tumour arises, or is implanted, and its vascular
characteristics will influence tumour perfusion. However,
the majority of studies investigating the effect of tumour
site on blood flow do not confirm that this is the case.
Edlich et al, (1969), Tveit et al, (1984) and Suzuki et
al, (1979) examined a number of anatomical locations
including intrahepatic, sub-renal capsule, intramuscular,
renal and gastrointestinal and were unable to demonstrate
dependence on tumour site. To the contrary, Young has
reported variation in blood flow according to tumour site.
Using a microsphere technique and comparing only viable
tumour areas, it was observed that high blood flow organs
bore high blood flow tumours (Young et al, 1979).
67
2.6.v Systemic Blood Pressure
In experimental tumours, blood flow can be very
sensitive to changes in systemic blood pressure (Algire et
al, 1954; Vaupel, 1975). Suzuki has induced escalating
hypertension in rats given Angiotensin II (Suzuki et
al, 1981). Thermoelectric and hydrogen clearance techniques
showed that while blood flow remained unchanged in normal
tissue up to a mean arteriole pressure of 150mm of mercury,
an average 6.5 fold increase in flow was seen in tumours.
The findings were reproducible in tumour transplanted to a
variety of organs, and also in induced primary tumours. The
important inference is that by manipulating systemic blood
pressure, selective and specific enhancement of tumour blood
flow is possible. The therapeutic potential of this is
discussed later.
2.7 Extrinsic Factors Influencing Tumour Blood Flow
2.7.i Pharmacological Manipulation of Tumour Blood Flow
a. The Potential
Conventional anti-cancer treatment could theoretically
be improved by coincidental manipulation of tumour blood
flow. Increased tumour perfusion should permit better
drug access and distribution, and provide an improved
tumour micro-environment, particularly with respect to
oxygenation, with consequent sensitisation to radiation
and chemotherapy. With hyperthermia, higher
temperatures are achieved in regions of poor tumour
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perfusion which also provide an environment which
enhances heat cytotoxicity. Selective manipulation of
tumour blood flow, with flow to normal tissues remaining
unaffected or altered in the opposite direction, allows
the possibility of exploiting a tumour/normal tissue
differential. Augmented anti-tumour activity coincident
with diminished normal tissue toxicity constitutes a
therapeutic gain and an increased likelihood of
treatment success.
b. The Basis of a Therapeutic Gain
Structural and functional differences between normal
tissue and tumour vasculature make selective alteration
of tumour blood flow feasible. Vessel reactivity relies
on two parameters; the presence of tumour vessel
innervation and the presence of contractile elements.
Morphologically tumour vessels appear to be defective in
both (Hafstrom et al, 1980, Mattsson et al, 1979) and
pharmacoangiography, in which vasoconstrictive drugs aid
the visualisation of tumour vessels against a background
of constricted normal vasculative (Ekelund, 1979)
proffers functional evidence of contractile inadequacy.
That some tumours do show reactivity, however, has been
demonstrated and attributed to the incorporation of
preformed normal tissue vessels
(Gullino & Grantham, 1961a).
Vasoactive drugs influence local normal tissue capillary
flow by constricting or dilating feeder arteries and
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arterioles. The tumour vascular bed, effectively lying
in parallel with the normal tissue capillary network,
will necessarily be influenced by events in the latter.
For example a vasodilator causing smooth muscle
relaxation in the host vasculature, and consequent
increased blood flow, may diminish flow in the less
reactive tumour compartment on the basis of a "steel
phenomenon" (Kruuv, 1967) . Indirect means of adjusting
tumour flow by vasomotor agents are being investigated
in animal and clinical studies.
An alternative approach is to directly target drugs on
tumour vessels by exploiting any deviant
characteristics. For example, an unusual sensitivity to
circulating amines has been suggested by measurement of
oxygen tension in tumour and muscles following
administration of 5-Hydroxytryptamine (Cater et
al, 1966) . On the basis of this data Knapp et al,
(1985) measured blood flow changes in tumour and normal
tissues following intraperitoneal injection of
5-Hydroxytryptamine in rats. Tumour blood flow
decreased by 79±29% accompanied by a decreased muscle
blood flow of only 14±4.8%. The decreased likelihood of
systemic effects make agents acting primarily at the
tumour site an attractive therapeutic proposition.
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c. Experimental Studies
Most experimental studies have attempted to manipulate
tumour blood flow indirectly, by affecting the
surrounding normal tissue vasculature. Less commonly,
drugs directed at the intratumoural vessels have been
employed to induce tumour flow changes, on the basis
that tumours possess some vasoactivity (Cater et
al, 1962, Rankin & Phernetton, 1976, Jirtle et al, 1978,
Young et al, 1979, Tveit et al, 1981) . On the other
hand Mattsson, using xenon clearance to measure blood
flow, combined a vasoactive agent with intratumorally
injected xenon and demonstrated less reactivity in
tumour vessels compared with their normal tissue
counterparts (Mattsson et al, 1982). Other observers
agree with these findings (Tvete et al, 1981, Wickersham
et al, 1977) .
In essence, tumour vessel reactivity greater than, equal
to and less than that of normal vessels has been
reported. Since the microvasculature of the tumour and
that of the surrounding normal tissue are critical
determinants of the outcome of vasoactive stimulation
these conflicting results in experimental systems
encompassing technical, as well as biological and
pharmacological, variables are not surprising.
The importance of histological tumour type in
determining vascular reactivity has been proposed
(Rockoff, 1966) but is counterbalanced by observations
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of flow changes of similar direction and magnitude in
tumours of different morphology and growth kinetics
(Knapp et al, 1985) . The influence of tumour
vasculature on tumour reactivity has been elegantly
demonstrated using two experimental tumours derived from
the same squamous cell carcinoma which diversified with
respect to microscopic vascular pattern (Chan et
al, 1984) . In this study tumours were designated as
either "hard" or "soft", the former tumour showing a
distribution of vessel size in keeping with normal
tissue and containing a proportion of large vessels with
wall thickness greater than 7 microns, whereas "soft"
tumours displayed an abnormal distribution of vessels
and a striking paucity of large channels. Two drugs,
phenylephrine, a vasoconstrictor, and hydralazine, a
vasodilator, were given intravenously and changes in
tumour and normal tissue flow monitored using a
radioactive microsphere technique. In both tumours
phenylephrine decreased and hydralazine increased normal
tissue perfusion, but tumour blood flow was only
significantly altered in "hard" tumours exposed to
phenylephrine where a fall in flow was produced. Chan
concluded that the virtual absence of smooth muscle in
"soft" tumour, due to a predominance of small vessels,
produced a quantitatively different response compared
with "hard" tumours. The presence of vascular smooth
muscle in "hard" tumour was supported by their ability
to respond to phenylephrine.
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Since tumour blood flow is influenced by systemic
arterial pressure, manipulation of the former could be
achieved by alteration of the latter. Suzuki's work
with angiotensin II in rats suggests this may be a
realistic approach (Suzuki et al, 1981) . The potential
of this system has been further explored by combining
angiotensin with chemotherapy in solid transplanted
tumours in rats. Fig. 2 shows the effect of Mitomycin C
alone or in combination with angiotensin II on tumour
diameter. The conclusion drawn was that
angiotensin-induced increase in tumour blood flow could
be usefully employed in combination with chemotherapy to
enhance the biological effect (Suzuki et al, 1981) .
Figure 2
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The potent vasodilator activity of calcium antagonists
has been directed at tumour blood flow. The results
obtained to date are as confusing and conflicting as any
others concerned with tumour perfusion, but this may not
be surprising (Knapp et al, 1985). The use of different
calcium antagonists with different pharmacological
properties makes it likely that in different systems,
using different dosages, different effects will
predominate. However, with the described effects
ranging from an approximate 50% increase in tumour blood
flow with Verapamil (Kaelin et al, 1982) to a 63±8%
decrease in flow following Nisoldipine, it is difficult
to make any predictions as to their usefulness in a
clinical setting.
2.7.ii Physical Agents Affecting Tumour Blood Flow
a. Ionising Radiation
In experimental solid tumours the radioresistant hypoxic
cell population varies but is commonly in the order of
10-20% (Denekamp, 1983) . Following irradiation improved
tumour oxygenation is reflected by a fall in the
proportion of hypoxic cells, which may be a consequence
of increased blood flow (Thomlinson 1968, Van Putten &
Kallman, 1968 , Du Sault 1969) . There is no comparable
data on hypoxic cells in human tumours but evidence of
reoxygenation following irradiation, for example in
cervical and breast tumours, supports the parallel
(Bergsjo & Evans 1968 , Evans & Naylor 1963) . However,
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in addition to improved oxygen supply diminished tissue
metabolism may contribute to post irradiation
reoxygenation (Thomlinson, 1968).
Radiation-induced vascular changes in mouse mammary
tumours have been observed using a modified algire
chamber system (Reinhold, 1971) . A course of
fractionated radiotherapy, giving 576 rads daily,
produced an improvement in tumour microcirculation, in
terms of vascular density and flow velocity. The peak
of these changes coincided with tumour regression,
consistent with the idea that the vascular effect is
partly attributable to tumour cell decay and
elimination.
The published data on vascular changes during and
following single dose and fractionated radiotherapy has
been reviewed (Mattsson & Peterson, 1979). The effect
of single fraction radiation appears to be
dose-dependent with low dosage generally increasing, and
high dosage decreasing, tumour blood flow. Fractionated
irradiation does not seem to damage tumour vascular
endothelium to the same extent (Gillette, 1975).
The effect of radiation on human tumour blood flow is
virtually unexplored. However, measurement of xenon
clearance during and following a course of radiation
showed significant changes in flow, with an increase
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after the first week of treatment and a progressive
decrease thereafter (Mantyla et al, 1982).
b. Hyperthermia
Although it is not infrequently stated that blood flow
in tumours is less than that in the normal tissue of
origin (Vaupel, 1977, Gullino & Grantham, 1961a,
Cataland et al, 1962, Peterson, 1979), a generalisation
to this effect cannot be made from the limited available
data. However, the application of heat seems to
accentuate any disparity between the two by a
differential action on tumour and normal tissue
vasculature. This has important consequences for heat
delivery during hyperthermia treatment and also in
promoting a selective tumour effect.
2.8 Heat Effect on Blood Flow
2.8.i Heat and Normal Tissue Vasculature
Normal vasculature responds to heat by vasodilation with
consequent increase in blood flow. In skin, this is apparent
in the development of a transient erythema. The area
immediately adjacent to tumour may not be representative of
normal tissue having higher than usual resting flow values,
perhaps as a result of inflammation (Song et al, 1980s.) .
Temperatures within the therapeutic range induce significant
increases in normal tissue flow which are rapidly and totally
reversible. Vascular volume and permeability generally
increase following heating at 43°, with total recovery within
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hours after completion (Song et al, 1980a & b;
Ackerman & Heckner, 1978) . Vascular induced changes in
different normal tissues are qualitatively similar but
quantitatively different.
2.8.ii Heat and Tumour Vasculature
The effect of heat on the tumour circulation depends on
the temperature delivered. In general, modest temperatures
of 40-41°C either exert no effect (Gullino et al, 1978; Song
et al, 1980b) or cause a reversible increase in tumour blood
flow (Bicher et al, 1980; Emami et al, 1980; Vaupel et
al, 1980). However, temperatures in the therapeutic range of
42-44°C have produced a significant decrease in tumour blood
flow in a number of experimental studies (Bicher et al, 1980;
Vaupel et al, 1980 ; Eddy, 1980 ; Endrich et al, 1979) . The
damage induced by these higher temperatures is irreversible
(Emami et al, 1980 ; Song et al, 1980a & b) . The development
of thermotolerance to heat vascular damage has been suggested
by Eddy & Chmielewski (1982) who observed a decreased
vascular effect when an interval of only 5-24 hours separated
two sequential heating sessions.
Histological examination of the vascular damage induced
in tumours heated to different temperatures shows a dose
response which correlates well with the physiological changes
described above (Emami et al, 1981) . Up to 40.5°C there
seems to be no specific change, but heating to 43°C produces
dilatation and congestion within the tumour vessels. When
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the temperature is increased further, hemorrhage, necrosis
and blood vessel disruption occur.
2.8.iii The Anti-tumour Effect of Hyperthermic Vascular
Damage
The vascular component of heat damage may contribute to
tumour cell death in a number of ways.
a. Ischaemic Tumour Cell Damage
A continuous decrease in the number of surviving
clonogenic cells in tumours left in situ post
hyperthermia implicates a delayed cell death process
(Song, 1980c) . Similarly tumour growth delay after a
given treatment is considerably longer than that
expected from cell survival measured immediately after
treatment (Rofstad et al, 1984).
This progressive hyperthermic cell death is thought to
be due to protracted hypoxia, increasing acidity and
nutrient deficiency caused by heat-induced vascular
damage. This suggestion is supported by a measured
reduction in tumour vascular volume prior to the onset
of delayed cell killing (Kang et al, 1980) .
b. Enhanced Selective Heating of Tumours
The opposed responses of tumour and normal tissue
vasculature to therapeutic temperatures probably
facilitates selective tumour heating (Kim et al, 1982).
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Thus, as local perfusion rate is an important
determinant of temperature rise (Jain et al, 1979),
increased normal tissue and decreased tumour flow,
consequent on heating, provides a useful tumour:normal
tissue differential.
c. Promotion of a Favourable Micro-environment
Collapse of the tumour capillary network could procure
local environmental conditions favourable for direct
heat toxicity. The importance of pH has been repeatedly
observed and is probably the most critical factor in the
thermosensitivity of mammalian cells (Gerweck &
Rottinger, 1976; Overgaard & Bichel, 1977).
2.8.iv Pharmacological Manipulation of Blood Flow to
Enhance the Heat Effect
Pharmacological exaggeration of naturally occurring
selective tumour heating should provide a therapeutic
advantage. Approached by either vasoconstriction of the
tumour vascular bed, or by vasodilation of the surrounding
normal tissue vasculature animal studies suggest that this
may be a feasible manoeuvre. Improved selective heating was
achieved in an experimental study involving three species,
three tumour types and three different vasodilators
(Babbs et al, 1982). Normal tissue blood flow, measured with
thermal clearance and radioactive microspheres, increased to
several times that in tumour allowing steady state
intratumoural temperatures of over 45°C to coexist with
normal tissue temperatures of 40°C. The most pronounced
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effect was seen with large masses. This manoeuvre has not
been attempted in clinical hyperthermia but intra-arterial
prostaglandin , a potent vasodilator, increased blood flow
in normal tissue relative to tumour in an angiographic study
in patients (Jonsson et al, 1978).
Many human tumours appear to be heat resistant in that
they fail to reach therapeutic temperatures. Preservation of
some heat/stress response within tumours may increase blood
flow during hyperthermia and dissipate the delivered heat.
Retained reactivity may predict for tumour heating capacity
and subsequent therapeutic response (Olch, 1983a). In heat
resistant tumours a locally infiltrated vasoconstricting drug
could sufficiently inhibit blood flow to allow an adequate
temperature rise (Olch, 1983b) but this has not yet been
investigated in the clinic.
2.8.v Mechanisms of Heat Vascular Damage
The reason for increased heat susceptibility in tumour
vessels remains speculative. The possible contributing
mechanisms are outlined below, but the responsibility may not
be singular:
a) Decreased Red Cell Deformability
Red blood cell membranes lose their deformability at the
pH levels commonly detected in tumours after
hyperthermia and become rigid spherical corpuscles,
which tend to stick in tumour microvessels and cause
vascular occlusion (Vaupel et al, 1980).
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b. Increased Leukocyte and Platelet Adhesiveness
During hyperthermia leukocytes become adherent to the
postcapillary wall with the result that there may be up
to a 300-fold increase in postcapillary resistance
(Ferguson et al, 1982) . Alteration in the leukocyte
membrane, or changes in the endothelial surface, may be
responsible for this effect.
c. Direct Endothelial Damage
Normal vascular endothelium is generally considered to
be very heat resistant but marked morphological changes
have been reported in tumour endothelium. A short
exposure of only 12 minutes to 43°C produced deeply
staining endothelial cells which became vacuolated and
protruded into the lumen (Fallin et al, 1972). Heating
to 66.3° for only 40 seconds caused total endothelial
destruction. Emami has demonstrated the temperature
dependence of tumour endothelial damage, with obvious
rupture and destruction of the capillary wall at
therapeutic temperatures (Emami et al, 1981). The
disrupted vascular endothelium may impede blood flow and
promote hemorrhage in heated tumours.
d) Normal Tissue - "Steal" Phenomenon
Heat-inducted increase in adjacent normal tissue blood
flow may effectively shunt blood from the tumour
vascular bed producing a "Steal" phenomenon. As a
result, decreased pressure within the tumour vasculature
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allows collapse of the fragile walled, rapidly
constructed vessels.
2.9 The Potential Implication of Tumour Blood Flow in
Clinical Oncology
Published tumour blood flow data overwhelmingly concerns
experimental animal tumours. Extrapolation from this to
human tumours may be inappropriate because of fundamental
biological differences between the two systems.
In order to exploit tumour blood flow in patient
management, a means of assessing individual tumour perfusion
is essential. This requires availability of a non-invasive,
reproducible, quantitative technique for measuring flow, with
the ability to detect intra-tumoral heterogeneity. At
present, PET scanning is the only technique which approaches
this ideal but its application is confined to centres
possessing a Cyclotron.
An appropriate human tumour flow measuring technique
could provide answers to important biological and clinical
questions. For example, the assumption that tumour perfusion
influences the effectiveness of radiotherapy, chemotherapy
and hyperthermia remains unproven and, in fact, there is
experimental evidence to suggest that blood flow cannot be
used as a prognostic indicator of the radiation or drug
response of individual animal tumours (Pallavicini &
Hill, 1979). Tumour characterisation with respect to blood
flow, and subsequent correlation with response to treatment
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and local control, could elucidate this point. If n~-r fu ■-; '•
is a critical factor then flow characteristics might predict
the likelihood of response and help to determine treatment
policy for a group of tumours in general, or for an
individual tumour in particular.
Quantitative and qualitative changes in perfusion are
likely to accompany therapeutic intervention and may have
important consequences particularly for combined modality
management. The radiation-induced alteration in flow
described by Mantyla (Mantyla et al, 1982) could be construed
either as a therapeutic benefit or hindrance. The described
early increase in flow should improve oxygen and drug
delivery to the tumour, enhancing the effect of further
radiation or concomitant drug administration. The later fall
in flow, however, would have the opposite effect, but might
indicate a more appropriate time to attempt hyperthermia.
Serial flow measurements throughout the course of active
management could permit optimal utilisation of the most
appropriate treatment.
Compromise of the tumour vasculature may be a useful
therapeutic tool but its development relies on a means of
assessing human tumour perfusion. The possibility of
harnessing this vulnerable component of the tumour has been
discussed, but properties of the tumour microcirculation can
be exploited in other ways. Tumour capillary permeability for
example, can be exaggerated by heat or calcium blocking drugs
to allow better cellular access of cytotoxic agents. The
necessity for continued endothelial proliferation in growing
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tumours makes inhibition of angiogenesis a potentially useful
mechanism.
Detection and control of angiogenesis has other
intriguing clinical implications. Angiogenic activity
emerges early in the transformation of normal cells to a
neoplastic state, making its detection a valuable
preneoplastic marker. This could provide a pioneering
approach to screening programmes for the early detection of
cancer, which now begin to appear fruitful in their aims to
reduce cancer mortality (Tabar et al, 1985). Similarly,
monitoring high risk tissue for angiogenic activity might
provide a sensitive indicator of early metastatic growth and
allow treatment to be instigated at a time of minimal tumour
burden.
Tumour progression, in terms of metastatic potential,
seems to require vascularisation of the primary mass. The
number of cells shed into the circulation correlates with
vascular density and with the number of lung metastases later
observed (Liotta et al, 1976) . Prevention of
neovascularisation or destruction of the network at an early
stage might influence the metastatic potential of cancers.
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3.1 Clinical Endpoints
Objective evidence of tumour response is vital to
establish antitumour activity but is only useful if it
correlates with clinical benefit to the patient. This is
particularly so in palliative treatment settings where
alleviation of a symptom, such as pain, may be a more
relevant endpoint than tumour shrinkage. Table 5 gives a
summary of the clinical endpoints commonly used in the
evaluation of radical and palliative cancer treatment.
TABLE 5








Although survival is the ultimate endpoint it usually
involves a long follow-up period, and may be inappropriate in
experimental treatments which are generally evaluated in
advanced disease. Alternative endpoints providing more
immediate information generally require precise tumour




although indirect measurement, for example by monitoring
tumour markers, is appropriate in certain malignancies.
3.2 Tumour Volume Measurement
Direct tumour measurement is achieved either by calipers
in accessible superficial lesions, or by imaging techniques
in deeper seated tumours. Although the bulk of measurement
data in humans is derived from radiological assessment of
lung lesions, the availability of ultrasound, computerised
tomography and magnetic resonance imaging will expand the
range of tumours suitable for study and allow more accurate
volume measurement of irregular masses (Husband et al 1982) .
Ideally, the three dimensions of a tumour should be measured
and used to calculate the tumour volume. However, in
practice this is rarely achieved and it is usually considered
acceptable to confine measurement to length and width. The
adequacy of this compromise will deoend on the configuration
of the tumour and is obviously more appropriate in spherical
lesions such as is commonly the case in lung metastases where
growth is generally spatially unrestrained.
Gurland & Johnson (1966) have shown that with such lesions a
simple measurement of greatest diameter will suffice. At
other sites, and particularly in superficial lesions, tumours
often assume an eccentric shape during growth, and may show
eccentric regression in response to treatment. In such
circumstances a single measurement is obviously inadequate
and at least the tumour "area" should be calculated from the
product of the longest perpendicular diameters. The most
accurate expression of change in tumour extent will be
obtained from a three-dimensional measurement which may
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require a combination of techniques. For example, in this
study, superficial lesions were measured by calipers in the
longitudinal and transverse lateral dimensions, and by
ultrasound in depth. It was felt that this combined the
advantages, and minimised the drawbacks, of both methods
(Yarnold et al 1986). Computer reconstruction of tumours
imaged by ultrasound, computerised tomography, and magnetic
resonance imaging provide accurate volume assessment in
irregularly shaped and inaccessible masses (Bamber et
al, 1987, Husband et al, 1982) which are a more realistic
clinical proposition.
3.3 Reliability of Tumour Volume Measurement and its
Influence on Clinical Endpoints
Consideration of measurement error will be confined
mainly to superficial tumours in keeping with the interests
of the present study. In these accessible lesions, caliper
evaluation is the commonest approach to tumour measurement
and has been investigated for source and magnitude of
variation in measurement simulation experiments
(Moertel & Hanley, 1976, Lavin & Flowerdew, 1980, Warr et al
1985) . Moertel invited 16 experienced oncologists to apply
their usual clinical measurement technique to 12 simulated
lesions constituting a range of sizes which included two
identical pairs. With the same investigator, there was a
7.8% chance that two sequential measurements, on a single
nodule, would demonstrate an objective response, a.s defined
by a 50% reduction in the product of perpendicular diameters.
This increased to a 19% chance when the criterion for scoring
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response was taken as a 25% reduction in the same parameters.
The degree of error between different investigators was of
similar magnitude with the chance of an objective response
rate of 6.8% and 25% respectively for a 50% and 25%
reduction. The authors therefore recommended that only the
50% reduction criterion be employed, with the anticipation of
a 5-10% objective response rate occurring by error alone.
This study encouraged investigator precision and offered
ideal conditions for measurement making it likely that the
error incurred in a less diligent clinical setting could be
greater than these estimates. On the other hand, Moertel's
results were derived from only two sequential simulated
measurements and in the clinical setting measurement
reliability increases considerably with the frequency of
observation.
In a similarly constructed simulation study, Lavin and
Flowerdew (1980) demonstrated a log-normal distribution for
tumour area measurements and proposed the use of the ratio of
tumour area at each evaluation as the most appropriate
parameter for determining, not only tumour response, but also
tumour progression. Applying power curves to determine the
probability of declaring tumour response or progression,
according to the criteria commonly used by the Eastern
Cooperative Oncology Group, they demonstrated that when
tumour volume was unchanged between consecutive measurements
there was a greater likelihood of scoring progression than
response. They calculated that in 100 patients given
treatment which stopped tumour growth, 64 would be falsely
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classified as having progressive disease on the basis of 4
follow-up evaluations conducted by different investigators.
New criteria of 50% decrease in tumour area for designation
of response and 100% increase in tumour area for declaration
of progression were suggested. Applied to the above example
false progression fell from 68% to 6%. It was felt that
similar simulation studies would be of value in identifying
appropriate statistical analysis for different approaches to
tumour measurement. The study also addressed the influence
of tumour texture and shape on measurement error with a
negative outcome.
More recently Warr et al (1985) designed a simulation
study which included clinically relevant lesions such as
lymphadenopathy, hepatomegaly and pulmonary metastases.
Although introducing some of the variables encountered in
clinical practice, only clearly defined lesions were assessed
by a group of consenting investigators, making it likely that
the derived error still underestimates clinical reality. The
calculated influence of measurement error on response rate
concurred with previous studies, showing a false partial
response rate of approximately 10% for most lesion types with
a greater frequency of false progression, in the order of
30%. More stringent criteria of response and disease
progression decreased the percentage of false
categorisations.
The reliability of caliper measurement in human tumours
has been evaluated by different approaches (Thomlinson, 1982,
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Yarnold et al, 1986) . In Thomlinson's large measurement
study of breast cancer the variation in perpendicular tumour
diameter obtained by two different observers was
investigated. Thirteen thousand five hundred measurements
were compared and the differences obtained were found to
follow an almost normal distribution with a mean difference
of 2.5mm for lesions ranging in diameter from 16 - 161mm.
Sixty per cent of the compared measurements were within 2mm
of one another. Assuming a spherical configuration for the
lesions, tumour volumes were derived from the mean of the
measured dimensions and, from the standard deviation of these
means, the 95% confidence limits of the volumes were
calculated and expressed as error bars on the growth curves.
In a small series of superficial excisable malignant
lesions, Yarnold (1986) compared tumour volumes derived from
preoperative caliper measurement with those directly obtained
by immersion of the excised specimen in a displacement
chamber. Caliper measurements tended to overestimate tumour
diameter, partly because of inclusion of overlying tissues,
but the significance of this error is minimised in serial
measurements which detect a change in relative tumour volume
rather than describing absolute values. In the same study
comparison of preoperative ultrasound measurement with
excised tumour dimensions indicated that ultrasound measured
tumour depth accurately but tended to underestimate the
lateral extent of the tumour. As a result of this,
ultrasound was used to provide a depth measurement in
superficial lesions measured in the present study.
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Satisfactory incorporation of tumour measurements into
response criteria in multicentre clinical trials requires
evaluation of the reliability of tumour measurement.
Henderson et al, (1984) attempted to assess the consistency
of tumour measurements, from chest X-ray and radionucleotide
scans, made by investigators at participating hospitals
compared with a central radiologist. Overall, differences in
mean tumour dimension, and products of dimension, between all
local investigators and the central radiologist were small,
although individually there were large differences in three
of the eight participating hospitals when compared with the
central radiologist. Classifying disease status on the basis
of these measurements as either progressive, stable or
remission, there was only 75% agreement between local and
central examiners, with particularly poor (41.7%) agreement
for the subset of patients regarded as having remission by
one of those examiners.
3.4 Human Tumour Doubling Time Data Derived from Clinical
Measurements
A single histological tumour type can include neoplasms
varying widely in biological behaviour, as demonstrated by
doubling times ranging from 23-280 days for adenocarcinoma of
breast (Batterman et al, 1981) , and 83-547 days in
adenocarcinoma of corpus uteri (Breur, 1966a). If tumour
growth rates could be determined readily, and without
delaying treatment, this information could be incorporated
into the design of clinical trials by stratifying according
to doubling time. Comparison of biologically similar groups
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of tumours could be advantageous in certain situations; for
example, tumour growth rate has been shown to correlate with
the relative biological effectiveness of neutrons (Batterman
et al, 1981).
However, information regarding doubling time is
generally not available at the start of treatment and
knowledge of tumour growth rate is generally confined to a
few carefully selected tumours. Thus, most of the available
doubling time data has been accrued from tumours which are
regular, discrete and accessible for measurement, by calipers
or radiological techniques, and those that can be monitored
over a period of weeks or months without therapeutic
intervention. The latter stipulation implies that tumours
are either indolent, incurable or metastatic and precludes
collection of information on early disease which is
potentially curable. Unless a serum tumour marker is
available which is stoichiometrically related to tumour
volume as in female choriocarcinoma (Bagshawe 1973), growth
rate data are limited to clinically detectable disease and
hence to a range of approximately 6-10 volume doublings.
(Fig. 3) . The major component of tumour expansion is
therefore excluded from observation although earlier
detection of metastatic lesions by C.T. scanning permits some
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Human data generally demonstrate exponential growth
rates (Collins et al, 1956, Schwartz 1961, Breur, 1966a,
Brenner et al, 1967, Weiss et al, 1966, Van Peperzeel, 1972).
However, where frequent observations are made over an
extended period of time, examples of both growth retardation
(Breur 1966a) and abrupt acceleration are available
(Spratt & Spratt, 1964). In a study of growth rate in soft
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tissue metastases, Lee and Spratt (1972) were unable to
differentiate between linear and exponential growth, taking
into account frequency of observation and measurement error.
On the assumption that human tumours grow in a continuous
exponential fashion, attempts have been made to construct the
natural history of a tumour from the moment of its inception
by extrapolating backwards (Collins et al, 1956).
Despite the problems of accruing and interpreting human
data the number of published estimates of volume doubling
time runs into several hundreds and a summary of the data on
780 human tumours has been presented (Steel, 1977).
Consolidation of this data demonstrated the very considerable
range of growth rates found with any particular tumour type.
Adenocarcinomas, for example, had a geometric mean doubling
time of 77.8 days but in 36% of tumours the doubling time
fell outside the range 37-163 days, and 4% lay outside the
range 18-343 days. However, individual series report a
log-normal distribution for tumour doubling time, considering
either a specific tumour type or observations on a mixed
population of tumours (Spratt and Spratt 1964, Charbit et al
1971 and Lee and Spratt 1972).
3.5 Tumour Growth Delay and Other Endpoints
Growth delay is an established experimental endpoint
which has been successfully used to evaluate a wide variety
of treatments, particularly those involving radiation. This
approach was used by Thomlinson (1960) to investigate the
potential of hyperbaric oxygen and subsequently has been
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widely employed in a range of radiobiological studies
including the investigation of fractionation, (Denekamp &
Harris, 1976), comparison of photons with high L.E.T.
radiations (Field et al, 1968, Barendsen & Broerse, 1969) and
evaluation of hypoxic cell radiosensitisers (Denekamp &
Harris, 1975, 1976). Growth delay has also been successfully
applied in the assessment of other treatments including
cytotoxic drugs (Steel et al, 1983) and hyperthermia (Rofstad
& Brustad, 1986) . In the laboratory, growth delay has the
advantage of being applicable to almost all solid tumour
systems and of being sensitive over a wide range of
responses. However, because of the complex relationship
between cell kill and growth delay, it is not possible to
quantify the surviving cell fraction using this technique.
The proliferation kinetics of those cells surviving
treatment, from which repopulation will occur, critically
influence growth delay. This effect is amplified when
treatment modalities involving different mechanisms of cell
damage are compared. For example, Stephens & Peacock (1977)
investigated cell survival and growth delay in B16 melanoma
treated with cyclophosphamide or 1-(2-Chloroethy1)
3-Cvclohexly-l-nitrosourea (CCNU). Doses of the two drugs
that produced the same level of cell kill, resulted in
different growth delays due to slower clonogenic cell
repopulation after cyclophosphamide compared with CCNU.
Experiments involving comparison between radiation and drugs
(Rowley et al, 1979) and radiation and hyperthermia (Walker
et al, 1983) have demonstrated similar discrepancies. In the
latter experiment, at the treatment level producing 37% cure
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with each of the two modalities, the corresponding growth
delays were 22.9 days for hyperthermia and 69.5 days for
radiation.
Characteristics of the regrowth phase may also be
influenced by damage to the stroma, or bed, of the tumour.
For example, in animal experiments, prior irradiation to the
site of implantation results in slower tumour growth compared
with tumour sited in unirradiated host tissue (Stenstrom et
al, 1955, Hewitt & Blake, 1968, Urano & Suit, 1971). This
effect, termed the tumour bed effect (TBE), demonstrates that
tumour growth is not simply a reflection of the inherent
proliferation potential of clonogenic cells. This has
important consequences for growth delay; firstly, if the
growth curves for treated and untreated tumours are no longer
parallel, then the endpoint size selected influences the
estimated delay. Secondly, the non-linear variation in
magnitude of TBE with radiation dose (Urano, 1966)
complicates the use of growth delay in dose response
experiments (Begg & Denekamp, 1983) .
A reduction in growth rate has also been demonstrated
after cytoxic treatment although the magnitude of the effect
is usually less than that induced by radiation. In this
situation TBE is an unlikely explanation and, as general host
health has been shown to influence tumour growth rate
(Brown, 1979) , a systemic effect is more probable.
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Although localised hyperthermia can result in severe
normal tissue damage, a tumour bed effect is probably not
significant for clinical application. In animal experiments,
pre-transplantation hyperthermia taken to tolerance dose,
failed to demonstrate retardation of tumour growth
(Yerushalmi & Weinstein, 1979 , Urano & Cunningham, 1980) .
However, the addition of heat to radiation doses which alone
failed to produce a TBE, resulted in significant enhancement
of radiation effect, and consequent retardation of tumour
growth (Yerushalmi & Weinstein, 1979).
Clearly, a greater growth delay does not necessarily
imply greater cell kill but it does indicate a greater effect
which may in itself confer clinical benefit. Thus despite
the mechanistic problems of interpreting growth delay, it is
a valid clinical endpoint in its own right providing a means
of comparing severity of treatments in patients.
The clinical application of growth delay is now well
established (Ash et al, 1979, Dawes et al, 1978, Thomlinson
et al, 1976). Yarnold (1986) investigated the
reproducibility and sensitivity of radiation-induced growth
delay and was able to detect 20% differences in radiation
dose thus supporting the validity of the technique for
identifying enhancement ratios as low as 1.2. However, the
method was limited as a clinical endpoint because of the
scarcity of patients with measurable metastases and an
adequate prognosis, who were not receiving active antitumour
therapy. Urtason et al (1980) have also emphasised the
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difficulty of applying the growth delay assay to the
investigation of clinical problems.
3 . 6 Tumour Shrinkage
Two parameters, rate of regression and extent of volume
reduction, can be used to describe tumour shrinkage and need
to be clearly defined, although in many reports this
distinction is not made. Rate of regression, expressed as
tumour volume halving time in days, is an absolute measure
which can be used to compare treatment response in different
tumours. Calculation of regression rate requires
construction of a response curve derived from serial tumour
measurements following treatment. On the other hand, extent
of volume reduction is a less precise endpoint, often
employed in clinical studies and estimated variously by
assessment of complete response, tumour clearance and
percentage volume reduction. Extent of volume reduction is
usually based on comparison between the clinical assessment
prior to treatment with an assessment made at an arbitrary
time following treatment. This usually relies on clinical
judgement rather than precise measurement and is therefore a
crude endpoint. Figure 4 demonstrates the necessity for
serial tumour measurement and the inadequacy of tumour




Schematic Representation of Initial Tumour Volume, Rate
of Regression and Extent of Volume Reduction
Tumour
Two tumours of unequal volume, A and B, which regress at
the same rate appear to vary in extent of volume reduction
when assessed at time X, at which time A is designated
complete response, whereas B remains palpable. On the other
hand, if the two tumours regress at different rates, they may






tumour assessment adjusts for initial volume variation and
allows expression of percentage volume reduction. However,
this endpoint is assessed at a specified time so that, in the
example above, tumours A and B at time X would be classified
as 100% and 75% volume reduction respectively. Only serial
tumour measurements permit meaningful comment on tumour
regression and complete response is an inadequate endpoint
for measurement of either extent, or rate, of tumour
shrinkage.
Human tumour data suitable for construction of response
curves are sparse and confined to lesions accessible for
clinical measurement or repeated radiological assessment
(Friedman and Pearlman, 1955, Wambersie and Dutriex, 1980,
Thomlinson, 1982, Bartelink, 1983). Following irradiation,
tumour volume decreases in an exponential manner, at least
over the period of maximum change in tumour dimension.
However, considering the entire response curve, a sigmoid
shape may become evident (Friedman and Pearlman, 1955,
Thomlinson, 1982) . In a series of 168 patients with
irradiated breast cancer, Thomlinson was frequently able to
fit a second exponential to the terminal part of the response
curve. This second exponential represented a phase of slower
regression, compared with the first exponential, and commonly
became established when tumour shrinkage was of the order of
a quarter of the original volumes. Resorption of stromal
elements may be responsible for this terminal phase. Careful
observation, in the first few days after conventionally
fractionated radiation, has demonstrated that the initial
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portion of the response curve is flat (Friedman and
Pearlman, 1955, Wambersie and Dutriex, 1980,
Thomlinson, 1982). Because of this, it has been suggested
that a critical level of cellular damage is necessary to
trigger the mechanisms involved in tumour shrinkage, a
hypothesis supported by the more rapid onset of regression
after large single doses of radiation.
Tumour shrinkage is a complex mechanism reflecting the
multiple cellular processes, occurring in response to
treatment, in both malignant and stromal elements. These
include tumour cell kill, proliferation kinetics of surviving
and non-surviving tumour cells, kinetics of cell lysis,
mechanisms of debris clearance, proportion of stroma and its
response to irradiation and host reaction against residual
disease.
Animal experiments have demonstrated that tumour volume
regression does not provide a measure of clonogenic cell
kill. For example, Thomlinson and Craddock (1967)
demonstrated that rat tumours given single doses ranging from
5 to 60 Gray, regressed at the same rate regardless of
whether there was subsequent tumour regrowth or cure.
Similarly, Suit (Suit et al, 1965) reported an absence of
correlation between tumour regression rate and probability of
tumour control after single dose irradiation in spontaneous
mammary tumours in C3H mice. Over a range of doses,
corresponding to local tumour control rates of 0.3 to 99.7%,
the median tumour regression rate of 21 days did not differ
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between treatments. In a review of experimental studies
investigating the significance of tumour regression on local
control, Suit and Walker (1980) calculated that, at least for
tumour systems with no effective host resistance, virtually
all tumour failures represented regrowth from less than 10
surviving cells. The ensuing argument hinged on the
unlikelihood that the proliferation characteristics of these
1-10 surviving cells would be reflected in tumour regression
during irradiation. The same authors substantiated this
hypothesis with regression and regrowth data from Barendsen
and Broerse (1969). However, Denekamp, (1977) has challenged
the significance of these studies, which employed single,
large dose irradiation and investigated tumour regression
during fractionated irradiation, more representative of
clinical scheduling. In tumours of similar volume, tumour
size at the end of treatment was significantly correlated
with local control for three of the four fractionation
schedules, whereas, there was only a weak correlation in
those lesions given single doses. Although it was conceded
that tumour shrinkage is unlikely to reflect the number of
cells killed, it was postulated that it could influence
re-oxygenation and thus, sensitivity to subsequent
irradiation.
Human tumour regression rate, and extent, have been
investigated as indicators of radiocurability and as early
predictors of the outcome of treatment. The attraction of an
early determinant of radiocurability is that treatment could
be tailored accordingly and, for example, the radiation dose
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boosted or surgical salvage considered. To the clinician,
rapid tumour regression is an encouraging sign which it is
tempting to equate with radiosensitivity and, extrapolating
even further, with radiocurability. However, radiotherapy
experience refutes the general validity of this supposition
with, for example, prompt, and usually complete, regression
of small cell lung cancers after only moderate radiation
doses which rarely lead to tumour control. Similarly rapid
response in irradiated Hodgkin's disease led to the practice
of employing inadequate dose levels with consequent local
relapse and the eventual realisation that 40Gy. in four weeks
was required to achieve local control in more than 90% of
patients. On the other hand, very slow regression, or even
static disease following irradiation does not necessarily
indicate treatment failure (Choi et al 1979).
Accepting that there is variation in regression pattern
between different histological tumour types, and a lack of
clear connection with treatment outcome, it is nevertheless
still possible that tumour shrinkage is of prognostic
significance in a group of like tumours. For example, the
38 fold range in the slope of regression in 60 patients with
primary breast cancer, essentially treated in the same way,
might be expected to detect differences in treatment outcome
(Thomlinson 1979). A number of clinical studies have
investigated the influence of either regression rate during
treatment, or extent of regression shortly after completion
of treatment (Table 6) .
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As shown, data on regression rate are scanty and most
observations relate to the extent of tumour regression scored
either at the end of radiotherapy or within the first six
months after treatment. From these studies documenting
extent of regression, timing of assessment is obviously a
critical determinant of correlation with subsequent outcome.
For example, Sobel (Sobel et al, 1976) in a series of head
and neck cancers, documented response by scoring for tumour
clearance or persistence at specific time intervals during,
at the completion of, and following a course of fractionated
radiotherapy. The use of the term "rate of regression" by
these authors is imprecise as tumour volumes were not
calculated. However, the allocation of tumours into early
and late responders is valid and demonstrates that the time
of tumour clearance is less important than the completeness
of tumour clearance as a predictor of local control. In the
majority of sites studied, the third assessment interval,
30-90 days after the completion of treatment, most accurately
predicted outcome although this information obviously fails
to provide an early indication of treatment outcome and
therefore has less impact on individualising treatment. The
conclusions of the study challenge the practice of
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TABLE 6
CORRELATION OF PROGNOSIS WITH PARAMETERS OF TUMOUR REGRESSION
Tumour
No. of Regression parameter, Clinical
patients assessed at endpoint
Correlation Reference
Head & Neck Cancer
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R/T = Radiotherapy **TC = Tumour clearance
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LC = Local control
S = Survival
MFS = Metastases free survival
ET = effectiveness of treatment'
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evaluating tumour persistence during treatment as the
criterion for surgical intervention (Marcial & Bosch, 1970,
Lederman, 1972). In addition, Sobel's data suggests that the
apparent lack of concordance of results as shown in Table 6,
may arise from selection of an inappropriate time interval
for observation in different tumour types.
Suit & Walker (1980) re-examined those clinical series
in which tumour extent was evaluated at the completion of
treatment and could therefore contribute to management
policy. They calculated true and false positive rates with
regard to expected and actual local relapse on the basis of
residual tumour. False positive rates ranged from 2-86%,
demonstrating that the presence of statistically significant
correlation does not necessarily imply practical application.
Only one study addresses the prognostic value of
regression rate during a course of radiotherapy, by
calculating tumour volume halving time from serial tumour
measurements (Bartelink, 1983). The results suggest that
following a dose of 7 0 Gy to neck nodes involved with
metastatic squamous carcinoma, recurrence is significantly
(p = 0.044) more common in slowly regressing tumours with a
halving time of > 20 days. As the prediction could be made
as early as 28 days after the start of radiotherapy,
regression rate may provide an early indicator of response
and thus be of value in determining treatment policy, at
least in this particular clinical setting.
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In human tumours, both regression rate
(Thomlinson, 1982) and the extent of volume reduction
(Breur, 1966b, Van Peperzeel, 1972 and Bartelink, 1980) seem
to be related to pre-irradiation growth rate. However, the
influence of other factors has been defined with, for
example, more rapid regression occurring after large
(8-10 Gy) compared with small (2 Gy) fraction size (Holsti et
al, 1978, Wambersie & Dutreix, 1980).
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CONCLUSIONS OF REVIEW AND PROPOSALS OF STUDY
Hyperthermia now requires proper clinical evaluation and
definition of its role in improving local tumour control when
used in combination with radiotherapy. Concerns regarding
the adequacy of current technology, in terms of heat delivery
and thermometry, have, until very recently, discouraged the
introduction of a prospective randomised clinical trial to
test these questions. Although this has now been undertaken
by the European Society for Hyperthermic Oncology, it is
likely to be several years before clinical trials in man can
confirm or refute the value of hyperthermia in clinical
practice. For this reason, attempts to derive quantitative
clinical data provide more immediate information which can
subsequently be used to direct the design of future clinical
trials.
The aim of the present study was to provide quantitative
data regarding heat modification of the radiation response,
using multiple metastatic nodules in individual patients.
Because of interpretative difficulties with fractionated
studies and the possibility of invoking thermotolerance or
inducing vascular change, the therapeutic schedule was
confined to a single dose of radiation followed three to four
hours later by a single hyperthermia treatment. Further, it
was hoped to use the clinical measurements obtained during
the study to investigate the biological comparability, in
terms of growth rate and response to radiation, of these
multiple nodules and thus determine the most effective use of
clinical material of this sort.
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Tumour blood flow is an interesting aspect of tumour
physiology which may have important implications for
treatment modalities such as radiotherapy and chemotherapy.
Acquisition of means of manipulating this parameter may
provide mechanisms for enhancing the effectiveness of
conventional treatment, or for establishing an alternative
approach to tumour management. In hyperthermia, blood flow
has an even more crucial impact. Not only is heat delivery,
qualitatively and quantitatively, dependent on blood flow,
but also vascular changes induced by heat may contribute to
hyperthermic cell death and influence the effectiveness of
other treatment modalities. Because of this critical
relationship between heat and tumour blood flow, one of the
aims of the present work was to evaluate flow measuring
techniques which might be incorporated into hyperthermic
studies. In particular, it was hoped that a reproducible
technique could be used to demonstrate whether flow changes
do occur after a moderate heat delivery (43°C minimum for 30
or 60 minutes) and, if so, to assess roughly their direction,
magnitude and duration.
The studies included in this thesis employed the same
radiofrequency system to deliver heat to a series of small
superficial metastatic tumours. Standardisation of
thermometry was attempted by ultrasound localisation of the
thermometry cannula at the tumour base and minimum tumour
temperature used to control delivery of the treatment. It
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4.1 Patient Accrual and Selection
(a) Tumour Selection
Patients with multiple, discrete metastases were
referred by physicians, radiotherapists and surgeons,
providing access to a wide spectrum of disease.
Fifty-six of the total referred patient population had
suitable lesions and were considered eligible for
initial tumour measurement and eventual entry into the
treatment study (see Eligibility Criteria - Table 7).
TABLE 7
HEAT AND RADIATION IN SUPERFICIAL METASTASES:
ELIGIBILITY CRITERIA FOR ENTRY INTO STUDY
(1) Tumours considered incurable by conventional
therapy
(2) Presence of multiple, discrete superficial metastatic
nodules
(i) minimum nodule size 5 mm linear dimensions:
limited by spatial resolution of the measurement
technique
(ii) maximum nodule size 3 cm linear dimensions:
limited by heating capability of the system
(3) Patients with a life expectancy of at least 3 months
(4) Patients in whom the introduction of systemic treatment
was not anticipated during the course of study
(5) Patients fit and willing to attend hospital regularly
for clinical measurement






The commonest tumour type was locally recurrent
adenocarcinoma of the breast, which proved particularly
suitable in view of its tendency to develop accessible
metastases compatible with a relatively prolonged
survival. Breast cancer nodules from three patients
entered into the measurement study are shown in
Figs. 5, 6 & 7. Other histological types included
uncommon tumours such as chordoma and carcinoid, which
rarely present with superficial metastases (Fig. 8) .
Figure 5
Cutaneous Metastases Over the Chest Wall
in a Patient with Breast Cancer
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Figures 6 & 7
Fig. 6
Cutaneous and subcutaneous







Histological Tumour Type in 56 Patients with
Multiple, Discrete Superficial Metastases
Entering the Measurement Study
% Frequency
10 20 30 40 50 60 70 80 90
(b) Patient Selection
Patient Elibibility Criteria for entry to the study
are outlined in Table 7. The use of growth delay
as a clinical endpoint was only feasible in
patients with a life expectancy of at least three
months. Introduction of systemic treatment during
this period would have made interpretation of the
role of hyperthermia impossible and was therefore
avoided. However, some patients were already
established on endocrine therapy and they, or their
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physicians, were reluctant to discontinue
treatment. Therefore, these patients were only
included in the study if initial serial clinical
measurements, prior to radiation/hyperthermia,
demonstrated continued tumour growth, thus
indicating lack of response to endocrine
manipulation. A number of patients, particularly
those with breast cancer, were referred for tumour
measurement after failing to respond to cytotoxic
chemotherapy. In those patients, a period of at
least three weeks elapsed between final
administration of chemotherapy and initiation of
measurement observations, and treatment was only
subsequently implemented after demonstrating a
period of sustained growth.
Informed consent was obtained from all patients
participating in the study. Regular clinical
measurements, ideally on a weekly basis, required
considerable patient cooperation and commitment,
but the scheduling of measurements was adjusted in
accordance with the physical fitness of individual
patients at any time during the study.
After initial tumour measurement, only 18 of the
56 patients with suitable lesions proceeded to
treatment according to the protocol. Of the
remaining 38, the commonest reason for exclusion
was rapid clinical deterioration which either
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necessitated the initiation of systemic treatment
for symptomatic metastases, prevented adequate
hospital attendance, or shortened life expectancy.
Ten of the 18 treated patients are evaluable; of
the eight non-evaluable patients three died after
inadequate follow-up, two required systemic




(a) Frequency of Observation
Serial tumour measurements were obtained pre and
post-radiation/hyperthermia, and in control nodules
throughout the observation period. Ideally, a
minimum of 3-4 weeks prior to treatment was
documented to establish tumour doubling time, but
this was adjusted depending on the predicted life
expectancy, to allow sufficient follow-up time
during tumour regrowth. The time interval between
measurements depended upon the patient's fitness
and willingness to visit hospital. However, where
possible, weekly measurements were obtained
pretreatment and in the early post-treatment phase.
But in the later course of the disease, when
regrowth was established, measurement at two-weekly
intervals was deemed adequate and appropriate in
the face of general clinical deterioration. All
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measurements were carried out by the same
observer (D.T.). The tendency for further lesions
to develop in the vicinity of the treated nodule
during the observation period necessitated a means
of identifying the study nodule during subsequent
shrinkage and regrowth. This was achieved by
tattooing the skin over the centre of the nodule at
the time of irradiation (Fig. 7).
(b) Caliper Measurements
Engineers' calipers were used to measure each
nodule in two planes at right angles to one another
(Fig. 9 ). Tumour margins were located by palpation
to ensure inclusion of the maximum lateral
extension of disease.
Figure 9
Measurement of a subcutaneous nodule (breast
adenocarcinoma primary) using engineers' calipers
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Ultrasound Measurements
Real time ultrasound was available for calculating
maximum tumour depth, assessed in the same two
coordinates as the caliper measurements, at one of
the two hospitals taking part in the study. The
ultrasound equipment comprised a Hitachi
EUB 25 metre real-time machine linked to a
5 megahertz linear array with 3 centimetre
stand/off. Ultrasound images were recorded on
Polaroid film, from which tumour depth could be
calculated by applying the appropriate
magnification factor to the direct measurement
(Fig. 10).
Figure 10
Ultrasound Image of a Subcutaneous Nodule
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4 . 2 . ii Tumour Volume Calculation and Construction of Growth
Curves
(a) Formulae for Volume Calculation Where caliper
and ultrasound measurements were available,
tumour volumes were calculated using the
formula:-
V = „ (a,b . c.)
6
where a, b and c represents maximum
transverse, longitudinal and depth diameters
respectively. Where ultrasound assessment of
depth was not available volumes were
calculated from the formula
V = „ a2b
6
where "a" represents the minimum lateral
diameter.
(b) Computer Constructions of Growth Curves
Growth curves were obtained by plotting tumour
volume (mm3) against time (days) on a
semi-logarithmic scale. In each patient,
tumour volumes were normalised to the date of
treatment. All patients had at least one
control, one radiation and one heat/radiation
nodule.
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4.2.iii Data Derived from Growth Curves
Fig 11 shows the idealised growth curve of a tumour
responding to treatment. The endpoints used in the present
study are indicated and defined below:-
Figure 11
Idealised Growth Curve Showing Clinical
Endpoints in a Tumour Responding to Treatment
GD = Growth delay MVR = Maximum volume reduction
t% = Tumour halving time TMR = Time to maximum response
(a) Tumour Halving Time (t^)
Defined as the time interval necessary for nodules
to shrink to half their treatment-day volume,
has been used to quantify the rate of tumour
shrinkage in responding nodules. A line was drawn
by eye through data points obtained post-treatment,
during the phase of tumour volume reduction. A
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statistical regression technique was considered
inappropriate because of the variable number of
data points, within this phase of the curve, for
different nodules in the same patient.
(b) Maximum Volume Reduction (MVR)
MVR was defined as the ratio of tumour volume at
the time of treatment to tumour volume at the time
of maximum response. In nodules that became
impalpable, the last measurement obtained during
shrinkage was taken to indicate maximum response
for purposes of comparison.
(c) Time to Maximum Response (TMR)
TMR, from the treatment date, was measured in all
responding nodules.
(d) Growth Delay (GD)
Growth delay (GD), defined as the time required for
regrowth of responding nodules to pretreatment
volume, has been used as a semi-quantitative
endpoint in clinical studies with radiosensitisers
(Thomlinson, 1976, Dawes, 1978, Ash, 1979). In the
present study, although all evaluable
radiation-only nodules regrew to pretreatment
volume, in 2 patients regrowing heated nodules
failed to reach this value within the follow-up
period available. For these nodules, growth delay
was estimated by extrapolating from the regrowth
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phase of the curve. This was considered valid as,
in the group as a whole, heated nodules regrew at a
constant rate, equivalent to the rate of growth of
control nodules and to the pretreatment growth
rate.
(e) Tumour Doubling Time (TDT) and Regrowth Rate (RR)
Defined as the time interval necessary for
untreated nodules to double in volume, TDT was
estimated in control nodules and, where available,
from pretreatment measurements in treated nodules.
A line was drawn by eye through the data points as
application of a statistical regression technique
was considered inappropriate [see 4.2.3 (a)]. Rate
of tumour regrowth after treatment (RR) was
calculated in a similar way.
(f) Thermal Enhancement Ratio (TER)
A thermal enhancement ratio for tumour was derived
from the ratio of response to a given radiation
dose alone and to the same dose of radiation in
combination with heat.
The validity of this expression in clinical work
and its deviation from thermal enhancement derived
from dose response studies in animals will be
addressed in the discussion.
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4.3 The Heating Technique
4.3.i The Heating System
(a) Tissue Heating
The heating system used was developed specifically for
treating superficial lesions and is based on a physiotherapy
short wave diathermy unit operating at a frequency of 27 MHz
(Curapuls 418). The equipment has been modified to
incorporate an impedance matching unit, which allows more
efficient transfer of electromagnetic energy to the patient,
and a balanced transmission line connection to the applicator
electrodes so that stray electromagnetic fields are reduced
in the treatment room. The maximum power output of the unit
was rated at 450 W. Localised tumour heating was achieved by




Localised Tumour Heating Achieved Bv Electric
Field Divergence Beneath the Smaller
Applicator Electrode





may result from high
fringing field intensities
Good surface contact and temperature control
is achieved using a perfused saline cushion




The Heating System in Operation Showing the
Saline-filled Cushion Beneath the Smaller
of the Two Electrodes
The saline-filled cushion is shown beneath the smaller of the
two electrodes with the thermometry cannula visible at the
end of the cushion.
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A saline-filled cushion, positioned between the
electrodes and skin, fulfilled a number of functions (Figs.12
and 13) : -
(i) The provision of good electrode contact;
(ii) The avoidance of superficial overheating from high
fringing field intensity by allowing the fringing
field to diverge above skin surface;
(iii) Control of surface temperature by perfusion of the
cushion with temperature regulated saline; and
(iv) Definition of treatment field, shape and size, by
adjustment of cushion dimensions and degree of
inflation.
Clincial experience has demonstrated the system's
ability to achieve temperatures > 43°C, at a depth of 3-4 cm
in lesions with linear dimensions of up to 10 cm.
(b) Control of Skin Temperature
Accurate control of skin surface temperatures at 43°C
throughout the prescribed treatment time was necessary
for treatment of cutaneous nodules and for investigation
of normal tissue effects, and this was achieved by
perfusing the cushions with a temperature-regulated
saline solution. The temperature of the flowing saline,
measured at the entry and exit points, was taken as a
reliable index of skin temperatures provided that a
sufficiently high and turbulent flow rate was
maintained. A further requirement was that the
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contacting membrane of the cushion was of appreciably
lower thermal resistance compared with skin.
4.3.ii Thermometry and Temperature Control
(a) The Reference Temperature - Minimum Tumour
Temperature (MTT)
The non-uniform temperature distributions seen in
clinically heated tumours are complex in origin.
Considering physical parameters first, all heating
methods presently employed induce non-uniform power
absorption in tumours and adjacent normal tissues. This
is further modified by unpredictable physiological
characteristics of individual tumours and their
surroundings. The lack of a non-invasive thermal
measuring technique restricts temperature sampling to a
limited number of points which are inadequate for
describing treatment of the whole tumour and unlikely to
provide a reliable index of biological effect. Recent
experimental studies indicate that minimum tumour
temperature is the best predictor of long-term
biological response when heat is added to radiation
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(Dewhirst et al, 1984).
therefore been used as
present study.
Minimum tumour temperature has
the reference temperature in the
(b) Thermometry Localisation
Ultrasound was used to identify and position a 20 gauge
cannula at the macroscopic junction between tumour and
normal tissue at the tumour base before all heat
treatments. Details of the ultrasound equipment are
given in Section 4.2.i (c) . Local anaesthetic
(1% lignocaine) was used to infiltrate the skin at the
entry point and care was taken to ensure that this lay
outside the area of skin in contact with the saline
cushion (Fig.14).
A thermocouple probe was threaded into the cannula,
allowing temperature measurements to be made at between
two and four tumour points and four and two adjacent




Photograph and Ultrasound Image Demonstrating
the Position of the Thermometry Cannula
/
The black skin marks correspond to the position of




Ultrasound Image and Schematic Representation of the
Thermometry Cannula Lying at the Macroscopic




The position of the six thermocouples is shown with
reference to tumour and normal tissue.
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(c) Thermometry
An implanted linear array of 6 manganin/constantin
thermocouples, used under microcomputer control,
provided rapid information about linear temperature
distributions. The multijunction thermocouple sensors
were developed using the design principles discussed by
Carnochan et al (1986) .
4.3.iii Heat Treatment
(a) The Prescribed Heat Dose
The treatment aim was to give a minimum tumour
temperature of 43°C for the prescribed time of
60 or 30 minutes. Wide lateral field margins were
chosen to minimise lateral temperature gradients within
tumour tissue, thus increasing the likelihood that the
minimum tumour temperature would be located at the
tumour base. To increase this probability further the
skin surface was maintained at the specified minimum
tumour temperature.
(b) Scheduling of Heat with Radiotherapy
Hyperthermia was given 3-4 hours after radiotherapy.
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4.4. Radiation
(a) Selection of Radiation Employed
Forty-six nodules were irradiated with single doses of
electrons. Electron energies were selected to give as
uniform coverage of the lesion as possible, tumour depth
having been calculated from ultrasound images. Where
overlying skin was infiltrated with tumour, the
appropriate depth of perspex buildup was added to ensure
adequate dose throughout the nodule.
(b) Selection of Field Size and Radiation Dose
Field size was chosen to give good clinical coverage of
the lesion. Radiation dose ranged from 6-12 Gy and the
number of nodules given each dose level, with or without
hyperthermia, is shown in Table 8.
TABLE 8










The dose selected was that considered necessary to
induce tumour regression while permitting subsequent
regrowth within a feasible observation period. For each
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patient, this was judged on tumour type, previous
radiation response and tumour doubling time. Where
possible, a range of radiation doses was given to
different nodules in the same patient, but if only two
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5 .1 Xenon Clearance
5.1.i Reproducibility of Xenon Clearance as a Technique
for Measuring Blood Flow in Small Superficial
Tumours
133
Xe clearance has been evaluated for its suitability
as a technique for measuring vascular change induced by
hyperthermia in human tumours. The reproducibility of the
technique was assessed first in a group of small, superficial
metastases (< 10ml) and later in a group of larger
superficial tumours (>_ 10ml) in which lymph node metastases
were included. Patients were referred from, and investigated
at, two hospitals but the same procedure was followed at each
centre and carried out by the same operator (DT).
External conditions were carefully standardised with
respect to room temperature and patient positioning. A bolus
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of about 10 MBq of Xe in 0.1 ml saline was injected
directly into the tumour using a 25 gauge (16 mm) needle. To
ensure accurate repositioning of the needle the site of
injection was localised by skin tattooing. At one of the
centres Ultrasound was available to measure the depth of the
tumour centre beneath the skin surface and a marker placed on
the needle shaft at the appropriate height.
The barrel of the syringe was held perpendicular to the
skin surface during slow injection of xenon. On removal of
the needle the skin surface was wiped to remove any
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extravasated xenon and the detector rapidly positioned. The
equipment used to detect the gamma emissions was either:-
(i) A 5" diameter x 2" thick sodium iodide detector with a
focussing collimator connected to a Canberra
series 40 multi-channel analyser in multiscaling mode
(Royal Marsden Hospital, Sutton)
OR
(ii) a large field of view Siemens ZLC750 gamma camera
with a x 3.75 magnification, fitted with a
low-energy all purpose collimator (Royal Marsden
Hospital, London).
A scheme of the setup is shown in Fig. 16.
Data was collected at 10 second intervals over a
20 minute period. Washout curves consisted of background
plus either a single exponential or the sum of two
exponentials. A Gauss-Newton curve fitting programme was
applied to the data to extract the exponential functions from
the equation shown below:-
-Kit
^ -K2t , „
y (t) = Ae + Be + C













Blood flow was then calculated from the standard
formulae below and expressed in mis/min/100g:
(i) Bi-exponential decay Flow = AK^ + BK ^
A + B
(ii) Mono-exponential decay Flow = K
Delta, the partition coefficient between tumour and blood,
was taken to have a value of 1.0 ml/g.
For each tumour the procedure was repeated after a
2-4 hour interval during which time there was no therapeutic
intervention. This time interval allowed for adequate fall
in xenon activity within the tumour and would be an
appropriate schedule for use with hyperthermia.
5.2 Thermal Clearance
5.2.i Thermal Clearance Technique
A flexible multiple-sensor thermal clearance probe has
been used to study blood flow in human tumours and
surrounding normal tissues. The probe was based upon a
multiple-junction thermocouple array of the type commonly
employed to monitor localised hyperthermia treatments and the
essential features are illustrated in Fig. 17
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Figure 17
Illustration of the Essential Features of the
Multiple-sensor Thermal Clearance Probe
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Initially a nylon sheathed probe (0.5 x 0.63 mm.,
i.d. x o.d.) housing two thermocouple junctions, with a
separation of 10 mm, was used (Design 1). Later, this was
replaced by a polytetrafluoroethane (PTFE) sheathed probe
(0.4 x 0.6 mm) encasing six thermocouple junctions 5 mm.
apart (Design 2). The latter probe was considered superior,
despite the better thermal characteristics of the thinner
walled nylon sheathing, because of a decreased propensity to
kinking. The heating element was formed from a short length
of 25 Mm diameter enamelled manganin wire, prevented from
making close contact with the thermocouple wires by a PTFE
sleeve. Enamelled copper connecting leads (40 Mm diameter)
were soldered to the heating element for connection with a
constant current supply. The thermocouple junctions were
positioned symmetrically about the mid point of the heating
element, which was always at least 3 cm longer than the
thermocouple array. The design of the probe allowed it to be
fixed in position within the tissues so that serial
measurements could be taken at several points without the
need to mechanically disturb the local environment. The
probe was considered to reflect flow changes over a radius of
approximately 2-3 mm from each sensing point but the precise
distance is dependent upon the thermal characteristics of the
surrounding median (Perl, 1962) .
Probe heating, using a current of 60mA, was maintained
for a period of 5 minutes and the subsequent cooling phase
recorded at 5 second intervals until a steady state was
achieved (5-15 mins.). Temperature recording was computer
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controlled (K3000E, Keraitron Ltd.) and measurements made to a
resolution of 0.025°C with an accuracy of ± 0.15°C. A linear
fitting procedure was used to characterise the cooling phase,
in terms of a single exponential decay constant, for each set
of data. The analysis was based upon the assumption that
changes in the cooling rate constant, beyond those expected
from experimental error, correspond to changes in blood flow.
5.2.ii Initial Probe Characterisation and Assessment of
the Reproducibility of the Technique
Preliminary physical characterisation of the thermal
clearance probe was performed in a polyacrilamide gel phantom
considered to be thermally representative of non-perfused
tissue of moderate water content, such as necrotic tumour.
Thermal characteristics of the nylon sheathed probe,
following a 5 minute heating period with a 60mA current are




Thermal Characteristics of the Nylon Sheathed
Probe in Tumour and Phantom, Following





























Cooling Curves, in Phantom and Tumour, Following
a 5 Minute Heating Period
O
• phantom (j3 = 6.0 x 10"^ sec."-'-)





Inspection of cooling data revealed two distinct
components; a fast initial phase and a slower, single
exponential component described by the decay constant (beta)
derived from the expression:
log1Q (T - Tf) = log1Q (To - Tf) - Bt
In(10)
where T is the probe temperature at time t, Tf the final
steady state probe temperature and To the "apparent" probe
temperature at the start of cooling. Reproducibility of the
system was initially assessed by ten consecutive measurements
within the gel phantom. Mean values of beta, and respective
-3 -1
standard deviations were found to be 6.6 (0.47) x 10 sec
-3 -2
for position 1 and 5.9 (0.28) x 10 sec for position 2.
Thermal clearance characteristics were compared for the
gel phantom material and a cutaneous tumour nodule. Two
interesting differences are demonstrated in Figs. 18 and 19;
firstly, the temperature rise during heating is lower for the
tumour and secondly the value of beta is higher. Although
dissimilar thermal conduction parameters may account for some
of this difference, it seems reasonable to suggest that the
presence of blood flow in the tumour is influencing the
observations.
The reproducibility of the technique was assessed in a
group of 10 patient volunteers with previously untreated
superficial tumours. Tumours were selected to reflect the
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type of lesion commonly considered suitable for hyperthermia
studies. The thermal clearance probe (Design 1) was
introduced into tissue such that point 1 lay within the
central part of the tumour and point 2 in the surrounding
subcutaneous normal tissue. This was achieved in six
patients, while the remaining four experienced discomfort
which prohibited insertion of the probe to the desired
position. In these patients temperature measuring points lay
within normal tissue, so that in total six tumour and 13
normal tissue points were assessed. Thermal clearance
measurements were repeated at least three times over a
60-90 minute period, resulting in a total of 74 measurements.
5.2.iii Thermal Clearance - Hyperthermia Study
A multiple junction thermocouple probe (six junctions,
5mm spacing) positioned at the base of the lesion, as
described in Chapter 4, provided thermal dosimetry and
treatment control. In a similar way, the insertion of the
thermal clearance probe was guided by placement of 20 gauge
PTFE cannulae after infiltration of skin entry and exit sites
with local anaesthetic (lignocaine hydrochloride 1%) . This
second cannula was introduced in a direction perpendicular to
the thermometry probe and advanced in a more superficial
plane such that the central part of the tumour was traversed.
The distal portion of the cannula was exteriorised and,
after inserting the probe, the guide cannula was removed.
Both proximal and distal parts of the probe were securely
taped to the patients during thermal clearance measurements
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and layers of gauze placed over the area to ensure good
thermal insulation. Fig. 20 shows the thermal clearance
probe secured by tape and, at right angles to it, the cannula
which houses the thermal dosimetry probe. the positions of
the thermocouple junctions for both probes are marked on the
skin.
Figure 20
Thermal Clearance Probe and Thermometry Cannula
Positioned at Right Angles to One Another
The position of the thermocouples, in tumour
and normal tissue is indicated on the skin surface.
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Single doses of hyperthermia, with the aim of achieving
a minimum tumour temperature of 43°C for 60 minutes, were
delivered using the capacitively coupled electromagnetic
field heating system described in Chapter 4. The prescribed
dose of heat was considered, in our experience, to be the
highest consistent with a reasonable probability of technical
success and avoidance of significant normal tissue damage.
It was also felt to be within the range where a substantial
difference between the vascular response of tumour and normal
tissue might be expected.
Thermal clearance measurements were only made during
periods of tissue thermal stability better than ± 0.2°C in
any 10 minute period and this required a delay after initial
probe insertion or following hyperthermia of typically
20 minutes. The thermal clearance probe was disconnected
from the recording equipment during hyperthermia sessions to
minimise the probability of electromagnetic interference.
Care was taken to avoid placing thermocouple sensing points
within a centimetre of areas infiltrated with local
anaesthetic. Where possible, thermal clearance measurements
were made before hyperthermia, immediately following
hyperthermia, 4 hours and 24 hours after hyperthermia.
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6.1 Quality of Heat Treatments.
The ability of the heating system to deliver a
prescribed treatment has been tested by examining the
physical characteristics of 56 single hyperthermia treatments
in small superficial circumscribed tumours. Clinically,
these formed a fairly homogeneous group with some patients
contributing different lesions to more than one study
included in this thesis. The 56 treatments have been
designated as successes or failures according to the criteria
in Table 9. In the present analysis, the term success is
used to describe the physical quality of the heat delivery
and has no biological implication.
TABLE 9
CRITERIA USED TO ESTABLISH SUCCESS OR FAILURE.
OF HEAT DELIVERY
Successful heat delivery MTT of 43°c for the prescribed time
of either 60 or 30 mins.
Failed heat delivery F1 Failure of MTT to reach 43°c.
F? Failure to maintain MTT at 43°cz
for the prescribed time.
(MTT = Minimum tumour temperature)
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Fifty-four percent (30) of heat deliveries achieved the
prescribed aim. The remainder (26) were classified as
failures and allocated to one of the two groups according to
the criteria in Table 9. Fl failures were more common than
F2 failures, with 16 and 10 treatments in each respectively.
The physical characteristics which have been analysed
are temperature distribution along the multijunction
thermocouple probe, power deposition requirement and time
taken to reach treatment temperature. In addition, tumour
characteristics, such as volume, site and histology, have
been examined to identify factors influencing heat delivery.
Patient variables, such as pain tolerance and ability
comfortably to maintain the treatment position have also been
considered in this study.
6.2 Analysis of Heat Delivery Treatments by Temperature
Distribution
A typical arrangement of the six thermocouples used to
monitor temperature in tumour and normal tissue is shown in
Fig 21 . Depending on tumour size, between 2 and 4 points
were considered to lie at the tumour base and this was
confirmed by ultrasound imaging with the probe in situ.
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responses summarised in Fig. 44 showed no significant
difference in each group (single tailed x2 test,
p = 0.05 level). This result was also supported by a careful
inspection of temperature data recorded during hyperthermia,
which did not reveal any significant relative changes between
tumour and normal tissue temperatures throughout the heating
period.
Figure 45
Transient Erythema Following Heating of the Skin





Temperature Profile Obtained from Measurement at
Six Thermocouple Junctions, in Tumour and Normal
Tissue
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Temperatures measured at this time varied within the range
32-36°C, depending on the depth of the cannula beneath the
skin surface. After positioning the saline cushion over the
treatment area, temperatures were further observed before
turning on the power. During this period, an initial
temperature rise was seen and following an interval of
5-10 minutes, the temperature stabilized, usually in the
region of 37-40°C.
The initial power input was 25-50 watts, depending on
the field size, and was subsequently adjusted manually, with
the aim of achieving a temperature rise of 0.5°C per minute.
This usually required power adjustment every one to two
minutes until the minimum tumour temperature reached the
prescribed level. The time of application of non-ionizing
radiation is indicated in Fig. 22 by "power on" and, as in
this example, was usually followed by a period of linear
temperature elevation. The plateau phase indicates the
time/temperature specifications of the delivered treatment.
The patterns of temperature distribution observed along
the six thermocouples has been classified as shown in
Fig. 23. The initial part of the plateau phase of the
temperature profile was used to allocate treatments to
temperature distribution pattern types, in order to avoid the
influences of heat-induced vascular changes likely to occur




A Classification of the Patterns of Temperature
Distribution Observed Along the Multi-junction













Other tumour points 2 43°C
cold spot > 43°C (success)
cold spot < 43°C (failure)











Temperature gradient < l°C/cm
As above but with highest terminal
Normal tissue point > 43.5°C
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Although temperature fluctuations were seen at
individual measurement points during heating, the overall
distribution patterns were unaffected during the course of
treatment in all but one patient. In this instance a
progressive, differential, decline in temperature at the most
proximal normal tissue measurement point resulted in a change
from Tib to Tl. However, Tib was the dominant pattern
considering the plateau phase as a whole. Temperature
gradients, or change in temperature with distance, were
indicated by the slope of the plateau phase, and expressed as
degrees centigrade per centimetre.
In temperature profile types Tl and Tib, a smooth
distribution was arbitrarily defined as a temperature
gradient of < l°C/cm, or < 0.5°C variation between adjacent
thermocouples. The distinction between the two was the high
lateral normal tissue temperature in Tib, as a result of
progressive small temperature rise in one direction along the
probe. With Tl distributions, several profile shapes were
possible while maintaining the criteria for a smooth
distribution (see Fig. 23). T2b was similar to Tib, with a
high normal tissue temperature, but allocation to the former
required the presence of a temperature gradient of > 1°C per
centimetre. Type T3 temperature profiles displayed a single
tumour cold spot which could either be above 43°C (successful
treatment) or below (treatment failure).
The aim of this analysis was to examine the homogeneity
of heating achieved with the hyperthermia system employed in
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6.3 Homogeneity of Heat Delivery
The frequency of temperature distribution types in the
56 hyperthermia treatments is shown in Fig. 24. A smooth
distribution was achieved in 73% (41/56), of which the
majority (68%) were included in category T1. A single cold
spot in tumour, in an otherwise adequate temperature profile
(T3) accounted for a further 20% of heat sessions. There
were no T3b distributions and only two completely
heterogeneous profiles.
Figure 24
Frequency of Temperature Distribution Patterns
(T Type) As An Expression of Homogeneity of
Heating in 56 Heat Deliveries
100 -i
1 lb 2 2b 3 3b 4
Temperature distribution Type (T)
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Treated lesions have been ranked according to tumour
volume for each of the temperature profile types (Fig 25) .
Within the range of volumes treated (0.1 - 15 cm2), tumour
size did not appear to influence uniformity of heating,
although the number of lesions in - T^ is small.
Figure 25






































Combining all non-T^ temperature profiles for comparison
with type , the range of values and median volumes are
remarkably similar (Fig. 26) .
Figure 26
Range of Tumour Volume and Median Values For











































6.4 Influence of Temperature Distribution on Success of Heat
Delivery
From the definition of success, as described in Table 9,
any type of temperature distribution could occur with either
a successful or failed heat session, apart from T3b, a
distribution pattern which implies failure. Therefore, to
examine whether temperature distribution influenced failure,
the patterns have been analysed for the two groups (Fig. 27).
A smooth temperature distribution (Tl, Tib) occurred in
86% (26/30) of the 30 successful heat deliveries, and of
these 77% were type Tl. Of the remaining 4 successes, 3
displayed single hot or cold spots in the temperature
profiles. There was one completely heterogeneous
distribution (T4) which nevertheless fulfilled the criteria
for success.
In the 26 failures, smooth temperature profiles were
less frequent (58%) and type T3 distribution more prominent
(35%), compared with the group of successful heat deliveries
(Fig. 27). However, grouping temperature distributions as Tl
or non-Tl, for the successes and the failures, there was no
statistical difference between the two groups (x2 = 4.5,
df = 1, p = 0.34) .
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Figure 27
Frequency of Temperature Distribution Patterns in
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Temperature type distribution
(3b) excluded from success analysis by definition - see Table )
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TABLE 10
CHARACTERISTICS OF THE SEVEN EXCLUDED FAILURES
Reason for Temperature
discontinuing treatment Failure type distribution
pattern
( F2 T1
Non-related symptoms or ( F2 T1
Inability to maintain position ( F2 T1
C F2 T3
( FX T1
Excessive sensitivity to low ( FX T1
temperature ( FX T1
Treatment failures were also examined after exclusion of
seven patients on the grounds that these failures were not
related to temperature distribution. Thus, in 4 patients
treatment had to be terminated early because of the onset of
non heat-related symptoms and/or the inability to maintain
the treatment position after the prescribed minimum
temperature had been achieved. By definition these were F2
failures. Table 10 shows that three of the four had smooth
distributions (Tl) until the power was switched off. In the
three other excluded patients, localised discomfort was
experienced despite uniform temperature distributions (Tl)
below the prescribed minimum tumour temperature.
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This suggested excessive sensitivity to lower temperatures,
as a result of which the treatment aim could not be achieved,
making these F1 failures. These seven patients therefore
contributed 40% of the T1 distributions in the entire failure
group.
Analysis of temperature distribution in the adjusted
failure group reveals only 10% (2/19) T1 distributions,
compared with 31% (8/26) in the total failure group. After
making the exclusions, T3 distribution is an even more common
occurrence (42%). Repeating the analysis by T1 and non-Tl
grouping, there was a statistically greater proportion of T1
temperature distributions in the successes compared with the
adjusted failure group (x2 = 6.84, df = 1, p = 0.009).
6.5 Analysis of Heat Delivery by Power Requirements
The steady state power applied during the 56
hyperthermia treatments ranged from 11 to 370 watts.
Dividing this range into 40 watt intervals, a comparison has
been made between power requirements in the successful and
failed heatings (Fig. 28)
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Figure 28
Steady State Power Application in Successful
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Sixty-six percent of successful heat deliveries achieved
the prescribed aim of 43 °C (MTT) for 60 minutes with an
applied power of 80 watts or less. The majority of the
remainder required between
successful treatments were
210 and 250 watts respectively.





Anatomical site, adjacent normal tissue structures and
histological type have been considered, but in this small
group of treatments, no contributory factors have been
identified.
Temperature profiles have been examined to see whether a
tumour cold spot (Type T3) might have been responsible for
the high power application necessary to achieve success.
However, only one of the 10 treatments showed a T3
distribution, with Tl and Tib profiles accounting for 8 and 1
treatments respectively.
In 73% (19/26) of failed heat deliveries, power was
increased to > 80 watts in an attempt to reach the prescribed
temperature. In 6 of the 19, the application of a high power
level was in an attempt to elevate a single tumour cold spot
(T3) to the prescribed temperature. In five of the failure
group treatment temperatures were not achieved despite
application of 170-370 watts.
6.6 Analysis of Time Taken to Reach Treatment Temperature
Eighty-three percent of successful heat deliveries
achieved the prescribed temperature within 10 minutes and the
remainder did so in less than 20 minutes. Eighty-four
percent (21/25) of rapid temperature achievers {<_ 10 mins.)
had smooth temperature distributions kut one ^2' tWO
T^ and one T^ patterns were included in the group.
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Only the 10 F2 type failures can be included in this
part of the analysis as by definition F1 failures did not
reach the treatment temperature. Of these, 50% achieved the
prescribed temperature in 10 minutes or less. The remaining
50% reached 43°C between 10 and 20 minutes after turning on
the power.
6.7 Analysis of Successful Heat Delivery by Tumour Volume
Tumour volumes, calculated from measurements taken on
the day of treatment, show a wide overall range from
0.1 cm3 - 15 cm3. The distribution of volumes in the
successful and failed heat delivery groups have been analysed
and are displayed in Fig. 29.
Comparing the range of values, 0.1 - 6.9 cm3 and
0.1 - 15cm3, with median values of 0.7 cm3 and 1.7 cm3
respectively for successful and failed treatment there was
evidence using the Mann Whitney U test (p = 0.02) that the
tumour volumes were larger in the failure group. However,
using the same test to investigate the similarity of the two
failure subgroups F^ and F^, there was no difference in the
medians of the two groups (p = 1.00).
The influence of tumour volume on uniformity of heat
delivery and steady state power requirement has been
described in Sections 6.3 and 6.5.
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Figure 29
Tumour Volume Range and Median Values in































6.8 Analysis of Treatment Success by Tumour Site
The majority of the 56 treated lesions were located on
the chest wall and there was no other site that predominated
in either group.
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6.9 Analysis of Treatment Success by Tumour Histology
The distribution of histological tumour type was similar
between the successful and failed treatments with
adenocarcinoma of breast, adenocarcinoma from other primary
sites, squamous and small cell carcinoma accounting for 86%
and 96% of the two groups. Seventy percent of successful,
and 61% of failed, treatments were in metastases from breast
cancer.
6.10 Patient Variability
Patient variables, such as age, sex, extent of other
metastatic disease and general condition did not predict for
success of heat delivery. However, patients who were
generally anxious, or who were specifically apprehensive at




Difficulty in quality assurance in hyperthermia remains
one of the major deterrents to evaluation of the modality in
Phase III clinical trials (Nussbaum, 1984). It is widely
reported that variations in temperature distribution occur
not only between tumours, but also between successive
treatments in the same tumour, and even during the course of
a single treatment session. This inability of currently
available heating devices to reproducibly deliver a standard,
uniform heat dose is a major complication to the convincing
demonstration of a therapeutic gain. However, careful
recording and analysis of temperature variation can provide
useful physical and biological information which may
influence future application. For example, the importance of
temperature distribution in predicting response was first
recognised in murine systems (Wallen et al, 1981, Gibbs et
al, 1981) . Subsequently, a correlation between minimum
monitored intratumoral temperature and prognosis, for both
complete response and long term control, was demonstrated in
spontaneous pet animal tumours treated with hyperthermia and
radiation (Dewhirst et al, 1984) . Human data are also now
available which suggest that minimum tumour temperature has a
critical influence on biological outcome in clinical
hyperthermia (Arcangeli et al, 1985; Oleson et al, 1984).
The rationale for using minimum tumour temperature as a
reference temperature in the studies described in this thesis
has been presented in Chapter 1. In a further attempt to
standardise treatment, the macroscopic junction between
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tumour and normal tissue, at the tumour base, was selected as
the reference for minimum tumour temperature measurement, and
located with the aid of ultrasound imaging.
On the basis of prescribing treatment to a minimum
tumour temperature for a specified time, strict criteria have
been used to determine success, in terms of heat delivery,
and to classify failure. The distinction between and F^
failures is fundamentally important in an analysis of heat
delivery. In F^ failures the heating set-up and/or tissue
anatomy and physiology prevent adequate tempeature rise at
the point of interest. By contrast, in F^ failures the same
parameters permit the required minimum tumour temperature to
be achieved but, for a variety of reasons, this cannot be
sustained for 60 minutes. Thus, analysis of heat delivery by
tumour volume showed that failure overall was more likely in
larger lesions, an association which could be attributed to
the thermometry probe lying at the greater depth. However,
this reasoning is inconsistent for F^ failures which achieved
the minimum treatment temperature, and raises the possibility
that F^ lesions formed a subgroup which were not in fact
larger, and the observed difference in volume between
successes and failures was due to the impact of large lesions
confined to the F^ group. For this reason tumour volume was
compared for F^ and F^ heat deliveries, but was found to be
similar. This suggested that with this heating system, large
lesions are not only less likely to reach the required
minimum tumour temperature, but are also less likely to
sustain the temperature rise. With only 10 F£ heat
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deliveries, it has not been possible to identify why tumour
volume might be responsible for the latter, but the larger
size nodules may reflect general disease status and thus
patient fitness and tolerance of the procedure.
Very little performance data are available in the
hyperthermia literature for comparison with the present
series in which 54% of small superficial lesions achieved
43°C (MTT) for 60 minutes. In an evaluation of treatment in
116 small superficial tumours, Dunlop et al, (1986) addressed
the question of technical performance by calculating minimal
thermal dose in terms of minutes equivalent at 43 °C (see
Chapter 1) . Twenty-four percent of treatments reached a
level of heating equivalent to 43°C for 60 minutes, of which
more than half were not first time treatments, a factor which
may bias the outcome towards success. One of the reasons for
the difference in success between the two series may be the
variety of technical systems employed by Dunlop and his
colleagues. The authors considered that the 58% of
treatments resulting in the equivalent of 43°C for 20 mins.
were "biologically useful". Using the same criteria, 68% of
treatments in the present series, all first time treatments,
were successful.
The construction of temperature profiles provided an
immediate temporal and spatial assessment of each treatment,
although the available information was obviously limited by
the number of temperature measurement points and their
distribution in tissue.
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Despite standard positioning of the thermometry probe at the
base of the tumour, the selection of an axis of insertion was
an arbitrary decision which at certain anatomical sites could
have influenced power requirement, subsequent temperature
profile, and categorisation as success or failure. Patient
comfort and optimisation of equipment positioning were the
major considerations taken into account when making this
decision. However, visualisation of the thermometry probe,
in the treatment position, provided useful information not
only indicating the position of each thermocouple with
reference to tumour and normal tissue, but also permitting an
estimate to be made of the depth of each temperature sensor
beneath the skin surface. To minimise temperature gradients,
probe alignment would ideally have been parallel to the skin
surface. However, as probe insertion was necessarily
oblique, there was a gradual increase in depth towards the
distal end, the magnitude of which depended on the depth of
the lesion. This obliquity was reflected in the range of
temperature observed after insertion of the thermocouple
wire, before positioning the saline cushion. The extent of
the initial temperature rise observed at each thermocouple,
as a result of positioning the saline cushion, demonstrated
that with a skin surface temperature of 43 °C heat transfer,
by conduction alone, was very poor and, even over very
shallow depths, there was a rapid fall off in temperature.
Temperature recordings taken before switching on the power
allowed identification of anomalous values which might
influence subsequent temperature profiles (Fig 30) .
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Figure 30
Temperature Profiles Recorded Across Six Thermocouple


























PLATEAU PHASE OF HEATING
SALINE CUSHION IN POSITION
BASELINE MEASUREMENTS
THERMOCOUPLE NUMBER
Baseline observations indicate lower temperatures at
proximal measurement points, in keeping with their
superficial situation. Positioning the cushion, perfused
with warm saline (43°C), results in a temperature rise which
is most marked at the proximal, superficial thermocouples,
but at this stage a cold spot is detected at junction 3. The
suspicion that vascular influences are responsible for this
isolated temperature variation is supported by the
persistence of a cold spot, at the same site, throughout the
plateau phase of heating.
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Temperature distribution was remarkably constant during
the plateau phase of the profiles in those tumours
successfully heated. As a consequence, the minimum tumour
temperature, on which treatment was controlled, remained at
the same measurement point throughout treatment in most
cases. Inadvertent movement of the applicator was generally
responsible for shift in the site of minimum, but the
previous distribution could always be restored by simole
adjustment of the applicator setup.
A classification of temperature profile was constructed
with the aim of examining uniformity of heating and of
identifying reasons for treatment failure in terms of
temperature distribution. The categories of distribution
type were selected to represent the present series, after
initial inspection of temperature profiles. For this reason
it was generally easy to allocate treatments to distribution
type by analysis of initial part of the plateau phase.
Uniformity of heating was remarkably good, with 73% of
the 56 treatments showing a smooth temperature profile.
Although inhomogeneity of temperature distributions is
generally correlated with lesion size, no such tumour volume
effect was seen over the range of lesions included in this
series. This confirms the adequacy of the heating system in
the studies described.
In an attempt to define reasons for treatment failure,
in terms of temperature distribution, a number of exclusions
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were made from the failure group. This was considered valid
as the reasons for failure in the exclusions were well
defined in each case, and not related to temperature
distribution. Having made this adjustment, non-T^
distributions, in particular T^, were significantly more
common in those treatments which failed.
In the present series of small lesions, these isolated
cold spots were a significant finding in the heat sessions
which failed to deliver the treatment aim. The occurrence of
cold spots in larger tumours is presumably just as likely,
provided the density of vessels is similar. However, as the
density of temperature sampling is unlikely to be as great, a
higher proportion of these tumours will be unmonitored,
making the detection of cold spots less likely. Because of
thermometry limitations, it is not possible to define the
exact boundaries of a cold spot, but, from temperature
measurement at adjacent points, it seems likely to be only in
the order of millimetres. As power deposition problems are
unlikely to result in such localised temperature variation,
vascular influence remains the most likely explanation.
As yet, the biological significance of cold spots has
not been established. Although Dewhirst et al, (1984)
clearly demonstrated the impact of minimum tumour temperature
on biological outcome, no distinction was made between
isolated cold spots and uniformly underheated tumours. As
the cold spots described here represented temperature in a
small core of tissue, it may be impossible to demonstrate
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their influence except at a critical level of cell kill. In
addition, when combined with radiation, these underheated
areas of tumour should theoretically coincide with the more
radiosensitive zones so that in practical terms of clinical
application they may be insignificant. However, as the
oxygen diffusion distance in tissue is likely to be less in
magnitude than the radius of influence of a cold spot the
possibility of a biological effect cannot be excluded.
In this study of hyperthermia delivery in 56 small
circumscribed superficial tumours, correlation of physical
parameters of treatment with biological effect has not been
possible because the lesions were pooled from a number of
studies designed to examine different effects. The influence
of the physical characteristics of heating on biological
outcome in terms of growth delay is addressed in Chapter 7.
Analysis of power requirement and time to achieve
minimum temperature in successful heat deliveries showed that
in 63% of instances < 80 watts was necessary to achieve the
presribed tumour temperature of 43°C within 10 minutes. It
is therefore possible that a test heating, with this level of
power operating for 10 minutes, might discriminate between
tumours in which temperatures adequate to produce direct
cytotoxicity could be expected, from those tumours in which
only lower temperatures, possibly useful for
radiosensitisation, will be likely. This information would
in turn influence the timing of hyperthermia in relation to
irradiation. However, a predictive system employing test
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hyperthermia risks the possibility of inducir"^
thermotolerance.
Apart from lesion size, tumour characteristics do not
seem to influence treatment success. However, taking the
group as a whole, there was little variation in the
parameters considered, with most lesions being small, chest
wall recurrences from adenocarcinoma of breast. It is
therefore unlikely that the present analysis would identify
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7.1 Heat Modification of Tumour Response to Single Dose
Irradiation
The results have been derived from tumour volume
measurements on 96 nodules in 10 evaluable patients. The
number of nodules observed in each patient and their
characteristics are listed in Table 11.
TABLE II
NUMBERS AND CHARACTERISTISC OF NODULES STUDIED











1 12 Melanoma SC 20
2 12 Adenocarcinoma (B) SC 24
3 7 Adenocarcinoma (B) C 77
4 19 Adenocarcinoma (B) C 28
5 12 Adenocarcinoma (B) C 36
6 9 Adenocarcinoma (B) C 175
7 8 Adenocarcinoma (B) C 33
8 7 Adenocarcinoma (U) SC 64
9 3 Squamous carcinoma(U) SC 40
10 7 Squamous carcinoma(S) C 12
(B) = Breast primary
(U) = Unknown primary
(S) = Skin primary
(SC)= Subcutaneous nodule
(C) = Cutaneous nodule
The composition of the nodule group with respect to
treatment is shown in Table 12 .
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TABLE 12
CLASSIFICATION OF NODULE POPULATION
ACCORDING TO TREATMENT
Treatment Untreated Radiation Heat & radiation Heat Total
No. of
nodules
48 31 15 2 96
Growth curves were used to quantify the effect of
applying heat 3-4 hours after single dose irradiation.
Examples of curves constructed from tumour measurements in
three patients with melanoma, adenocarcinoma of unknown
primary and metastatic breast carcinoma respectively, are
shown in Figs. 31, 32, 33. These are patient number 1, 2 and
8 in Table 11.
Figure 31 illustrates 3 of the 12 nodules measured in
Patient no. 1. Only two treated lesions and a control are
included for clarity but a second nodule treated with 8 Gy
plus heat responded very similarly and has a response curve
which can almost be superimposed on the heat/radiation nodule
shown. A further nodule given 10 Gy alone failed to regress,
but growth after treatment slightly deflected from that
plotted for control lesions.
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Figure 31
Growth Curves Derived from Tumour Measurements












Arrow indicates date of treatment
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Ficrure 3 2
Growth Curves Derived from Tumour Measurements
in a Patient with Adenocarcinoma Nodules of
Unknown Primary
Time (days)
Arrow indicates date of treatment
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Figure 33
Growth Curves Derived from Tumour Measurements in
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The gross effect on tumour response of adding heat to
radiation has been scored as either greater than, equal to,
or less than, the effect of radiation alone. In 9 patients
the effect was greater with heat, and in the remaining one
patient there was no demonstrable effect in terms of tumour
volume reduction with either radiation or heat/radiation
(Table 13).
TABLE 13
COMPARISON OF THE OVERALL EFFECT OF RADIATION ± HEAT
IN MEASUREABLE SUPERFICIAL METASTASES
Tumour





R = Radiation H = Hyperthermia
7.1.i Tumour Volume Halving Time (t^)
In the seven patients in which tumour volume halving
time could be calculated, nodules heated after radiation
regressed faster than those treated with radiation alone.
For heated nodules, th ranged from 7-34 days with a median
value of 15.5 days. Without heat, the range was from
12-102 days with a median of 70 days (Fig. 34). Of the three
radiation-only nodules which regressed rapidly, each had a
heated counterpart which regressed at an equal or even
greater rate. There was no instance where the addition of
heat was associated with a slower regression rate.
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Figure 34
Tumour Volume Halving Times in Superficial Nodules
Treated with the Same Single Dose of Radiation





























(ii) Maximum Volume Reduction (MVR)
Six patients could be assessed to compare MVR in nodules
irradiated with or without the addition of heat. In all
cases a greater maximum volume reduction was recorded in the
heated nodules (Table 14) .
TABLE 14
MAXIMUM VOLUME REDUCTION OBSERVED IN SUPERFICIAL NODULES
TREATED WITH THE SAME DOSE OF RADIATION, WITH OR
WITHOUT THE ADDITION OF HEAT 3-4 HOURS LATER
r, . Pretreatment tumour volume
„ Ratio of: r :Patient tumour volume at time of max. response
No.














* Ratio for 12 Gy - all other data refer to 8 Gy
** Ratio derived from last tumour measurement before nodule became
impalpable
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(iii) Time to Maximum Volume Reduction (TMR)
Five patients have been analysed to compare TMR in
superficial nodules treated with the same single dose of
radiation, with or without the addition of heat 3-4 hours
later (Table 15) . A ratio has been derived from TMR with or
without the addition of heat. In each case TMR was slightly
longer with the addition of heat resulting in ratios close to
one. There was no instance where maximum tumour response was
achieved in a shorter time in heated nodules.
TABLE 15
TIME IN DAYS FROM TREATMENT TO MAXIMUM VOLUME REDUCTION IN
SUPERFICIAL NODULES TREATED WITH THE SANE SINGLE
DOSE OF RADIATION, WITH OR WITHOUT THE
ADDITION OF HEAT 3-4 HOURS LATER
Ratio: time H & R













8 54 61 1.1
(In Patient 1 the radiation only dose (12Gy) was not the same as for the
heated nodules (8Gy), in all other cases the same doses were employed)
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(iv) Growth Delay
Twenty-one nodules in 6 patients provided information on
growth delay either by direct measurement or by extrapolation
from the regrowth phase of the growth curves. Table 16
outlines the values obtained for nodules treated with single
doses of radiation (6-12 Gy) with or without the addition of
heat.
TABLE 16
GROWTH DELAY IN SUPERFICAL NODULES TREATED WITH SINGLE DOSES

































* NR = no regression
** Estimated by extrapolation from regrowth phase to treatment volume
°
Nodule remained impalpable to last observation date (day 105)
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In all instances growth delay was greater with
heat/radiation than with radiation alone. Where more than
one nodule received the same treatment in any individual
patient, there was good internal consistency of response.
The exception to this was Patient 5 where 8 Gy alone produced
growth delays ranging from 93-210 days.
(v) Thermal Enhancement Ratio (TER)
A thermal enhancement ratio for tumour response has been
calculated in 6 patients (Table 17). A TER of >1.6 was
assumed in patient 1 as the only nodule treated with
radiation alone which regressed received a higher dose
(12 Gy) compared with the two nodules heated after
irradiation (8 Gy) . Discounting Patient 5, in which there
was marked heterogeneity of response to radiation alone
making interpretation of TER difficult, the range of values
was from > 1.6 to 4.2. In Patients 2 and 8 extrapolation of
the regrowth phase in heated nodules was necessary to derive
a growth delay. In these patients, with inadequate
follow-up, TER has also been calculated from the date of the
last observation on heated nodules not yet regrown to
pretreatment volume. These values, included in parentheses
show that a considerable TER is still obtained.
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TABLE 17
THERMAL ENHANCEMENT RATIOS DERIVED FROM GROWTH DELAY












* Estimation of growth delay in heated nodules by
extrapolation from regrowth curve
° TER estimated from latest observation in heated nodules not
yet regrown to treatment volume
7.2 Correlation of Heat Modification of Radiation Response
with Physical Parameters of Heat Delivery
Clinical outcome in the 50 nodules heated after
irradiation was examined for correlation with physical
parameters of heat delivery (Table 18). According to the
criteria for successful and failed heat delivery (see
Chapter 6), 10 were classified as successful, two as
failures and two as failures. One further nodule was
unclassifiable because of inadequate thermometry, and
assessment in this lesion was complicated by a wide range of
growth delay in the four other nodules in the same patient,
given the same dose of radiation, without the addition of
heat.
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As the measured biological effect of hyperthermia in
assessable patients varied, with TER values ranging from
1.6 - > 4.2, it was difficult to make comparisons between
treatments in different patients in terms of heat delivery
and clinical outcome. However, four patients each had two
heat-radiation nodules which allowed a more direct
evaluation. One patient (Patient 7) showed no response to
8-12 Gy irradiation alone, and the addition of neither an
inadequate, nor a successful heat delivery altered this.
There was discordance between physical parameters and
biological effect in one patient (Patient 2) who had two
successful heat deliveries of which only one produced a
definite clinical effect. In the remaining two patients
where was good correlation between heat "dose" and tumour
response. Lack of influence of an isolated cold spot on




CORRELATION OF HEAT MODIFICATION OF RADIATION RESPONSE















1 J S T1 110 Yes
H S T1 45 Yes
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* = Limited thermometry
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Despite failing to fulfill the prescribed
time-temperature requirements, the two heat deliveries
produced a greater clinical effect compared with the same
dose of radiation alone. In the two F^ failures, one
produced a response which was marginally superior compared
with radiation alone, and the other occurred in a patient in
which there was no response to any of the treatments given.
7.3 Tumour Response to 8Gy Irradiation
The homogeneity of response to 8 Gy single irradiation
was explored in a group of superficial nodules of one tumour
type, breast cancer. Ten of the 18 breast cancer patients
who provided doubling time data in the tumour measurement
study (see Chapters 4 and 9) collectively contributed 58
superficial tumours in which growth rate could be correlated
with radiation response.
7.3.i Tumour Doubling Time and Clinical Features in Breast
Cancer Nodules
The range, and median value of tumour volume doubling
time for each of the ten patients is shown in Fig. 35.
Although the overall range varied between 16 and 206 days,
seven of the patients had remarkably similar median doubling
time values with little intra-patient variation. Seven of
the 10 patients (patients 1-6 and 8) had clinically
comparable lesions in terms of size, cutaneous involvement
and anatomical location on the breast or chest wall. Of the
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remaining three patients, one had subcutaneous lesions, one
had both cutaneous and subcutaneous lesions of a wider size
range and the third had cutaneous lesions situated on the
back.
Figure 35
Range and Median Tumour Volume Doubling Time in






















7.3.ii Correlation of Tumour Doubling Time with Parameters
of Radiation Response
Tumour response was measured by rate of regression,
expressed as tumour volume halving time, and growth delay.
There was no correlation between pretreatment doubling time
and regression rate following 8 Gy single dose irradiation.
As shown in Fig. 36, the more rapidly growing nodules, with
doubling times of 50 days or less, had half time values
ranging from 14-94 days with a median of 51 days.
Figure 36
Correlation of Tumour Volume Halving Time
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Grower, delay was calculated for the six nodules which
earew to pretreatment volume after irradiation. Correlatir.c
hese values with pretreatment doubling time there appears to
e a trend towards longer growth delay with slower growing
esions but the numbers are small (Fig. 37).
Figure 37
Correlation of Growth Delav Following 8 Gv Irradiation











7.3.iii The Contribution of the Components of Response to
Growth Delav
The components of growth delay, tumour regression and
regrowth were examined independently to assess the influence
of each on the calculated value for growth delay. In this
nodule population, there was no correlation with halving time
(Fig. 38) but growth delay did correlate with tumour regrowth
doubling time (correlation coefficient 0.81) (Fig. 39).
Figure 38
Correlation of Growth Delav with Tumour






















Correlation of Growth Delav with Tumour Regrowth
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7.3.±v Investigation of a Tumour Bed Effect Following
8 Gv Irradiation
Regrowth doubling time data was available for 15 nodules
from five patients and ranged from 19-65 days. In 12 of
these nodules serial measurements prior to irradiation also
provided a measurement of pretreatment doubling time which
varied between 16 and 98 days. In these 12 nodules, from
four patients, the ratio of pre to post-treatment doubling
time was calculated and is shown in Fig. 40. Within the
errors of clinical measurement and growth curves analysis
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there was no consistant change in growth rate. Further, nine
of the 12 nodules regrew at approximately the same rate pre
and post-irradiation.
Figure 40
Ratio of Pre to Post Treatment Doubling Time in






7.3.v Investigation of the Influence of Tumour Volume
on Response to 8 Gy Irradiation
In individual patients, the range of tumour volume for
irradiated nodules was generally not sufficiently great to
permit investigation of a volume effect.
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7 . 4 Discussion
This study aimed to demonstrate a quantitative and
qualitative difference in tumour response, as documented by
tumour growth curves, when irradiated nodules were heated
after an interval of 3-4 hours. Despite the difficulties
involved in clinical heat delivery, and the problems
encountered with tumour measurements and their subsequent
utilisation to derive clinical endpoints, an overall greater
effect was observed for heated nodules in 9 out of the
10 patients studied. This initial encouraging impression was
consolidated by the more specific demonstration of
therapeutic enhancement ratios ranging from > 1.6 - 4.2.
However, the term TER is used with caution on two accounts.
Firstly, because radiation and heat were applied
sequentially, with a 3-4 hour interval between them, it is
likely that the two modalities were non-interactive and that
there was no true modification of radiation response by, for
example, a heat-mediated inhibition of repair. Secondly, in
experimental animal tumours, values for TER are derived from
ratios of radiation doses giving the same biological effect
in the absence, or presence, of heat (Robinson, 1974) .
However, construction of dose-response curves from clinical
data is difficult, and TER values for human tumours have
often been derived by comparison of tumour responses to the
same dose of radiation, with or without the addition of heat
(Arcangeli et al, 1983, Kim et al, 1982, Scott et al, 1982).
This derivation of TER has been employed in the present
study, but a TER determined in this way may be greater than
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that based on a uniform biological response
(Gillette, 1982 , 1984) .
In the present internally controlled study, TER values
were calculated in the six patients for whom growth delay
could be measured, directly or by extrapolation. However, in
one of these patients the heterogeneous response observed in
four nodules treated with 8 Gy alone made the derivation of
TER from the single heated nodule meaningless. In the
remaining five patients, values for TER ranged from
> 1.6 - 4.2 suggesting that the advantages of combining heat
with radiation may not be the same for all tumours. However,
there is some evidence to suggest that a dose response exists
for hyperthermia alone (Maher & Carnochan, 1986) and it seems
likely therefore that, in part, this variation can be
attributed to the problem of administering a reproducible
heat treatment. The influence of the physical parameters of
heat delivery on biological outcome was examined in the
present series. The possibility of variation in biological
effect between different tumour types makes analysis of this
data difficult. However, examination of those patients with
more than one heat-radiation nodule provides a better basis
for comparison. Unfortunately, there were only five such
patients and in one of these inadequate thermometry prevented
definite allocation by physical parameters. From this small
number it was not possible to determine a direct correlation,
but individual patients provided useful information. There
is scope for expansion of this area of investigation with the
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aim of establishing the importance of achieving uniform
heating in clinical practice.
Despite the variables encountered in this study,
evidence of thermal enhancement was obtained in breast
cancer, melanoma, squamous carcinoma and in an adenocarcinoma
of unknown primary. This suggests that hyperthermia may
improve the radiotherapeutic management of a wide range of
tumours, but more extensive information is required to define
the optimum utilisation of the two modalities in specific
cancers.
Table 19 summarises available data on the TER values for
human tumours derived from both radiation dose ratios and
tumour response ratios. As predicted by
Gillette (1982, 1984), TERs derived from 1iso^effective
radiation doses (Overgaard & Overgaard, 1984) tend to be low
compared with values derived from response ratios. The
treatment and endpoint variables encompassed in the studies
summarised probably account for the range of TERs obtained.
Archangeli (1983) has demonstrated the variation in thermal
enhancement obtained by modifying the therapeutic protocol in
a study which compared four different schedules of combined
radiotherapy and hyperthermia. The influence of the tumour
endpoint selected has been emphasised by Scott (1982), who
demonstrated a decrease in TER from 2 to 1.3 when initial
complete response rate and that after 6 months were used as
endpoints for calculation of TER in the same group of
tumours. Radiation dose also influences the degree of
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thermal enhancement, with suboptimal radiation likely to
produce a higher TER value (Scott et al, 1983) . The effect
of radiation fraction size is probably dependent on tumour
type. For example, in Arcangeli's study the greatest effect
was seen with conventional radiation fraction size whereas,
in a series of melanomas large fractions induced the greatest
enhancement (Kim et al, 1982) .
Only 18 of the 56 patients on whom tumour measurements
were initiated were considered suitable for entry into the
hyperthermia protocol, and of these only six contributed
growth delay information. Patient deterioration or
introduction of systemic treatment were the main reasons for
exclusion. In those proceeding to the treatment protocol,
acquisition of measurement data appropriate for estimating
growth delay was difficult. For example, the radiation doses
selected were those judged necessary to induce tumour
regression while permitting subsequent regrowth within the
estimated available follow-up period. However, as individual
tumour radiosensitivity to single dose irradiation and
patient prognosis could only be guessed at, there was a high
probability that the available information would be
inadequate. Further, as discussed in Chapter 9, tumour
measurement pretreatment provided doubling time information,
valuable to the design and assessment of treatment in
individual patients. But time devoted to this was always at
the expense of post-treatment observation. However, the
value of estimating tumour growth rate pretreatment is
indicated by the range of doubling times obtained from
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multiple metastases in individual patients (Chapter 9). This
information allowed selection of comparable nodules for entry
into the treatment protocol and to act as untreated controls.
All but two of the 10 evaluable patients had more than five
nodules from which to make this selection, and most had
considerably more. Of the two patients with only three
nodules, one developed further lesions after treatment which
provided confirmation of the uniformity of nodule growth rate
in this instance.
Allocation of nodules to treatment type or control group
was non-random and selection was based on increasing the
likelihood of achieving successful heat delivery. As the
entire heating procedure, from insertion of thermometry probe
at the start to collection of cooling data on completion of
heat delivery could take up to two hours it was essential
that patients were able to lie comfortably. As this was
generally best achieved in a supine position, anteriorly
situated lesions were usually selected for heating. A
further consideration was the provision of good contact
between skin and saline cushion, which implied avoiding
lesions in body folds.
Substantial thermal enhancement of the radiation
response provided further obstruction to the successful
application of growth delay as an endpoint. In the present
study, of the six patients with measurable growth delay, all
nodules receiving only radiation regrew to their pretreatment
volumes within the observation period. Amongst the
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heat/radiation nodules in the same patients, the magnitude of
the effect was such that one nodule remained permanently
inpalpable and three others, though regrowing, did not reach
the pretreatment volume within the follow-up period. For
these regrowing nodules, growth delay was calculated by
extrapolation from the observed regrowth phase, with the
assumption that regrowth would continue at the same rate.
This was considered valid as, in the group as a whole,
treated nodules regrew at a constant rate equivalent to their
pretreatment doubling time. The only exception to this was
one of the heat only nodules in which very rapid regression
was followed by a regrowth rate greater than that observed
pretreatment (Fig 33) . From the available period of
follow-up it is not possible to determine whether this
increased rate was sustained or whether the pretreatment rate
was re-established after a "catch-up" phase.
There was no convincing evidence of a tumour bed effect
in nodules irradiated with single doses of 6-12 Gy without
the addition of heat. This finding was supported by
observation in the breast cancer subgroup, in nodules
irradiated with 8 Gy. This may not be surprising as the
effect is dose dependent and animal studies have similarly
failed to demonstrate growth retardation after small dose
irradiation with 8 Gy (Yerushalmi & Weinstein, 1979). In
addition, other clinical growth delay studies have not shown
a tumour bed effect after single dose irradiation with
4-11.2 Gy (Thomlinson et al, 1976, Ash et al, 1979, Yarnold
et al, 1986) . However, as a result of an enhanced radiation
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response, Yerushalmi & Weinstein (1979) observed an
appreciable TBE when 8 Gy radiation was combined with heat.
The fact that this was not the case in the present study
supports the supposition that a 3-4 hour interval between
irradiation and heat application provides selective
enhancement of tumour effect, and thus allows a therapeutic
gain. This scheduling of the two modalities mainly relies on
the additive effect of their direct cytotoxicities and
probably prevents any true radiosensitisation. As thermal
cytotoxicity is enhanced by the microenvironmental conditions
commonly found in tumour, a selective tumour effect can be
expected.
Conversely, acceleration of tumour growth rate following
irradiation has been observed in animal tumours after both
single dose and fractionated radiation (Barendson &
Broerse, 1969, 1970). This has also been documented in human
lung metastases three to six days after irradiation, with
gradual return to pretreatment doubling time (Van
Peperzeel, 1972). In the present study there was no evidence
of a similar period of accelerated growth rate in the
irradiated nodules, with or without the addition of heat. In
Van Peperzeel's study histological tumour type and lung site
probably accounted for the extremely rapid reduction in
volume, which was maximal at 3-6 days after irradiation. By
contrast, the maximum response in soft tissue nodules in the
present study was usually not seen until at least 20 days
after treatment, and was often considerably later.
Therefore, any initial acceleration of repopulation was
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likely to be masked by the slower resolution of these
nodules. However, measurement of labelling indices in human
tumours biopsied after irradiation has also failed to
demonstrate accelerated repopulation (Courdi et al, 1980) .
Despite the problems inherent in deriving and
interpreting growth delay as a clinical endpoint, as yet
there is no better alternative for quantifying the effect of
treatment in terms of clonogenic potential. Local regrowth
of tumours from surviving clonogenic cells is the only
available means of attempting to detect differences in the
numbers of survivors, and although a greater growth delay
does not necessarily indicate greater cell kill it is a valid
endpoint in its own right by virtue of the conferred clinical
benefit.
Tumour shrinkage was documented by calculating the
extent (maximum volume reduction - MVR) and rate (t%) of
regression. The clinical impression that heated tumours
regress faster than their irradiated counterparts has
previously been anecdotal (Scott, 1984). However, the th
values calculated in the present study demonstrated more
rapid tumour shrinkage with the addition of heat. Although
some irradiated nodules regressed rapidly, they were always
equalled or exceeded in their regression rate by their heated
counterpart.
The rapid shrinkage observed in these nodules is most
likely to represent the enhancement of the process of
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resorption. Although the extent of cell kill does not seem
to influence the rate of tumour shrinkage (Thomlinson &
Craddock, 1967) , the timing of expression of cell damage may¬
be important since resorption is presumably initiated by the
presence of dying cells. Following irradiation, there is
evidence that cells do not die immediatly but often undergo
one or more divisions before dying in mitosis (Trott, 1972).
By contrast, cell death as a result of hyperthermic
cytotoxicity is much more abrupt, with cells in G^ dying
before entering mitosis (Coss & Dewey, 1983) . Although cells
heated in S phase lyse following mitosis, damage is
nevertheless usually expressed after a period of hours
(Leeper, 1984) . Cell resorption may therefore be initiated
early, leading to more efficient tumour clearance.
Alternatively, or additionally, the effect of heat on the
tumour microcirculation may contribute to rapid tumour
shrinkage. In animal tumours, depending on the time and
temperature of heating, a fall in tumour blood flow has been
observed with a concurrent reduction in the vascular
compartment (Eddy, 1980, Emami et al, 1980, Song, 1980a).
However, it is unlikely that this mechanism was important in
the present study, as it was not possible to demonstrate a
decrease in tumour blood flow, using the thermal clearance
technique, following single hyperthermia treatment at 43°C
for 60 minutes in similar, small, superficial metastases
(Chapter 8).
In breast cancer nodules given 8 Gy radiation alone,
tumour regrowth seemed to be a more important determinant of
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growth delay than rate of regression. On the other hand, in
the hyperthermia study, despite equivalent regrowth rates,
heat-radiation nodules had greater growth delay compared with
their radiation only counterparts. However, in general,
heated nodules not only regressed faster but also achieved a
greater volume reduction, with the maximum response occurring
at approximately the same, or slightly later, time after
treatment compared with unheated nodules. A greater degree
of cell kill in the heated nodules is implied and is in
agreement with the demonstration of prolonged growth delay.
For all nodules measured in the present studies,
calculation of tumour doubling time and regression rate
relied on lines drawn by eye through data points, as there
was no available measure of the variation which might be
expected at individual points. As data collection in this
study could not be standardised, the application of complex
statistical techniques were considered irrelevant. Thus, the
number of nodules studied in each patient, their allocation
to treatment type and dose, and the frequency of observation
were all individualised according to disease status and
patient fitness. However, the chance of observing a greater
effect in the heated nodules in 9 out of 10 patients would be
very remote if there were in fact no true difference between
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8.1 Reproducibility of Xenon Clearance as a Technique for
Measuring Blood Flow in Small Superficial Human Tumours
Two sequential xenon clearance measurements were
performed in 31 tumours; 18 in cutaneous or subcutaneous
malignant deposits, and 13 in lymph node metastases. Paired
blood flow values for the two groups, expressed in
ml/min/lOOg, are shown in Tables 20 and 21 respectively.
Initial blood flow measurements varied widely with
values ranging from 0.34 - 31.04 ml/min/lOOg for superficial
metastases and 0.63 - 62.27 ml/min/lOOg for lymph node
metastases, the median values being 6.3 and 20.1 ml/lOOgm/min
respectively. Applying a Mann Whitney U test and confidence
interval to the median values of the two groups, there is a
marginally significant difference in flow between the two
types of lesion at p = 0. 0475. Tumour volume and



















as % of mean
Chordoma S/C 18.2 0.34 1.54 + 128
Adenocarcinoma (B) S/C 18.4 0.56 0.97 + 71
Chordoma S/C 10.0 0.60 0.30 - 150
Melanoma S/C 59.7 0.82 1.42 + 54
Adenocarcinoma (U) S/C 17.97 3.32 4.26 + 25
Adenocarcinoma (B) C 0.65 4.96 9.58 + 63.5
Adenocarcinoma (B) S/C 6.5 5.10 6.80 + 29
Adenocarcinoma (B) S/C 56.12 6.07 17.35 + 96
Myeloma S/C 8.18 6.21 7.42 + 18
Adenocarcinoma (U) S/C 5.58 6.36 2.64 - 83
Carcinoid S/C 13.44 7.07 2.77 - 87
Melanoma S/C 1.44 9.40 21.80 + 79.5
Adenocarcinoma (B) C 0.75 16.62 6.9 - 83
Adenocarcinoma (0) S/C 1.77 18.98 15.17 + 22
Adenocarcinoma (B) C 1.29 19.45 10.5 - 60
Clear cell carcinoma S/C 4.29 19.98 10.81 + 60
Adenocarcinoma (B) c 17.97 29.58 31.53 + 6
Adenocarcinoma (B) S/C 28.73 31.04 12.01 - 88
(B) = Breast
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as % of mean
Lymphoma Groin 0.63 2.34 + 115
Adenocarcinoma (B) Axilla 2.06 0.32 - 145
Adenocarcinoma (B) Neck 4.63 15.5 + 108
Adenocarcinoma (B) Ne ck 9.17 19.58 + 72.4
Adenocarcinoma (B) Groin 12.82 14.89 + 14.9
Adenocarcinoma (B) Axilla 16.52 14.24 - 14.8
Adenocarcinoma (B) Neck 20.1 18.96 5.8
Lymphoma Neck 20.12 22.33 + 10
Squamous carcinoma
(H & N)
Neck 28.21 38.85 + 32
Adenocarcinoma Groin 42.98 55.24 + 25
Squamous carcinoma
(H & N)
Neck 43.13 8.64 - 133
Squamous carcinoma
(H & N)
Neck 58.83 55.92 5
Lymphoma Axilla 62.27 48.19 - 25
(B) = Breast + = Flow^ > FloWj
(H & N) = Head and neck - = Flow^ < FloWj
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Of the total 62 Xenon clearance washout curves carried
out in 31 tumours, 37 showed mono-exponential and
25 bi-exponential decay. Only one tumour showed a difference
in pattern between the two sequential measurements
(Table 22).
TABLE 22
PATTERNS OF EXPONENTIAL FIT IN 62 XENON
WASHOUT CURVES FROM 31 TUMOURS
Exponential fit in B.B. M.M. M.B.
2 sequential clearance
measurements
No. of tumours 12 18 1
B. = bi-exponential
M. = mono-exponential
Significantly lower flow values were obtained from
mono-exponential, compared with bi-exponential curves
(p = < 0 .005) , and the range of values for each is shown in
Tables 23 and 24 respectively. Other tumour characteristics
(histology, volume and site) included in these tables
demonstrate a preponderance of lymph node metastases (76%) in
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0.34 1.54 Chordoma 18.2 S/C
0.56 0.97 Adenocarcinoma (B) 18.90 S/C




0.82 1.42 Melanoma 59.7 S/C
2.06 0.32 Adenocarcinoma (B) - L.N.
3.32 4.26 Adenocarcinoma (U) 17.97 S/C
4.63 15.50 Adenocarcinoma (B) - L.N.
4.96 9.58 Adenocarcinoma (B) 0.65 C
5.10 6.80 Adenocarcinoma (B) 6.50 S/C
6.07 17.35 Adenocarcinoma (B) 56.12 S/C
6.21 7.42 Myeloma 8.18 S/C
6.36 2.64 Adenocarcinoma (U) 5.58 S/C
7.07 2.77 Carcinoid 13.44 S/C
9.4 21.80 Melanoma 1.44 S/C
16.62 6.90 Adenocarcinoma (B) 0.75 c
19.45 10.50 Adenocarcinoma (B) 1.29 c
20.10 18.95 Adenocarcinoma (B) - L.N.
4.63 Bi-exponential Adenocarcinoma (B) - L.N.
B = Breast L.N. = Lymph node
U = Unknown S/C = Subcutaneous
C = Cutaneous
* = volume not assessable
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TABLE 24










9.17 19.88 Adenocarcinoma (B) - L.N.
12.82 14.89 Adenocarcinoma (B) - L.N.
16.52 14.24 Adenocarcinoma (B) - L.N.
18.98 15.17 Adenocarcinoma (0) 1.77 S/C
19.98 10.81 Clear cell 4.19 S/C
20.12 22.33 Lymphoma - L.N.
28.21 38.95 Squamous carcinoma - L.N.
31.04 12.01 Adenocarcinoma (B) 28.73 S/C
42.98 55.24 Adenocarcinoma (?) - L.N.
43.13 8.64 Squamous carcinoma - L.N.
58.83 55.92 Squamous carcinoma - L.N.
62.27 48.19 Lymphoma - L.N.
Mono-exponential 15.5 Adenocarcinoma (B) - L.N.
B = Breast L.N. = lymph node
0 = Ovary S/C = Subcutaneous
C = Cutaneous
The difference between the two flow measurements in the
reproducibility study was expressed as a percentage of the mean of
the two readings (Fig. 41) and calculated as follows




Comparison of Two Sequential Xenon Clearance Measurement
in Superficial Human Tumours Expressed as Percentage





























































Wide disparity between the two blood flow measurements
was observed regardless of tumour histology, site or volume.
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8.2 Reproducibility of Thermal Clearance as a Technique
for Measuring Blood Flow in Small Superficial Tumours
The procedure for measuring thermal clearance was
repeated up to 5 times in 10 patients, providing
74 observations in a total of 6 tumour and 13 normal tissue
sites (Table 25 ) . A wide distribution of values for the
decay coefficient beta (B) was obtained, with tumour and
normal tissue observations ranging from
7.14 - 23.2 x 10~3/sec and 6.99 - 19.6 x 10~3/sec
respectively (Table 24) . The median beta values for the two
-3 -3
groups were 14.1 x 10 /sec for tumour and 11.6 x 10 /sec
for normal tissue. Having allowed for variation between
patients and using analysis of variance techniques, beta
values were significantly greater (p < 0.001) in tumour
compared with normal tissue.
The variation in beta values obtained at each
measurement site has been expressed as a percentage of the
mean of the first and last measurement (Fig. 42), and
calculated from:-
2 (B1 - Bx) x 100
B^ + Bx
where B^ is the decay coefficient for the first thermal
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Figure 42
Variation in Thermal Clearance Measurement
in Superficial Human Tumours Expressed








































































The variation in beta was greater in normal tissue than
in tumour, although the number of tumour observations was
small. Overall, the percentage differences were considerably-
less than with Xenon clearance. There was no consistent
pattern of change from the first tc the last thermal
clearance measurement.
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Additionally, an overall estimate of reproducibility was
derived from the pooled mean beta value for each patient
— 3 — 1
point and their deviations, giving 0.53 x 10 sec for use
as a guide to the significance of any changes in beta
observed in prospective studies of heat treated tissue.
8.3 The Effect of Hyperthermia on Thermal Clearance in
Tumour and Normal Tissue
Patterns of thermal clearance, at specified intervals
following a prescribed dose of heat, were documented and
compared with pre-treatment thermal washout in 10 additional
patient volunteers. In seven of these patients, the protocol
could be followed exactly so that four thermal clearance
measurements were obtained for each patient (i.e. immediately
before hyperthermia and at 20 minutes, 4 hours and 24 hours
after hyperthermia). Of the remaining three patients, one
volunteered for three measurements only, and in the other two
the probe was accidentally damaged after only two
measurements. Lesions ranged in ellipsoidal area (estimated
from caliper measurements) from 0.6 - 8.2 cm2 (median 3 cm2),
permitting 2-4 intratumoural thermal clearance measurements
to be made per patient (probe: Design 2) . Tumour
characteristics for these ten patients, together with details
of temperatures achieved during a prescribed heat treatment,
are given in Table 26. Five of the treatments fulfilled the
time/temperature aim of a minimum tumour temperature of 43°C
for 60 minutes. In the remainder, patient discomfort limited
temperature elevation in three treatments.
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TABLE 26
CLINICAL AND HYPERTHERMIA TREATMENT DETAILS
Tumour Primary
measured temperature range










Chest ca. breast 43.0-43.5 43.5-44.0 60
Chest ca. breast 43.0-45.0 - 60
Chest ca. breast 41.5-42.0* 40.0 60
Chest ca. breast 43.0-44.0 44.0 60
Chest ca. breast 43.0 42.0-45.0 60






Scapula ca. breast 41.0-43.0 - 60
Chest ca. breast 43.0-43.5 40.0-43.5 60
Chest ca. breast 40.5-42.5* 42.0-43.0 *30
H & N = Head and neck = limited by patient discomfort
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Figure 43 illustrates the effect of hyperthermia on
thermal clearance in a single patient experiment.
Figure 43
Beta Values (B) at Six Measurement Points in
Tumour and Adjacent Normal Tissue; Pre-hyperthermia
and at Intervals of 20 Minutes, 4 Hours, and




O 20 minutes following hyperthermia
■ 4 hours ,, M
□ 24 hours ,,
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As indicated, the first three observation points (1-3)
on the thermal clearance probe were positioned within tumour,
the last two (5 & 6) within normal tissue, and the fourth
point was estimated to be at the boundary between tumour and
normal tissue. For each observation point, the sequence of
beta values derived from thermal clearance measurement
before, immediately following, and at 4 and 24 hours after
hyperthermia are displayed. Each of the 24 data points
plotted represents the arithmetic mean of the beta values
derived from two clearance measurements (± 1 S.D.). In the
example shown in Fig 43, an increase in beta is seen at all
six measurement points immediately following hyperthermia.
The significance limit for immediate change (20 minutes
post hyperthermia) was taken to be the separation of
deviations associated with successive pairs of observations,
-3-1
or a change in beta of > 10 sec . The initial increase in
beta was deemed to be sustained if the magnitude of change
was reduced by < 50% at the four hour post-hyperthermia
measurement. However, where there was a substantial return
towards the pretreatment value (> 50% reduction), the initial
increase was considered transient. At 24 hours the change
was classified as either an overall increase in beta, a
decrease, or a return to pretreatment values. Observations
obtained from the 10 patients in the hyperthermia treatment
study have been summarised according to these criteria and
are illustrated in Fig. 44.
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Figure 44
Percentage Beta Measurements Showing an Increase,
Decrease or No Change in Thermal Clearance, with
Reference to Pretreatment Values, at 20 minutes,
4 Hours and 24 Hours After Hyperthermia























Increase Decrease No change
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Immediately following hyperthermia, there was an
increase in beta in the majority of normal tissue (86%) and
tumour (76%) points. A decrease in the magnitude of beta
occurred at only one tumour point, and the remainder of
observations, 14% and 21% for normal tissue and tumour
points, showed no significant change from pretreatment
values.
The initial increase in beta was generally not
sustained, with 79% of normal tissue and 65% of tumour points
returning to pretreatment values by 4 hours after
hyperthermia. After an interval of 24 hours even fewer
observation points, 13% of normal tissue and 11.5% tumour
points, demonstrated an increase in beta compared with
pretreatment values. Overall, there was no difference in the
pattern of change of beta in tumour and normal tissue.
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8.4 Discussion
Ideally, the Xenon clearance reproducibility study would
have been best carried out by performing a series of
measurements on the same tumour so that an average and
standard deviation could be established. However, ensuring
reproducibility of patient positioning, external conditions,
injection technique and radioactivity monitoring involves the
patient in a time-consuming technique which is difficult to
justify performing repeatedly on an experimental basis.
Additionally, the time scale required for a greater number of
observations would make it more difficult to control other
parameters which might affect blood flow, such as patient
medication.
The flow values derived in the present study were in the
same general range as previously reported clinical
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observations using Xe clearance (Table 27 ).
It has not been possible to stratify the results of the
present study according to tumour histology, as the majority
of lesions (17/31) were adenocarcinoma, the remainder being
distributed among seven different histological groups.
However, Mantyla demonstrated significantly higher flow
values in lymphomas compared with superficial metastatic
differentiated or anaplastic carcinomas (Mantyla, 1979a,
1982). This finding may be related more to local differences
between lymph nodes and other sites rather than histological
type. The results of the present series would support this
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view, with the lymph node metastases showing a marginally
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Both single and bi-exponential equations have been used
to fit Xenon clearance data in previous studies (Gelin, 1968,
Daly, 1980, Mantyla, 1979a, Handel, 1976). Where the curve
is biphasic, blood flow can be calculated from the initial
phase (Daly & Henry, 1980, Handel et al, 1976, Lassen, 1967),
from the later steady state component (Sekins et al, 1980) or
from a combination of the two (Mantyla, 1979a) . It can be
argued that the initial portion of the curve may be the
appropriate determinant of blood flow where the injected
tissue has a significant fat content, and consequently a high
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Xenon affinity. Alternatively, avoidance of this early phase
of the curve may be advisable if it represents a transient
needle-induced hyperemia rather than steady state blood flow.
Analysis of the present data showed a preponderance of
mono-exponential fits (60%), and the consistency within
individual tumours (98%) suggests stability of the clearance
mechanism. The finding of significantly lower blood flow
values from mono-exponential, compared with bi-exponential,
curves parallels Mantyla's observations (Mantyla, 1982).
This is probably not surprising as a bi-exponential curve
implies incorporation of an initial rapid phase into the
blood flow calculation. However, it is interesting that
there was a preponderance of lymph node metastases in the
bi-exponential group, and it seems plausible to suggest that
the vascular architecture of lymph nodes provides a different
mechanism of clearance. The initial rapid portion of a curve
may be a reflection of preservation of normal vasculature and
its functional capacity to vasodilate in response to needle
injection.
The technique, as described here, was not sufficiently
reproducible for use as a measure of change of flow following
hyperthermia, and possible contributing factors have been
considered. Firstly, the volume of fluid injected (0.1ml)
represents a considerable proportion of the volume of small
lesions (< 3ml) and might be expected to disturb the
micro-environment with disruption of the capillary system.
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This would be particularly likely where considerable pressure
was necessary to introduce Xenon into the tumour substance.
Furthermore, preservation of normal vessels capable of
vasodilation would permit a needle-induced hyperemic reaction
in small lesions whereas the structural and functional
changes that occur in incorporated vessels with tumour
expansion would prevent reactivity in larger lesions. As
previous use of the technique has generally involved lesions
of volume _> 10ml, the present series was adapted to include
larger cutaneous/subcutaneous lesions and lymph node
metastases. However, the present results indicate that
tumour volume had no influence on the reproducibility of the
technique. Conversely, decreasing the injected volume to
0.01 ml. might reduce interstitial injury, but varying the
volume between 0.1 and 0.2 ml. in larger lesions did not
affect the outcome in Mantyla's series.
Secondly, interpretation of the washout curve is
difficult and therefore susceptible to error. A variable
initial accumulation of activity reflects the non-uniform
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rate of interstitial injection of Xe and is followed by a
decay curve which can be either mono or bi-exponential. A
biphasic clearance curve is interpreted as indicating the
presence of two mechanisms of Xenon clearance. The initial
rapid phase may reflect the influence of a transient
hyperemic response at the site of injection, whereas Xenon
diffusing beyond this region may be cleared by steady state
blood flow. In previous studies, both portions of the decay
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curve have been examined to determine blood flow. A
criticism of the method is that the point beyond which decav
follows an exponential curve is selected arbitrarily. In the
present study, great care was taken to reproduce patient
position, external conditions, the site of injection, and the
means of detecting radioactivity. As a result, the technigue
was time consuming but could have been incorporated into a
hyperthermia programme had this seemed appropriate.
There are no detailed reproducibility studies on the
application of this technique in human tumours in the
literature. It is important to be aware of the problems of
the technique, and to emphasise the extent of variation that
can occur, before incorporating Xenon clearance into
protocols designed to investigate blood flow change as a
result of therapeutic intervention (Olch, 1983a). Mantyla
refers to the reproducibility of the method as checked by
repeated measurements in eight patients, but no further
details are given. The present results do not concur with
the finding of a deviation from the mean of < ± 10%.
In the present study, a thermal method for the
qualitative description of heat induced blood flow change has
been evaluated as to its suitability for clinical application
in small volume tumours and surrounding normal tissue. The
aim was to employ the technique to investigate changes in
blood flow after a moderate hyperthermia treatment (43°C for
60 minutes) such as is commonly attempted in the clinic.
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Comparison of thermal clearance in tissue with that in
non-perfused phantom models supports the suggestion that both
conductive and convective mechanisms of heat transfer
contribute to clearance measurements in vivo. However, no
attempt has been made to quantify the rate of influence of
these components in the present comparative, qualitative
study, which aimed to demonstrate whether flow changes do
occur and, if so, to assess roughly their magnitude and
duration. Much of the controversy associated with the use
of thermal clearance stems from interpretive difficulties
inherent in applying simple mathematical models, particularly
the "bio-heat" equation (Eberhart et al, 1980), to estimate
absolute blood flow (Sandhu, 1986), and is therefore not
relevant to the present application of the technique.
In using thermal clearance as a qualitative index of
heat-induced blood flow change, two important assumptions
have been made. Firstly, as the heat-induced vascular damage
reported in animal studies is predominantly a capillary
phenomenon, any meaningful index of blood flow must be
capable of reflecting changes at this level of vessel
calibre. The assumption is generally made that convective
heat transfer within tissues takes place at the capillary
bed, a situation analogous with the exchange of other
metabolites such as oxygen. However, recent theoretical
modelling and experimental studies (Chen & Holmes, 1980,
Lagendijk, 1985, Weinbaum & Ji Ji, 1985) fail to support this
view, and suggest that patent vessels having diameters in the
range 40-300jim are of much greater significance. These
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studies have been exclusively concerned with normal tissues,
and the findings may not be relevant in tumours, where the
vasculature differs both morphologically and rheologically
(Warren, 1979). Within the context of the present study,
therefore, it is reasonable to suggest that the biological
significance of thermal clearance measurement rests upon the
assumption that flow at the level of terminal arterial
branches down to arterioles is affected by heat, either
directly or influenced by flow changes at the capillary level
(i.e. imperfect arteriovenous shunting). This is supported
in a recent report illustrating the relationship between
tissue temperatures and mean volume blood flow assessed by a
microsphere method, during water bath immersion heating of
rat normal tissues (Lokshina et al, 1985). Secondly,
parameters influencing thermal conduction, such as tissue
water content, are assumed to be constant throughout the
series of measurements in each patient. This assumption is
probably valid as considerable changes in tissue water
content would be necessary to alter thermal conduction and
have not been reported to occur in response to hyperthermia
within the 24 hour time scale considered here.
The practicality of introducing the thermal clearance
probe and securely maintaining the desired position was
established before proceeding to the reproducibility study.
In this study, manipulation of the probe within normal
tissues was always achieved painlessly, but penetration into
the tumour substance was prevented by discomfort in four of
the ten patients. In three of these, both measurement points
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were positioned in adjacent normal tissue, but in the fourth
only one of the points could be accommodated. Aside from
insertion of the probes, all volunteers considered the
procedure to be painless and consequently patient positioning
was easily maintained. As the sites studied were
superficial, room temperature was controlled and heat
transfer from skin surface minimised by a covering of
insulating material.
Considering both tumour and normal tissues, beta values
-3 -1
overall ranged from 6.99 to 23.2 x 10 sec . There are no
directly analogous derivations of beta values from thermal
clearance in human tissues with which to compare the present
series. However, the small multi-junction heating probe used
here provided thermal washout curves not dissimilar to those
derived from cooling data in our series of 56 heat treatments
in superficial tumours. In addition, beta values obtained
from animal data are in general agreement with the result of
this study (Cater et al, 1965).
Although the clinical data in the literature are not
adequate to establish that tumour blood flow is generally
lower than normal tissue blood flow, the aberrant
morphological features of tumour vasculature and the
phenomenon of selective tumour heating suggest that this is
the case. In the present study however, beta values obtained
in tumour were significantly greater than in adjacent normal
tissue The small size of the lesions studied may account for
this finding as, at least in experimental tumours, blood flow
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decreases with increasing tumour size (Vaupel, 1977). A lack
of differential blood flow between small lesions and
surrounding normal tissue has been implied by Kim et al
(1982) , who were unable to demonstrate selective tumour
heating in metastatic melanoma lesions of < 10 mis.
There were too few tumour observations to make any
comment on the effect of tumour size, site or histology on
the beta values derived from thermal washout curves.
The reproducibility of the technique has been assessed
by calculating the percentage difference from the mean of two
observations, in the same way that the Xenon clearance
technique was evaluated. As 3 - 5 measurements of beta were
obtained at each observation point, the first and last
measurements were used to derive this expression, being those
considered most likely to reflect any inconsistency. The
percentage difference between beta values was much less than
that obtained with two sequential Xenon clearance
measurements, although the direction of change was equally
unpredictable. For thermal clearance, the percentage
differences ranged from + 16 to - 17, whereas the
corresponding values for Xenon clearance were +130 and -150.
On the basis of this, thermal clearance was considered
sufficiently reproducible for investigation of changes in
blood flow associated with hyperthermia. However, assessment
of reproducibility also provides an index of sensitivity of a
technique as some fluctuation in the parameter under
investigation is inevitable. The lack of consistent
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variation between sequential Xenon clearance measurements,
despite careful control of conditions, makes it unlikely that
this is a useful reflection of sensitivity.
Using the technique, a consistent pattern of
heat-induced blood flow change has been observed. After
moderate heating, a clear majority of thermal clearance
measurements imply an increase in flow through tumours (T)
and their surrounding tissues (NT) (T:76% and NT:86% of
points sampled.) A substantial reduction in this change was
often seen after an interval of four hours (T:65%, NT:79%).
This was in agreement with the subjective attenuation of
hyperemic skin reactions observed within the hyperthermia
treatment field (Fig. 45). A small number of measurements
showed no immediate flow change (11/48), and of those
approximately one half (6/11) showed no later evidence of a
delayed change. A return to pretreatment flow values within
24 hours was observed in 73% and 60% of tumour and normal
tissue measurements respectively. The small group of
observations showing an overall flow reduction (T:4/26,
N:4/15) was influenced considerably by one case (T:3, N:2)
following the lowest HT dose achieved in the series
(T:40.5-42.5°C, N:42-43°C x 30 minutes). In this patient,
the consistent reduction in flow at 24 hours (5/6 points) was
striking, and the preceding pattern of flow change was
qualitatively similar to other cases. The significance of
this anomalous pattern of flow change remains in doubt in the
absence of control data from unheated tissues in the same
patient. A comparison between the tumour and normal tissue
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responses summarised in Fig. 44 showed no significant
difference in each group (single tailed x2 test,
p = 0.05 level). This result was also supported by a careful
inspection of temperature data recorded during hyperthermia,
which did not reveal any significant relative changes between
tumour and normal tissue temperatures throughout the heating
period.
Figure 45
Transient Erythema Following Heating of the Skin
to 43°C for 60 Minutes
Prehyperthermia Posthyperthermia
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Although the present data are consistent with
experimental studies in normal tissues (e.g. Song
1984), there is an apparent contradiction between the
observed human tumour response and the general conclusions
drawn from transplantable animal tumour studies. Of the 18
reports reviewed by Song (1984), 15 suggested that doses less
than 43 °C for 60 minutes were sufficient to achieve vascular
stasis within tumours during the period of heating. It is
possible that a differential vascular response may occur in
human tumours taken to a higher heat dose. However, from
clinical experience, hyperthermia treatment of 43°C for
60 minutes is close to the upper practical limits of
tolerance for a minimum tumour dose delivered in a single
treatment. Increasing thermal dose beyond this level raises
the probability of normal tissue toxicity, as demonstrated by
the substantial damage sustained in rat skin following 45°C
for 60 minutes (Okumura & Reinhold, 1978). Increased heat
dosage is therefore likely to require a fractionated regime
which introduces the possibility of significant
thermotolerance effects (Overgaard and Nielsen, 1983).
Therefore, the present data suggest that enhanced tumour cell
killing, mediated by microvascular damage, is unlikely to
contribute to the hyperthermic effect, at least in its
current clinical application.
The present series of observations on carefully selected
small superficial tumours does not permit general statements
concerning vascular response of human tumours, and the need
for further investigation with regard to the effect of tumour
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size, site and histological type is emphasised- However,
some of the commonly reported features of clinical
hyperthermia, such as lack of selective tumour heating in
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9.1 Tumour Doubling Time in Human Metastases.
Tumour doubling times have been calculated for 163 metastatic
nodules in 31 patients contributing between 2 and 12 nodules
each (Fig. 46). The number of measurable nodules available
per patient has important implications for study design in
\ y \&*.W j} v'* 4 ' " >:». • «SVS
terms of inclusion of control lesions and the range of dose
'-'.J ' ; •levels investigated.
Figure 46
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Number of measurable nodules in individual patients
Classification of nodules by histology showed a
preponderance of adenocarcinoma of primary breast origin




CLASSIFICATION OF NODULE POPULATION BY
HISTOLOGICAL TYPE
Histological type No . nodes No. of patients
ADENOCARCINOMA breast 101 18
- bronchus 11 2
- unknown origin 3 1
- corpus uteri 4 1
SQUAMOUS CARCINOMA - bronchus 5 2
- skin 3 1




Data analysis has been carried out on the entire
population (163 nodules) and, separately on the breast
carcinoma lesions (101 nodules) to investigate growth
characteristics in this specific tumour type.
Overall, nodule doubling time varied between
4 and 310 days and the range of values and median for each
patient are displayed, ranked in order of increasing median
doubling time, in Fig. 47.
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Figure 47
Median and Range of Tumour Volume Doubling Times
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Patient identification
The number of nodules measured in each patient is
indicated above the corresponding range of
doubling time values.
In 71% (22/31) of patients the median doubling time was
less than 40 days.
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In breast cancer patients median tumour doubling time
ranged from 14 to 175 days and was less than 40 days in
13/18 (72%) patients (Fig. 48). In the remainder, median
values ranged from 5 to 206 days with a similar proportion,
9/13 (69%), being less than 40 days (Fig. 48). There was a
suggestion that the growth rate observed in breast cancer
patients was relatively homogeneous since 11/18 (61%) of the
median values fell within the range of 21-40 days.
Figure 48
Frequency Distribution of Median Tumour Volume
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9.2 Consistency of Tumour Growth Rate in Multiple Metastases
Measurement of more than one tumour nodule in each
patient allowed uniformity of growth rate to be assessed. As
some patients had only two or three nodules, the application
of rigorous statistical tests was inappropriate in evaluating
uniformity. For this reason an index of uniformity was
derived from the ratio of maximum to minimum doubling times
in individual patients. A ratio of one indicated uniform
growth rate in different nodules in the same patient, whereas
values > 1 suggested heterogeneity of doubling time. The
uniformity ratio, and the median doubling time, for each
patient is shown in Fig. 49. There was a suggestion of
greater intra-patient uniformity in breast tumours, where
13/18 (72%) patients had ratios of less than 3.0, compared
with 4/13 (31%) in other tumour types. There did not appear
to be any correlation between the uniformity of tumour
doubling time for each population of nodules and the median
doubling time for that population.
An example of uniform growth rate in 10 nodules from a
patient with breast cancer is shown in Fig. 50.
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Figure 49
Uniformity of Tumour Volume Doubling Time
in Multiple Metastases in Relation
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Figure 50
















In patients with nodules growing at different rates,
such as the example shown in Fig. 51, tumour volume and site
were considered as possible factors contributing to
non-uniformity of growth rate:-
Fiqure 51







9 .3 Factors Influencing Tumour Doubling- Time in Multiple
Metastases in Individual Patients
9.3.1 Tumour Volume
The ratio of initial tumour volume, in the largest and
smallest nodule, has been used as an indicator of uniformity
of tumour size within individual patients (Fig. 52).
Figure 52
Uniformity of Nodule Size Within Individual Patients
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Patient identification
The 11 patients who showed wide variation of nodule size
as demonstrated by a ratio of greater than 10, were analysed
to investigate the effect of volume on doubling time in the
same individual. In three of these 10 patients,
heterogeneity of doubling time was demonstrated, with a
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uniformity index of greater than four. However, only one of
the three (patient 30) showed a significant correlation
between volume and growth rate (Fig. 53) . In this patient,
11 nodules with initial volumes ranging from
34 mm3 - 15 , 492 mm3 provided doubling time data. In the
other two patients (patient 4 and 24) , with 11 and 6 nodules
respectively, despite a wide range of volumes and doubling
times, correlation coefficients were not significant
(Table 29 and Fig. 54) .
Figure 53
Correlation of Volume Doubling Time with Nodule
Size in a Patient with Breast Cancer (Patient 30)
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Correlation coefficients for tumour volume against
doubling time were calculated for the 21 patients who had
four or more nodules. These are shown in Table 29, together
with the number of nodules per patient on which the analysis
was based and the volume ratio for each individual. In the
group with volume ratios of less than 10, two patients
(Patient 9 and 28) showed a significant correlation
(p <0.005). In those patients with more variation in tumour
size, volume ratios greater than 10, a further two
individuals (patients 1 and 30) demonstrated a significant
correlation between tumour volume and doubling time
(p <0.001)
TABLE 29
CORRELATION COEFFICIENTS FOR TUMOUR VOLUME AGAINST
DOUBLING TIME IN PATIENTS WITH FOUR OR MORE NODULES
Volume ratio < 10 Volume ratio > 10
Patient No of Volume Correlation Patient No. of Volume Correlation
No. Nodules ratio Significance No. nodules ratio coefficient
7 10 6.5 0.486 1 7 29.5 0.979***
9 4 6.1 0.988* 2 4 10.5 0.863
10 5 2.2 0.365 4 10 22.1 0.234
14 9 4.1 0.191 5 5 12.6 0.553
16 7 1.4 -0.308 18 12 37.7 0.263
17 6 9.2 0.704 19 5 18.2 0.574
21 6 2.1 0.501 20 5 16.3 0.213
25 6 7.4 0.116 22 8 16.2 0.605
26 4 1.8 0.194 24 6 18.2 -0.053
28 4 2.9 0.965* 30 11 460 0.913***
29 4 4.1 0.267
* p < 0.05
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9.3.ii The Effect of Tumour Site on Doubling Time
Breast cancer nodules usually occurred in a localised
cluster on the breast or chest wall (15/18 patients) and were
therefore unsuitable for analysis by site except in three
patients. In a further six patients with other histologies,
the distribution was adequate for investigation of a site
effect. Of these nine patients, only one (patient 9) showed
any variation of growth rate by site with two subcutaneous
neck nodules doubling in 34 days compared with a 10 day
doubling time in two subcutaneous abdominal wall lesions.
Two patients (patient 1 and 4) had lesions widely scattered
over the torso without any detectable effect on growth, and
the same was the case in a third patient (patient 18) who
also had limb lesions.
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9.4 DISCUSSION
The reason for investigating tumour growth in the
present study was to assess variation in growth rate between
individual metastases in the same patient and to see whether
nodule size or geographical site influenced volume doubling
time. Ideally, standard deviation from the mean would have
best reflected variation in doubling time in each nodule
sample, but the small number of observations (2 and 3) in 10
of the patients precluded this approach. For this reason the
ratio of maximum to minimum doubling time, within individual
patients, was used as an index of growth rate uniformity.
Applying this index of uniformity, variation in nodule
doubling time was three-fold, or less, in 19/31 (61%)
patients. A greater than three-fold variation was due to a
single nodule in only three patients, and in the remainder
the values were spread fairly evenly within the individual's
range. Consistency of growth rate was not related to the
number of nodules studied nor to the median doubling time of
the sample.
A similar expression was used for evaluation of
uniformity of nodule size within individual patients, i.e.
the ratio of maximum to minimum tumour volume. Again, the
small number of observations prohibited the use of more
stringent statistical methods. The most significant
correlation (p <0.001) between tumour volume and doubling
time was detected in two patients with volume uniformity
ratios of > 10, i.e. 460 and 29.5, but there was no
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significant correlation in the other 8 assessable patients in
this group. Only two patients in the group with less volume
variation demonstrated a correlation and this was at a lower
level of significance. In one of these, patient 28, the
correlation may have been misleading as ultrasound was not
available for depth measurement in plaque-like lesions making
it likely that the volume range obtained from two-dimensional
measurements was exaggerated. The results suggest that in
patients with lesions suitable for entry into the measurement
study, the variation in volume is unlikely to affect the
calculated doubling times unless the size range is extreme.
Likewise, nodule site did not appear to have any influence on
growth rate within individual patients.
The breast cancer tumour volume doubling time data
derived in the present study demonstrates wide biological
heterogeneity, with an overall doubling time range of
10 - 206 days and median values varying between 14 and
175 days. However, the finding that 72% of patients had
median doubling time values within the range 14 - 39 days and
that 62% of all breast nodule doubling times were between
14 and 40 days indicated a more uniform subset of tumours.
In addition, considering the crudeness of the technique for
establishing doubling time, consistency within individual
patients was reasonable with a less than three-fold variation
in doubling time range in 72% of the patients.
Consistent with previous reports on breast cancer
metastases, growth was considered rapid, with 78% of nodules
259
doubling in volume in 60 days or less (Spratt & Spratt, 1964,
Lee & Spratt, 1972) . The slower growth rate reported in
primary breast cancers (Ingleby & Moore, 1956, Ingleby et
al, 1958) seems likely to reflect selected biological
behaviour in that data is only available for indolent primary
tumours not requiring immediate therapeutic intervention, and
there are no reports of serial measurement of both primary
tumour and metastases in the same patient. The tumours
studied in the present series were also highly selected in
that they were recurrent or metastasising, resistant to
conventional therapy and therefore biologically aggressive.
Shackney (1978) has used the discrepancy between growth rate
of primary breast cancer (advanced disease) and that of
mastectomy scar recurrence (early disease) as evidence of
growth retardation with advancing tumour age. Although this
is an attractive approach, the two tumour groups cannot be
considered biologically comparable in terms of growth
potential. In the present study, measurement of variably
sized metastases within individual patients has provided an
opportunity to assess doubling time at different stages of
tumour growth. Only two of the 18 breast cancer patients
displayed a significant correlation between doubling time and
tumour size and it seems likely that over the range of tumour
volumes encountered in suitable patients with superficial
multiple metastatic nodules, variation in doubling time is
not sufficiently great to influence results.
Other series also report a wide range of doubling time
values both within the same tumour type and between
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histological types. Batterman (1981) reported on a series of
pulmonary metastases from different primary tumours and was
unable to show any correlation with tumour type. There was
however, a significant relationship between histological
grade and volume doubling time.
In this series, histological type did not appear to
influence volume doubling time. For example, the four
patients with malignant melanoma had median doubling times of
18, 46, 56 and 206 days respectively. The general range of
values was consistent with those obtained in other series
(Batterman et al, 1981; Steel, 1977) , despite the fact that
most reported observations have been made on pulmonary
metastases.
Multiple measurable metastases provide a potentially
useful model for obtaining quantitative information on the
modification of tumour response to radiation and have been
employed to investigate neutrons and radiosensitizers
(Battermann et al, 1981; Thomlinson et al, 1976; Dawes et
al, 1978; Ash et al, 1979; Urtasun et al, 1980). The system
permits direct comparison of different treatments on like
tumours and allows observation of untreated control lesions
for reference. However, success of the technique relies on
the assumption that multiple metastases grow at the same rate
and behave similarly. Careful selection of patients with
similarly sized nodules, growing in the same tissue, at the
same site increases the likelihood of biological uniformity,
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but in practice such patients are rare and less ideal
candidates must be considered.
Pre-treatment serial tumour measurements allow
calculation of doubling time in individual nodules and thus
provide a basis for selecting comparable tumours in which to
evaluate the effect of treatment. In addition, doubling time
information allows calculation of specific growth delay. In
the treatment protocol presented in this thesis, where
possible serial tumour measurements were obtained 3-4 weeks
prior to treatment (see Chapter 4). This permitted selection
of nodules growing at a similar rate in which to compare the
effect of adding heat to radiation (see Chapter 7).
Accuracy of Tumour Measurement
Provision of a "measurement clinic" allowed optimum
conditions, in terms of time and space, for obtaining
accurate, reproducible, quantitative data. Individual
patient tumour measurements took up to lh hours depending on
the number of nodules, ease of visualisation on ultrasound,
patient mobility etc. Incorporation of studies of this sort
into routine clinical practice is therefore not recommended.
The frequency of attendance at the clinic was determined by
patient factors such as time required off work, distance
between hospital and home, general patient condition etc.,
but where possible weekly observations were made to increase
the reliability of measurement.
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The accuracy of caliper and ultrasound measurement have
previously been evaluated in superficial lesions similar in
type to those included in the present study
(Yarnold et al, 1986). The data showed that ultrasound
provided an accurate measure of tumour depth, but tended to
underestimate the lateral margins. Conversely, caliper
measurement tend to over-estimate tumour dimensions partly
because of the unavoidable inclusion of two layers of skin
and subcutaneous tissue. The importance of incorporating
tumour depth into serial volume calculations is emphasised by
ellipsoid lesions which demonstrate that tumour growth is not
necessarily equal in all dimensions. Likewise, regression in
superficial nodules after treatment is often more pronounced
in the depth than in the transverse dimension so that tumour
shrinkage may be underestimated by caliper measurement alone.
In the present study calipers were therefore used to obtain
longitudinal and transverse lateral dimensions and, where,
possible, ultrasound provided a measure of tumour depth. In
general, subcutaneous lesions were easier to visualise on
ultrasound than cutaneous nodules but the depth of the latter
could always be precisely measured above a depth of 2 mm.
The tendency for cutaneous nodules to occur in clusters
and to become confluent with progressive growth necessitated
careful identification of study lesions. An example of
extensive breast cancer metastases becoming confluent over
the chest wall is shown in Fig. 56. The development of new
lesions within the area of interest provided further
difficulty in this respect. Ulceration of cutaenous lesions,
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with subsequent central necrosis or crust formation further
hampered tumour measurement. The patient in Fig. 57 had a
fore-quarter amputation for extensive axillary nodal disease
secondary to a squamous carcinoma on the dorsum of the hand.
Discrete superficial nodules, covered by intact skin,
appeared adjacent to the scar and each evolved in a similar
way with central necrosis occurring at tumour dimensions
greater than 4mm. Lesions continued to enlarge but volumes
calculated from linear measurements are difficult to
interpret. In addition, ultrasound images were not able to
determine the depth of the lesion because of the shadow cast
by the ulcer crater.
Figure 56
Cutaneous Metastases Becoming Confluent
Over the Chest Wall
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Figure 57
Evolution of Ulceration in Nodules of Squamous





Technical inadequacies in heat delivery and thermometry
remain major problems in the clinical evaluation of
hyperthermia, but are perhaps overstated. Non-uniformity of
dose distribution for example, is not unique to heat delivery
but is a significant consideration in other non-surgical
approaches to cancer treatment. A close parallel can be made
with chemotherapy where drug delivery, like heat, is probably
very dependent on tumour physiology, in particular blood
flow, and where the variation in dose throughout a tumour is
likely to be large. The comparison can be further extended
to the inability to measure drug levels throughout the tumour
volume in individual patients. Thus, power application for a
hyperthermia treatment and drug dose administered in a
chemotherapy regime may be considered similarly remote from
tumour cell "dosage". By contrast, the dose variation within
a radiotherapy treatment volume is dependent on anatomical
considerations rather than physiological parameters and these
are generally static apart from exceptions such as bowel
mobility and lung expansion. This allows the absorbed
radiation dose at any particular point to be predicted and
the setup adjusted to optimise uniformity. However, although
dose can be expressed in physical terms, microenvironmental
variations, such as hypoxia, may introduce incalculable
variation in effect.
The shortcomings in chemotherapeutic dosimetry have not
prevented attempts of the evaluation of this modality in
clinical trials. The ensuing experience with chemotherapy
can either be taken as an inducement or a deterrent to
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accepting shortcomings of hyperthermia, and embarking on a
clinical trial using the best technical facilities available.
There is a further biological rationale for accepting
temperature inhomogeneity within a treatment volume, at least
when heat is used in combination with radiation. Thus,
temperature cold spots within tumour are likely to correspond
to well-oxygenated radiosensitive areas, and greater
temperatures are likely to be achieved in poorly perfused
regions which may harbour radioresistant cells.
A major concern in applying hyperthermia with only
limited thermometry is the occurence of undetected normal
tissue hot spots and risk of consequent damage. Total
exclusion of normal tissues from the treatment volume is
rarely possible even with interstitial or implantation
techniques. However, when used in combination with radiation
the scheduling of the two modalities may help to reduce this
hazard. Thus, delaying hyperthermia by more than 3-4 hours
after irradiation probably minimises radiosensitisation, and
direct heat cytotoxicity is likely to be the dominant
mechanism. As intratumoural microenvironmental conditions
favour heat toxicity, this allows the possibility of a
therapeutic gain. Although simultaneous application of heat
and radiation produce a greater tumour effect by implicating
both radiosensitisation and direct toxicity, the magnitude of
normal tissue effect detracts from an overall therapeutic
gain. The sequential scheduling employed in the present
study provided considerable enhancement of the tumour
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response to radiation and justifies optimism regarding the
clinical role for heat in improving local tumour control by-
radiation .
Spacial limitations in thermometry necessitate that the
available temperature measurement points be used to best
advantage. This requires selection of biologically relevant
reference points on which to control treatment temperature,
and accurate location of the thermometry equipment at the
specified site. So far, collection of clinical thermometry
data has tended not to be systematic but this approach is
essential in attempting to deliver standardised heat
treatments in a clinical trial.
Performance analysis for heat delivery is another area
which requires careful scrutiny. Essentially, failure of
heat delivery implies either inadequate temperature rise or
an inability to maintain treatment temperature for the
prescribed time, but the biological implications of the two
are likely to be very different. Analysis of temperature
profiles, in successful and failed heat delivery, was
attempted in the present study and indicated that an isolated
cold spot in tumour was a significant cause of failure to
deliver the prescribed heat treatment. The contribution of
this phenomenon to biological outcome is an important
question in terms of defining what can be considered a
clinically useful heat treatment. Unfortunately, in the
present work there were inadequate numbers of heated nodules
with a standardised biological outcome in which to make this
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correlation. However, this would seem to be an important
area of study which has not yet been addressed in human
heating.
Hyperthermia and blood flow are inextricably linked.
Current interest in tumour blood flow will, one hopes, be of
benefit to hyperthermia and may supply mechanisms for
controlling this physiological variable which has such an
influence on heat delivery. The other side of the coin,
heat-induced vascular change may critically determine the
role of hyperthermia in clinical oncology, if the
observations on animal tumours reflect events in clinical
cancers. In the present study, tolerable heat treatments did
not induce the vascular status reported in transplantable
animal tumour studies. This is encouraging, as it reduces
some of the constraints for scheduling hyperthermia when used
in combination with radiation or drugs. However, further
investigation is necessary to establish whether tumour type
influences vascular susceptibility to heat, and whether
higher temperatures, such as may be possible with
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